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Abstract 
Myotonic dystrophy type 1 (DM1) is caused by an expanded CUG repeat (CUG
exp
) that 
sequesters muscleblind-like 1 protein (MBNL1), a protein that regulates alternative splicing. 
CUG
exp
 RNA is a validated drug 
target for this currently untreatable 
disease. Herein, we describe the 
development of a bioactive small 
molecule (Chapter 2) and a small 
library of dimeric ligands (Chapter 
3) leading to an optimized bivalent ligand. These novel ligands target CUG
exp
 RNA and are 
able to inhibit the CUG
exp⋅MBNL1 interaction in cells that model DM1. In a DM1 cell model 
these ligands were found to disperse CUG
exp
 ribonuclear foci, release MBNL1, and partially 
reverse the mis-splicing of the 
insulin receptor pre-mRNA. Direct 
evidence for ribonuclear foci 
dispersion by this ligand was 
obtained in a live DM1 cell model 
using time-lapse confocal 
microscopy. In Chapter 4, We report a single-molecule approach to study the binding of 
MBNL1 to (CUG)n=4,6 and the effect of small molecules on this interaction. MBNL1 is able to 
bind to the (CUG)n･inhibitor complex indicating that the inhibition is not a straight forward 
competitive process. A simple bivalent ligand, shows a binding to (CUG)n almost 50-fold 
more tightly than the corresponding 
monomeric ligand and is more 
effective in destabilizing MBNL1･
(CUG)4. The single-molecule 
method and the analysis framework 
might be extended to the study of 
other biomolecular interactions. Chapter 5 includes a preliminary effort to solve the mystery 
of CUG
exp
 unfolding/folding upon interaction with MBNL1. To approach this unanswered yet 
key structural question about how MBNL1 binds CUG
exp
, preliminary bulk FRET 
(Fluorescence Resonance Energy Transfer) studies, as well as single-molecule FRET 
studies are described. 
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Chapter 1.  
Introduction 
1.1 RNA as a Drug Target 
Nucleic acids and proteins form the basic macromolecules of every living organism. 
As the central dogma of biology describes, DNA contains the genetic information which 
through the RNA intermediate may be translated into proteins. Traditionally RNA has 
been considered merely as a passive carrier of genetic information from DNA (genetic 
information depository) to protein, the functional macromolecules of the cell.1 As a result, 
drug discovery efforts have been largely focused on targeting proteins, in almost every 
disease.2  
For example, in genetic diseases it has been traditionally assumed that a mutated 
gene causes the expression of defective proteins, which then affects proper cellular 
function. Therefore, drug development programs have been historically focused on 
targeting the defective proteins in the corresponding disease.  
As Frith et al. explain, considering that over 50% of the genomic DNA of complex 
organisms is transcribed into RNA, whereas under 2% of this DNA actually encodes 
proteins,3 we expect to find RNA at many key regulatory steps of a cell’s life.4 the 
continuing functional and structural discoveries of RNA biochemistry is also an 
opportunity for the development of RNA-based therapeutics.5  
A classic example where RNA serves as a drug target is with ribosome-targeting 
antibiotics. In fact, to date the most common RNA drug targets have been ribosomal 
RNA and HIV RNA.6-8 Proteins are also capable of selective RNA complexation. 
However, they generally are not able to serve as therapeutic agents for two main 
reasons: poor pharmacological properties and structural complexity.9, 10 
Small molecules can bind specific RNA motifs and control biochemical processes in 
cells and for this reason have been called the missing link in the central dogma by 
Schreiber et al.11 Unlike proteins, small molecules often show good physicochemical and 
pharmacological properties as potential therapeutic agents. 
Small molecules that specifically bind RNA targets are less common than those that 
bind DNA targets,12 due to physicochemical differences between DNA and RNA. For 
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example, as described by Carlson et al. and Weeks et al. the 2’-OH group presents 
additional polar functionality at each residue of RNA. RNA is a versatile molecule, which 
usually exists in the single stranded form. However, it can fold into different structures 
and conformations such as hairpin-loops, duplexes, internal-loops, mismatches, and 
bulges. The most common form of duplex RNA, the A-form contains a shallow “minor 
groove” and a narrow and deep “major groove” which makes it less accessible for 
selective binding.13,14 Because of the polyphosphate backbone and the electronegative 
groups on the bases protruding into the grooves, RNA (and also DNA) exists as a 
negatively charged anionic polymer. Therefore, most RNA ligands are therefore 
positively charged molecules. As a result some of these molecules tend to be relatively 
nonspecific in binding RNA sequences. It is because of the positive charge of 
aminoglycosides that they bind with a low specificity to various RNA sequences, such as 
UU mismatch.15-17 
1.2 Non-coding RNA  
Thanks to recent structural and functional discoveries of RNA, it is known that RNA 
plays multiple essential roles in cells. For instance, RNA has a control over the 
fundamental process of genetic expression, by a variety of non-coding RNAs 
(ncRNAs).18, 19 Genetic expression involves the following four steps:  
 Step 1: DNA replication 
 Step 2: Transcription of DNA into a precursor messenger RNA (pre-mRNA) 
 Step 3: Splicing of this pre-mRNA to a mature mRNA 
 Step 4: Translation of the mRNA sequence into a protein sequence  
Riboswitch is an example of ncRNA that is able to bind specific metabolites and affect 
gene expression in steps 2 and 4.20 MicroRNAs are small ncRNAs that have been 
shown to be heavily involved in gene regulation by binding complementary sequences in 
messenger RNAs and degrading them via the RNA interference (RNAi) pathway in step 
3.21 In Step 4, RNAs can undergo self-catalysis or cleavage and also exogenously 
catalyze fundamental cellular processes as seen in ribosomal RNA and in 
spliceosomes.22, 23 In summary, ncRNAs are actively involved in transcription regulation 
(microRNA, siRNA and riboswitches), alternative splicing (snRNA), and catalyzing 
biochemical reactions similar to proteins (e.g., ribozymes).  
Mutations in certain regions of ncRNAs are linked to several human diseases. Some 
of these mutations affect the splicing of the transcript produced from the same gene, 
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which is called “in cis” i.e., RNA may indirectly play a role in diseases through the 
translation of a mutated gene, which may then lead to loss of protein function. On the 
other hand, some diseases result from mutations in the splicing machinery and the 
regulatory proteins that affect splicing of other transcripts , which is called “in trans” i.e., 
an RNA produced from a mutant gene may nonspecifically inhibit the function of a 
regulatory protein, such as the sequestration of splicing factors in RNA repeat disorders, 
and cause a disease. The discovery of these disease-causing mutations in RNAs 
provides a range of therapeutic targets,24, 25 
Some of pathogenic in trans mutations, including some forms of cancers, several 
developmental and neurological diseases like autism, myotonic dystrophy (DM),26 
fragile-X syndrome, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis 
(ALS), and Alzheimer’s disease (AD),27 are shown in table 1.1.28 
Table 1.1 Trans-Acting mutations affecting RNA-dependent functions that cause disease
 
Disease Gene/Mutation Function 
Prader Willi syndrome SNORD116 ribosome biogenesis 
Spinal muscular atrophy (SMA) SMN2 Splicing 
Dyskeratosis congenita (X-linked) DKC1 telomerase/translation 
Dyskeratosis congenita (autosomal dominant) TERC telomerase 
Dyskeratosis congenita (autosomal dominant) TERT telomerase 
Diamond-Blackfan anemia RPS19, RPS24 ribosome biogenesis 
Shwachman-Diamond syndrome SBDS ribosome biogenesis 
Treacher-Collins syndrome TCOF1 ribosome biogenesis 
Prostate cancer SNHG5 ribosome biogenesis 
Myotonic dystrophy, type 1 (DM1) DMPK (RNA gain of 
function) 
protein kinase 
Myotonic dystrophy, type 2 (DM2) ZNF9 (RNA gain of 
function) 
RNA binding 
Spinocerebellar ataxia 8 (SCA8) ATXN8 (RNA gain of 
function) 
unknown/noncoding RNA 
Huntington's disease-like 2 (HDL2) JPH3 (RNA gain of 
function) 
ion channel function 
Fragile X-associated tremor ataxia syndrome  FMR1 (RNA gain of 
function) 
translation/mRNA 
localization 
Fragile X syndrome FMR1 translation/mRNA 
localization 
X-linked mental retardation UPF3B translation/nonsense decay 
Oculopharyngeal muscular dystrophy (OPMD) PABPN1 3' end formation 
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Table 1.1 (cont.)    
Human pigmentary genodermatosis DSRAD Editing 
Retinitis pigmentosa PRPF31 Splicing 
Retinitis pigmentosa PRPF8 Splicing 
Retinitis pigmentosa HPRP3 Splicing 
Retinitis pigmentosa PAP1 Splicing 
Cartilage-hair hypoplasia (recessive) RMRP Splicing 
Autism 7q22-q33 locus breakpoint noncoding RNA 
Beckwith-Wiedemann syndrome (BWS) H19 noncoding RNA 
Charcot-Marie-Tooth (CMT) Disease GRS Translation 
Charcot-Marie-Tooth (CMT) Disease YRS Translation 
Amyotrophic lateral sclerosis (ALS) TARDBP Splicing, transcription 
Leukoencephalopathy EIF2B1 Translation 
Wolcott-Rallison syndrome EIF2AK3 translation (protease) 
Mitochondrial myopathy and sideroblastic 
anemia  
PUS1 Translation 
Hypertrophic cardiomyopathy TSFM translation (mitochondrial) 
Hereditary spastic paraplegia SPG7 ribosome biogenesis 
Leukoencephalopathy DARS2 translation (mitochondrial) 
Susceptibility to diabetes mellitus LARS2 translation (mitochondrial) 
Deafness MTRNR1 ribosome biogenesis  
MELAS syndrome, deafness MTRNR2 ribosome biogenesis 
Cancer SFRS1 Splicing, translation, export 
Cancer RBM5 Splicing 
Multiple disorders mitochondrial tRNA 
mutations 
translation (mitochondrial) 
Cancer miR-17-92 cluster RNA interference 
Cancer miR-372, miR-373 RNA interference 
a.  Table obtained from Cooper et al. 28 
1.3 Role of RNA in Myotonic Dystrophy and Other Diseases 
Myotonic dystrophy (DM) is an RNA-mediated disease caused by a non-coding CTG 
repeat expansion in the DMPK gene, chromosome 19q.13.3 (DM type 1, abbreviated 
DM1) or a CCTG expansion in the ZNF9 gene, chromosome 3q. (DM type 2, 
abbreviated DM2).29-31 These repeats are among the so called microsatellites or simple 
sequence repeats (SSRs).32 They are tandemly repeated tracts of DNA composed of 1–
6 base pair (bp) long units that can be found either in translated or untranslated 3'- or 5'-
regions of the genome. Tetranucleotide repeats are the most abundant type in exons 
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whereas trinucleotide repeats are found most often in introns. These repeats are a result 
of misalignment and slippage of complimentary strands during DNA replication and 
repair.33,34 This slipped sequence repeat can undergo expansion through a complex 
mechanism.35 Trinucleotide repeat expansion disorders (TRED) can be divided in the 
following two general categories36:  
 Polyglutamine (PolyQ) disorders (Table 1.2) 
 Non-polyQ disorders (Table 1.3) 
Table 1.2. Polyglutamine TRED diseases.
37 
PolyQ diseases originate from a CAG repeat in the coding region that translates into 
Polyglutamine in the protein. Non-polyQ disorders are caused by an expansion in the 
non-coding region. These disorders can be further divided into two categories:  
 Loss-of-function pathogenesis such as Freidreich ataxia and fragile-X syndrome 
 Gain-of-function pathogenesis such as fragile X-associated tremor ataxia syndrome 
(FXTAS), spinocerebellar ataxia 3 (SCA3) and myotonic dystrophy (DM1 and DM2).  
Myotonic dystrophy type 1 (DM 1), also known as Steinert’s disease, is the most 
common adult muscular dystrophy with a prevalence of 1:8000.38, 39 In general, DM is an 
autosomal dominant inherited disease, with multi-systemic disorders such as myotonia, 
myopathy, cardiac arrhythmias, insulin resistance and progressive muscle 
degeneration.38 Myopathy is described as muscle weakness whereas myotonia accounts 
for delayed muscle relaxation, often described as stiffness. DM2 has similar presentation 
to DM 1 but with milder symptoms, in general. 
Table 1.3. Non-Polyglutamine TRED diseases.
37
 
Disease Gene Number of repeats 
DRPLA (Dentatorubropallidoluysian atrophy) ATN1 or DRPLA 49 – 88 
HD (Huntington's disease) HTT (Huntington) >35 
SBMA (Spinobulbar muscular atrophy or Kennedy 
disease) 
Androgen receptor on the X 
chromosome. 
38 – 62 
SCA1 (Spinocerebellar ataxia Type 1) ATXN1 49 – 88 
SCA2 (Spinocerebellar ataxia Type 2) ATXN2 33 - 77 
SCA3 (Spinocerebellar ataxia Type 3) ATXN3 55 - 86 
SCA6 (Spinocerebellar ataxia Type 6) CACNA1A 21 - 30 
SCA7 (Spinocerebellar ataxia Type 7) ATXN7 38 - 120 
SCA17 (Spinocerebellar ataxia Type 17) TBP 47 - 63 
Disease Gene Codon Number of repeats 
Fragile X syndrome FMR1, on the X-chromosome CGG 230+ 
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 1.4 Pathogenesis of Myotonic Dystrophy 
In eukaryotic cells, pre-mRNA needs to be converted to mature mRNA in a process 
called splicing, in which non-coding introns are removed and remaining exons are 
ligated to each other. This process is carried out by spliceosomes which recognizes and 
cuts out introns.40, 41 Therefore, during this process, various mRNAs can be made from a 
single pre-mRNA transcript, depending on which introns are excluded and which exons 
are included.42 This process is called alternative splicing, a common event in human 
genome. Different studies have found that between 74% to 95% of human genes 
undergo alternative splicing.43, 44 DM is among the diseases that are caused from 
alternative splicing misregulation.45  
The pathogenesis of DM involves misregulation of alternative splicing by the 
sequestration of regulatory factors such as the MBNL (muscleblind like) protein family 
and CUG-BP1.46 The MBNL family of proteins, especially MBNL1, is sequestered by 
mutant transcripts containing C(C)UG repeat RNAs which form discrete ribonuclear foci 
and these, in turn, lead to the loss of MBNL1 function.29 CUG-BP1 binds to CUG and 
CCUG,47 but doesn’t colocalize with them in the nucleus.48 Other proteins, such as 
hnRNP H and the transcription factor Sp1 are also suggested to be involved in the DM 
pathogenesis,49 however their role is unclear at this time.50, 51 The current model for DM 
pathogenesis is a gain-of-function of CUG-BP1 and loss-of-function of MBNL1.46 As a 
result, various pre-mRNAs whose splicing is regulated by MBNL1 would be mis-spliced. 
For example, mis-splicing of chloride channel gives rise to myotonia symptoms and mis-
splicing of insulin receptor causes insulin resistance in DM patients.52, 53 Because 
MBNL1 is an RNA binding protein that regulates alternative splicing of a specific subset 
of pre-mRNAs during postnatal development, loss of this splicing factor, due to its 
sequestration, results in missplicing of MBNL1 target pre-mRNAs and perturbation of 
developmental signals. The following five findings support the role of MBNL1 in DM 
Table 1.3 (cont.)  
FXTAS (Fragile X-associated 
tremor/ataxia syndrome) 
FMR1, on the X-chromosome CGG 50-200 
POI (Premature ovarian insufficiency) FMR1, on the X-chromosome CGG 50-200 
DM1 (Myotonic dystrophy type 1) DMPK CTG 80- >2500 
HDL2 (Huntington’s disease-like 2)  JPH3 CTG 66-78 
SCA 8 (Spinocerebellar ataxia Type 8) SCA8 CTG 110 – 250 
SCA 12 (Spinocerebellar ataxia Type 12)  CAG 45-96 
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pathogenesis: 1) MBNL1 binds to CUGexp with a high affinity; 2) it is colocalized with 
CUGexp in ribonuclear foci; 3) a mouse knockout model of MBNL1 causes characteristics 
of DM;54 4) MBNL1 binds to introns of pre-mRNAs that are mis-spliced in DM;55 5) 
overexpression of MBNL1 in a DM1 mouse model corrects the related pre-mRNA 
splicing defects.56 These findings support the DM1 pathogenesis hypothesis and validate 
CUGexp as a drug target. In myotonic dystrophy, intervention at the RNA level might be 
the most advantageous. Elimination of DM symptoms by turning off the transcription of 
CUGexp in a mouse model, has confirmed the reversibility of DM1 pathogenesis.57 
1.5 Therapeutic Avenues for Myotonic Dystrophy  
Current therapeutics for DM patients is limited to palliative therapy with minimal 
clinical effects. Such palliative treatments include: selenium, vitamin E, baclofen, 
nifedipine, creatine monohydrate and testosterone, DHEA-S (dihydroepiandostrone 
sulfate) and bioflavonoids.58 They mainly relieve muscular degeneration, or relax 
delayed muscular contraction.59 Possible drug targets against myotonic dystrophy were 
described by Foff et al. as the follows:60 
 Targeting DNA repeat expansion and instability. Although this is an 
unexplored field small molecules that target the repeat sequence itself and 
interfere with the expansion can be promising ligands.61 For example, a 
naphthyridine-azaquinolone ligand selectively binds to CAG repeats and induces 
nucleotide flipping; it has been suggested as a diagnostic tool for repeat 
expansion.62  
 Targeting the toxic RNA. This approach mainly uses ribozymes (ribonucleic 
acid enzyme). Also called an RNA enzyme or catalytic RNA), ribozymes are RNA 
molecules that catalyze chemical reactions. Thus, they can cleave other RNAs 
and ultimately lead to degradation of their targets.63 Despite some progresses in 
this approach,64, 65 selectivity is still a big challenge.66 
 Targeting the Structural CUGexp Hairpin. As described by Foff et al.,67 CUGexp 
long hairpin structures have been shown to be substrates for Dicer, a 
ribonuclease whose main function in the RNA interference pathway is to 
recognize double-stranded RNA duplexes and induce cleavage of these 
structures into shorter, 21-nt duplexes. These duplexes are then incorporated 
into the RNA-induced silencing complex (RISC) and, as such, function to guide 
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substrate selection for degradation.68 A synthetic oligoribonucleotide (CUG)7 in 
DM1 fibroblasts led to a selective reduction in CUGexp level,69 supporting the 
hypothesis that using siRNAs (small interfering RNAs) to target the CUGexp in 
DM1 would tag it for destruction via the Dicer pathway. Delivery and selectivity 
remain the big challenges in this approach. 
 Targeting CUGexp⋅MBNL1 binding. The disruption of the CUGexp⋅MBNL1 
complex can be achieved by antisense oligonucleotides (AON) or small 
molecules. Two forms of AON are currently applied in DM1. One is 2'-O-methyl-
modified AONs (MOE), and the other is the phosphorodiamidate morpholino 
antisense molecules (PMO or morpholino). Morpholinos differ from other 
antisense strategies in that they provide inhibition via steric hindrance, rather 
than by any targeted degradation.70 2’-O-Methyl-phosphorothioate-modified 
(CAG)7 AON,
71 and AON containing (CAG)25,
72 have the effect of disruption of 
CUGexp⋅MBNL1 interaction and a significant degradation of the CUGexp itself.  
There are several small molecules at various stages of development as potential 
therapeutic agents for DM1. Kanamycin A was found as a high-affinity binder of 
pyrimdine-rich loops similar to CUGexp.73, 74 Bis-benzimidazole Hoechst 33258, 
binds to the DM1 motif as well.75 Pentamidine,76 benzo[g]quinolone-based 
heterocycles,77 a Hoechst derivative (H1),78 a modularly assembled Hoechst 
33258,79, 80 and an acridine-melamine conjugate, reported by our laboratory,81 
are examples of bioactive CUG repeat binders. 
Table 1.4. Small molecule inhibitors of CUG
exp⋅MBNL1 interaction. IC50 values are against 
different length of CUG repeats and cannot be directly compared. 
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 Altering Levels of RNA Binding Proteins. Increasing levels of MBNL1 or 
decreasing levels of CUGBP1 are two main options in this approach. Because 
MBNL1 is an RNA binding protein that regulates alternative splicing of a specific 
subset of pre-mRNAs during postnatal development, loss of this splicing factor, 
due to its sequestration, results in missplicing of MBNL1 target pre-mRNAs and 
perturbation of developmental signals. Treatment of a DM1 mouse model with a 
protein kinase C (PKC) inhibitor, Ro-31-8220, significantly improved mortality 
(from 80% mock treated to 20% treated). Concomitantly, CUGBP1 was not hyper 
phosphorylated, and protein levels were not elevated. Cardiac conduction and 
contractility were also improved in the treated mice.82 This finding shows that 
prevention of PKC mediated phosphorylation of CUGBP1 is effective. However, 
therapeutic impact is presumably low, given the complexity of the cellular 
process. 
 Alteration of Downstream Splicing Targets. As described by Foff et al.,67 
targeting this far down the pathway gives a limited return on the investment. In 
other words, anti-sense oligonucleotide designed to reverse the insulin receptor 
missplicing may fix the insulin resistance, but the rest of signs and symptoms 
would still be present. This may ultimately be a viable therapeutic approach, but 
only if a method for targeting each downstream process is developed. The fact 
that there are so many missplicing involved in DM disease, makes the success of 
this approach unlikely.49 
 Symptom Management. The use of mexelitine, which modulates sodium 
channels and thus lessens myotonia, and central nervous system stimulants to 
address fatigue are two such examples that are routinely applied in practice.83 It 
has been shown that injection of exogenous insulin-like growth factor 1 (IGF-1) 
could improve muscle strength and function in adult DM1 patients, presumably 
owing to its anabolic effect on muscle.84, 85 
1.6 Myotonic Dystrophy Drug Discovery Program 
As it was explained in detail in the previous sections, the CTGexp produces a toxic 
RNA transcript (CUGexp) that does not exit the nucleus but associates with proteins. One 
of these proteins, MBNL1, is an important regulator of alternative splicing.86 
Sequestration of MBNL1 in nuclear foci leads to multiple misspliced pre-mRNAs, 
incorrect protein levels, and ultimately the signs and symptoms of the disease.87 
 10 
 
Knowing that CUGexp is the causative agent of DM1, almost all of the DM drug discovery 
efforts have been focused on targeting CUGexp.  
Antisense oligonucleotides and small interfering RNAs control gene expression by 
triggering the degradation of mRNA by recruiting RNase H or the RNA-induced silencing 
complex, respectively.88 In a mouse model of DM1 a morpholino antisense 
oligonucleotide (ASO),72 a 2’-O-(2-methoxyethyl) ASO89 and a D-amino acid hexapeptide 
(ABP1)90 reversed this process, rescued the missplicing and reversed the phenotype in 
mice thereby validating CUGexp as a therapeutic target. Because no drugs are currently 
available to treat DM1, there is intense interest in finding small molecules that may 
function in a manner similar to the morpholino antisense oligonucleotides, but avoid the 
limitations inherent in the antisense therapeutic approach.60 Pentamidine,76 
benzo[g]quinolone heterocycle derivatives,77 a Hoechst derivative (H1),78 and modularly 
assembled Hoechst 3325879 are examples of bioactive CUGexp binders that are being 
developed in other laboratories and have been found to restore MBNL1 function in DM1 
cell and animal models.91 Recently, a CUGexp binder small molecule was appended with 
a moiety that generates hydroxyl radicals upon photolysis. This hydroxyl-mediated 
CUGexp cleavage improved DM1-associated defects in cell culture.92 
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Chapter 2.
1
  
A Novel CUGexp·MBNL1 Inhibitor with Therapeutic 
Potential for Myotonic Dystrophy Type 1 
2.1 Abstract 
Myotonic dystrophy type 1 (DM1) is caused by an expanded CUG repeat (CUGexp) 
that sequesters muscleblind-like 1 protein (MBNL1), a protein that regulates alternative 
splicing. CUGexp RNA is a validated drug target for this currently untreatable disease. 
Herein, we develop a bioactive 
small molecule (1) that targets 
CUGexp RNA and is able to 
inhibit the CUGexp⋅MBNL1 
interaction in cells that model 
DM1. The core of this small 
molecule is based on ligand 2, which was previously reported to be active in an in vitro 
assay. A polyamine-derivative side chain was conjugated to this core to make it 
aqueous-soluble and cell penetrable. In a DM1 cell model this conjugate was found to 
disperse CUGexp ribonuclear foci, release MBNL1, and partially reverse the mis-splicing 
of the insulin receptor pre-mRNA. Direct evidence for ribonuclear foci dispersion by this 
ligand was obtained in a live DM1 cell model using time-lapse confocal microscopy. 
2.2 Introduction 
RNA is an important, yet underutilized, drug target. To date, the most common RNA 
drug targets have been ribosomal RNA and HIV RNA.1-3 With recent structural and 
functional discoveries, non-coding RNA is gradually becoming an attractive drug target4-6 
and much is now known about designing ligands to interact with RNA.7-9 Myotonic 
dystrophy (dystrophia myotonica, DM) is among the pathologies where RNA stands as 
the most appropriate target for drug discovery.10 DM is the most common adult muscular 
                                                 
1 Adapted with permission from ACS Chemical Biology. DOI: 10.1021/cb400046u 
 19 
 
dystrophy with a prevalence of 1:8,000 to 1:20,000 worldwide.11 Currently there is no 
treatment for DM, only palliative therapy.12 
Myotonic dystrophy type 1 (DM1), originates from the progressive expansion of CTG 
repeats in the 3’- untranslated region of the DMPK gene. Thus, expanded CUG repeat 
transcripts (CUGexp) are the known causative agent of DM1.13, 14 The CUGexp RNA 
manifests its toxicity through a gain-of-function mechanism involving the sequestration of 
all three paralogs of human MBNL including MBNL1, a key regulatory protein of 
alternative splicing.15-17 The MBNL1⋅CUGexp aggregate forms ribonuclear foci, a hallmark 
of DM1 cells.18 In a mouse model of DM1, a morpholino antisense oligonucleotide 
(ASO),19 2’-O-(2-methoxyethyl) ASO,20 and D-amino acid hexapeptide, each targeting 
CUGexp, rescued the mis-splicing and reversed the phenotype.21 These studies validated 
CUGexp as a drug target and greatly increased interest in finding small molecules that 
function similarly. Pentamidine,22 benzo[g]quinolone-based heterocycles,23 a Hoechst 
derivative (H1),24 a modularly assembled Hoechst 33258,25, 26 and ligand 2, reported by 
our laboratory,27 are examples of bioactive CUG repeat binders at various stages of 
development as potential therapeutic agents for DM1.  
Our previously reported approach, which led to ligand 2 as a binder of CUG, was 
based on the notion that selectivity was paramount and could be achieved by rational 
design focusing on recognition of the UU mismatch in double stranded CUGexp.26 We 
found that the triaminotriazine ring (recognition unit) has a key role in the inhibition of 
(CUG)12⋅MBNL1 interaction as several acridine derivatives that lacked this unit showed 
no inhibition potency in our in an in vitro assay (Arambula, J. Ph.D. Thesis, University of 
Illinois, 2008). Although 2 proved to be among the most selective and effective inhibitors 
of the (CUG)12⋅MBNL1 interaction, despite its in vitro activity, it was not active in a 
cellular model of DM1. Its drugability was limited both because of its low water solubility 
and its inability to penetrate the cellular membrane. Herein we report further 
development of this small molecule into an active ligand in vivo through its conjugation to 
a cationic polyamine and the first observation using time-lapse confocal microscopy of 
foci dispersion in live cells that model DM1.  
2.3 Results and Discussion 
Synthesis and Characterization. Ligand 1 (Figure 2.1) is a conjugate of the 
previously reported in vitro active ligand 2 (Figure 2.1) and N-[3-({3-[(3-
aminopropyl)amino] propyl}amino)propyl] acetamide side chain. The synthesis scheme 
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of 1 is shown in Figure 2.17 in the experimental section. The choice of the side chain 
was guided by four objectives: (1) increasing its aqueous solubility, (2) increasing its 
affinity to RNA through electrostatic interactions with the phosphate backbone,28 (3) not 
adding to its cytotoxicity, and most importantly, (4) making it cell as well as nucleus 
penetrable. In fact, polyamine compounds are essential for cell growth and are easily 
transported across cellular membranes via the polyamine transporting system (PTS).29 
We were encouraged by the fact that previously reported acridine-polyamine conjugates 
were recognized by the PTS for cellular uptake.30, 31 These conjugates also exhibited 
increased activity for nucleic acids.32 
Stability of Model CUGexp and Effect of Ligand 1. The binding of 1 to a model of 
CUGexp was studied by UV melting experiments. Thus, a thermal denaturation study of 
(CUG)12, a validated model of CUG
exp,37 was carried out in the presence of one and 
three equivalents of ligand 1 (Figure 2.3a); simple monophasic melting curves with a 
ΔTm of 2.5 °C and 5.5 °C were observed, respectively (Figures 2.2 and 2.3b). 
 
Figure 2.1. Structures of 1 and 2 
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Figure 2.2. Melting curves of (CUG)12 in the absence and presence of one and three equivalents of 1; ΔTm 
of 2.5 ± 0.2 °C and 5.5 ± 0.8 °C were observed, respectively. Note: The assay was performed as described 
in the method section, however the flat part of the curve (10°C to 40°C) has been cut out and only The part 
of curve from 40°C to 90°C is shown here. 
This finding indicates binding of 1 to (CUG)12 and stabilization of the double stranded 
(ds) (CUG)12 hairpin. The latter finding is important because it has been proposed that 
MBNL1 displays a preference for single stranded (ss) RNA.38, 39 If this model is correct, 
any ligand that stabilizes the ds form of CUGexp may prove to be a more effective 
inhibitor of the (CUG)12⋅MBNL1 interaction. Thus, the observed stabilization of the ds 
form of (CUG)12 was an encouraging result, although not sufficient to ensure selective 
and effective inhibition of (CUG)12⋅MBNL1 interaction. 
 Figure 2.3. Ligand 1 stabilizes the ds form of (CUG)12. a) Schematic representation of (CUG)12. b) Tm of 
(CUG)12 hairpin in the presence of 1 and 3 equivalents of 1 in 1X PBS buffer. Values were measured in 
duplicate or triplicate with repeats agreeing within 1%. 
Inhibition of (CUG)12･MBNL1 Interaction by 1. To our knowledge, SPR has not 
previously been used to characterize the MBNL1⋅CUG interaction or its inhibition by small 
molecules.23, 40 Because the technique is particularly well suited for quantifying the 
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binding of proteins to a target on the SPR chip, we developed a simple SPR-based 
method to directly measure MBNL1 complexation of (CUG)12 in real time under 
equilibrium conditions and in a label-free format. Further, we were able to quantify the 
inhibition potency of 1 and its selectivity. The selectivity was assessed by performing the 
assay in the presence of a large excess of competitor tRNA.  
Thus, biotinylated (CUG)12 was immobilized on a streptavidin coated SPR sensor chip 
and incubated with different concentrations of 1 to reach a steady state response 
(response units, RU, see Figure 2.4a) over 150 s. The response to the binding of 1 was 
negligible in comparison to protein binding so the direct contribution of 1 could be 
ignored. Successive injections of a 0.65 µM solution of MBNL1 containing the same 
concentration of 1 as in the pre-incubation, led to varying responses depending on the 
concentration of 1. Because the SPR signal directly reflects the binding of MBNL1 to the 
biotinylated (CUG)12, the differences in the response curves are a direct result of 
inhibition by 1.  
The curves recorded in the presence and absence of 580 µM yeast tRNA were 
identical, indicating selective inhibition by 1. All of the data shown herein were from runs 
in the presence of tRNA. The maximum RU at 150 s was recorded for each 
concentration of 1 and converted to the fraction of (CUG)12 bound by MBNL1, all values 
normalized to that measured in the absence of 1. Fitting the data points in the plot of % 
(CUG)12 bound by MBNL1 versus increasing concentrations of 1 (Figure 2.4b) gave an 
apparent IC50 value of 15 ± 2 µM.  
These in vitro experiments demonstrate that 1 binds to (CUG)12, stabilizing the hairpin 
structure and inhibiting (CUG)12･MBNL1 interaction selectively. It is noteworthy that all of 
the in vitro experiments above were carried out with (CUG)12 in 1X PBS buffer. This 
particular buffer was chosen because it is the closest of common buffers to physiological 
conditions. It is also a more challenging buffer for small molecule inhibitors because it 
increases the (CUG)12･MBNL1 stability, as we obtained a KD value of 5.2 ± 2.5 nM for 
(CUG)12⋅MBNL1 interaction in this buffer by SPR technique whereas using EMSA we 
and others had reported KD values of 26 and 170 nM, respectively.
27, 37 
Bioactivity in DM1 Cell Model. It is a characteristic of DM1 cells that MBNL1 
aggregates with CUGexp in nuclear foci.41 To visualize the effect of 1 on these ribonuclear 
foci, we used confocal microscopy. This was accomplished using a model for a DM1 cell. 
Thus, HeLa cells were transfected with two plasmids, truncated DMPK-CUG960 and 
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GFP-MBNL1.42 As a negative control, HeLa cells were transfected with truncated DMPK-
CUG0 (i.e., no CUG repeat) and GFP-MBNL1 plasmids.
42 To detect (CUG)960 foci, Cy3-
(CAG)10 was used as a fluorescence in situ hybridization (FISH) probe. TO-PRO-3 was 
used to stain the nucleus, this particular dye was chosen because it has no overlap with 
the other three fluorophores in our system, i.e., the acridine ring of 1, the GFP of GFP-
MBNL1 and the Cy3 of the FISH probe. By taking advantage of the acridine 
fluorescence, the penetration of 1 to the cytoplasm as well as nucleus is tracked in the 
ligand-treated cells. 
 
 
TO-PRO-3 channel/ Nucleus Acridine channel/ Ligand 1 
  
GFP channel/ GFP-MBNL1 Cy3 channel/ CUG
exp
 
  
Figure 2.4. A magnified CUG960 transfected HeLa cell (DM1 cell model) showing ribonuclear foci.  
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Representative images from the confocal microscopy are shown in Figure 2.5a. The 
negative control cells lacking the (CUG)960 sequence showed no foci but rather MBNL1 
dispersed throughout the nucleus (Figure 2.5a, row 1). However, co-localized MBNL1 
and (CUG)960 foci were observed in the DM1 cell model (Fig 2.5a, row 2). Thus, in the 
untreated DM1 cells the merged GFP-MBNL1 (green fluorescence) and Cy3-(CAG)10 
(red fluorescence) images, showed yellow spots that correspond to MBNL1 and 
(CUG)960 co-localization in nuclear foci (last column Figure 2.5a). Likewise, incubation of 
the DM1 cell model with a negative control compound, 50 µM spermine for 48 h had no 
effect on the foci (Figure 2.5a, row 3). 
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However, incubation with 1, at 50 and 75 µM caused almost complete disappearance of 
the (CUG)960 foci and dispersion of the MBNL1 fluorescence (Figure 2.5a, rows 4 and 5, 
respectively). The foci disruption is observed as a disappearance, rather than dispersion 
of the FISH probe, because it is an exogenous antisense nucleic acid probe only visible 
when concentrated by a high-localized concentration of CUGexp RNA.43 Cells were 
classified as having or not having foci. The fraction of cells with (CUG)960 foci was 
reduced by ca. 86% with 1 at 75 µM with a two-tailed p-value of 0.004 (Figure 2.5b). 
Similar responses are seen at 50 and 100 µM ligand.  
 
 
 
 
 
 
 
 
 
 (b)  
Figure 2.5. Ligand 1 disrupts nuclear foci in fixed DM1 cell model. a) Columns 1-4 as labeled. Column 5 is 
merge of columns 3 and 4. Confocal fluorescent images show MBNL1 and CUG
exp
 foci are present in row 2 
where no ligand is added as well as row 3 where spermine (50 µM), as a negative control compound, is 
added. CUG
exp
 foci are not visible and MBNL1 is dispersed across the nucleus in negative control cells, row 
1, as well as rows 4 and 5 where DM1 cell model is treated with 1 at 50 and 75 µM, respectively, for 48 h. 
Each box shows a 150 m   150 m area. b) Plot of CUGexp foci-containing cell fraction at various 
concentrations of 1. These data are gathered from scoring over 100 cells. The error bars represent mean ± 
standard error of at least three independent experiments. A magnified CUG960 transfected HeLa cell (DM1 
cell model) showing ribonuclear foci is shown in Figure 2.4. 
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(a) 
(A)TO-PRO-3 channel Cy3 channel Acridine channel 
Nucleus Cy3-(CAG)10 FISH probe Ligand 1 
   
   
   
(b) 
 
 
Figure 2.6. CUG960 transfected HeLa cells (DM1 cell model) without ligand treatment. a) Three visible 
excitation channels (639, 555 and 408 nm) were used to detect To-Pro-3, Cy3 and acridine ring, 
respectively. These channels indicate the presence of nuclei, Cy3-(CAG)10 FISH probe and 1, respectively. 
b) 28% of DM1 model cells show CUG
exp
 nuclear foci in DM1 cell model. 
 
 
Total number of cells 64 32 18 
Cells with foci 17 (27%) 8 (25%) 6 (33%) 
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(a) 
TO-PRO-3 channel Cy3 channel Acridine channel 
Nucleus Cy3-(CAG)10 FISH probe Ligand 1 
   
   
   
 (b) 
 
 
Figure 2.7. CUG960 transfected HeLa cells (DM1 cell model) treated with [1] = 20 µM. a) Three visible 
excitation channels (639, 555 and 408 nm) were used to detect To-Pro-3, Cy3 and acridine ring, 
respectively. These channels indicate the presence of nuclei, Cy3-(CAG)10 FISH probe and 1, respectively. 
b) 18% of DM1 model cells show CUG
exp
 nuclear foci in the presence of [1] = 20 µM. 
 
 
Total number of cells 49 18 114 
Cells with foci 10 (20%) 3 (17%) 18 (16%) 
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(a) 
TO-PRO-3 channel Cy3 channel Acridine channel 
Nucleus Cy3-(CAG)10 FISH probe Ligand 1 
   
   
   
 (b) 
 
Figure 2.8. CUG960 transfected HeLa cells (DM1 cell model) treated with [1] = 50 µM. a) Three visible 
excitation channels (639, 555 and 408 nm) were used to detect To-Pro-3, Cy3 and acridine ring, 
respectively. These channels indicate the presence of nuclei, Cy3-(CAG)10 FISH probe and 1, respectively. 
b) 9% of DM1 model cells show CUG
exp
 nuclear foci in the presence of [1] = 50 µM. 
 
(a)       TO-PRO-3 channel Cy3 channel Acridine channel 
Total number of cells 50 58 43 
Cells with foci 4 (8%) 6 (10%) 4 (9%) 
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Nucleus Cy3-(CAG)10 FISH probe Ligand 1 
   
   
   
   
(b) 
  
Figure 2.9. CUG960 transfected HeLa cells (DM1 cell model) treated with [1] = 75 µM. a) 4% of DM1 model 
cells show CUG
exp
 nuclear foci in the presence of [1] = 75 µM.  
(a) 
Total number of cells 30 32 63 94 
Cells with foci 1 (3%) 2 (6%) 2 (3%) 5 (5%) 
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TO-PRO-3 channel Cy3 channel Acridine channel 
Nucleus Cy3-(CAG)10 FISH probe Ligand 1 
   
   
   
 (b) 
 
Figure 2.10. CUG960 transfected HeLa cells (DM1 cell model) treated with [1] = 100 µM. a) Three visible 
excitation channels (639, 555 and 408 nm) were used to detect To-Pro-3, Cy3 and acridine ring, 
respectively. These channels indicate the presence of nuclei, Cy3-(CAG)10 FISH probe and 1, respectively. 
b) 5% of DM1 model cells show CUG
exp
 nuclear foci in the presence of [1] = 100 µM. 
 
 
 Improvement of Pre-mRNA Mis-Splicing by 1. After confirming that 1 disperses the 
MBNL1 foci, we sought to study the alternative splicing as a downstream measure of 
Total number of cells 50 27 26 
Cells with foci 3 (6%) 1 (4%) 1 (4%) 
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recovered MBNL1 regulatory activity. MBNL1 is known to be a key regulatory protein in 
alternative splicing and affecting many pre-mRNAs, including the insulin receptor (IR).44 
The mis-splicing of IR in DM1 cells occurs with a predominance of isoform A (with exon 
11 exclusion) relative to isoform B (with exon 11 inclusion).45 As described above, 
truncated DMPK mRNAs containing (CUG)960 or no CUG repeats were expressed in 
HeLa cells to serve as our DM1 cell model and negative control cell, respectively. These 
cells were co-transfected with an IR mini-gene to study the regulation of splicing of IR by 
measuring the relative amounts of its two isoforms. Looking at the transcripts in the DM1 
cell model showed mis-splicing of IR with 35 ± 2 % isoform B (IR-B), whereas 57 ± 1 % 
of IR-B, measured in the negative control cell, was considered the baseline exon 
inclusion. Treatment of the DM1 cell model with a negative control compound, 50 µM 
spermine, had no effect on the IR mis-splicing (Figure 2.11). 
(a) 
 
 Ligand 1 Spermine 
 CUG0 CUG960  50 µM 75 µM 150 µM  50 µM  
+ exon 11 
 
- exon 11 
(b) 
 
Figure 2.11. Negative control ligand, spermine, at 50 µM does not improve the mis-splicing of IR in DM1 cell 
model. a) In this representative gel image of IR alternative splicing, two bands corresponding to IR isoforms 
A (+ exon 11) and B (- exon 11), respectively, are derived by reverse transcription-polymerase chain 
reaction (RT-PCR). DM1 cell model is treated with 1 at 50, 75 and 150 µM and spermine at 50 µM. Note: 
This image is derived from one gel but the lanes of interest have been cut and positioned adjacent to one 
another. b) A plot of the corresponding data shows no change in mis-splicing with spermine at 50 µM. The 
error bars represent mean ± standard error of 4-6 independent measurements for CUG0 and CUG960 cells 
and 3 measurements for spermine-treated cells. 
The splicing assay was repeated with different concentrations of 1 to see if it was 
capable of rescuing the mis-splicing of IR, i.e., increasing the fraction of IR-B (Figure 
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2.12a).46 Thus, the DM1 model cells were treated with 1 at 50, 75 or 150 M for 48 h. A 
rescue of 40% for the IR splicing defect was observed at 75 M with 45 ± 1% IR-B 
measured; two-tailed p-values of 0.002 (Figure 2.12b). 
Similar responses are seen at 50 and 150 µM ligand. A more quantitative approach 
would be needed to demonstrate a dose response. It is noteworthy that cytotoxicity of 1 
was evaluated by sulforhodamine B assay and less than 10% HeLa cell death was 
observed at the highest tested concentration (100 µM) after 24 h (Figure 2.13). 
Cytotoxicity assay was performed according to a previous method.47 98 L of DMEM 
supplemented 10% FBS per well was placed in a 96-well plate. 2 L of 1 with different 
concentrations from 0.5 M to 10 mM were added, five repeats for each concentration. 
100 L of HeLa cell suspension of 10,000 cells per well were added in the 96-well plate. 
The cells were incubated at 37 C for 24 h. 100 L of cold 10% (wt/v) trichloroacetic acid 
were added in each well, followed by incubation at 4 C for 1 h. The cells were washed 
twice with water and then air-dried. The cells were stained with 100 L of 0.0057 % 
(wt/v) sulforhodamine B in 1% acetic acid at room temperature for 30 min. The plate was 
rinsed twice with 1% (v/v) acetic acid to remove unbound stain. The bound protein stain 
 
Figure 2.12. Ligand 1 improves mis-splicing of IR in DM1 cell model. a) A representative gel image of IR 
alternative splicing. Two bands corresponding to IR isoforms A (+ exon 11) and B (- exon 11), respectively, 
are derived by reverse transcription-polymerase chain reaction (RT-PCR). DM1 cell model is treated with 1 
at 50, 75 and 150 µM. b) A plot of the corresponding data shows 40% rescue of mis-splicing at [1] = 75 µM. 
The error bars represent mean ± standard error of 4-6 independent measurements. 
 33 
 
was solubilized in 200 L of 10 mM Tris base, pH 10.5, and left for 30 min. The optical 
intensity was measured at 510 nm using a microplate reader. The cell growth inhibition 
was calculated using the following formula: 
% Cell growth inhibition =       
                                
                                      
        
The data was plotted using Excel. The curves were fitted using Table Curve (Systat).  
 
 
Figure 2.13. Ligand 1 shows less than 10% cytotoxicity in concentrations up to 100 M by the 
sulforhodamine B (SRB) assay.  
MBNL1 Foci Dispersion in Live Cells by 1. Although the reduction in the foci-
containing fixed cells was statistically significant, that experiment represents an indirect 
measurement of the foci dispersion; because with fixed-cell microscopy, we are not 
following the same cell directly over time to observe the dispersion of ribonuclear foci 
upon addition of 1. Thus, to further confirm our observation, we sought to investigate the 
effect of 1 in a live cell, by time-lapse confocal microscopy. 
To monitor drug uptake and foci dispersion in real time, model DM1 cells were 
incubated with 1 at 75 µM and individual live cells were monitored by confocal 
microscopy at several time points. The first observation at time point, t = 0, was made 
immediately before addition of 1 and MBNL1 nuclear foci were clearly present (Figure 
2.14a, t = 0). We found it necessary to use a Petri dish with an imprinted 500 μm grid to 
relocate the cell following the incubation interval.  
The ability to monitor the location of 1 was made possible by the inherent fluorescence 
of the acridine unit. Over time, 1 penetrated the cellular and nuclear membrane and the 
MBNL1 foci gradually dispersed over the entire nucleus (Figure 2.14a, t = 2, 4 and 7 h). 
The intensity of a representative MBNL1 focus (the most intense focus) at these four 
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time points shows this dispersion (Figure 2.14b). A negative control experiment was 
performed at the same time points and conditions but without incubation with 1 (Figure 
2.14c). This negative control confirmed the stability of foci over time as the intensity of 
the GFP-MBNL1 foci was steady (Figure 2.14d). These results provide direct evidence 
of the ability of 1 to enter the cell and nucleus and disperse most of the MBNL1⋅CUG 
aggregates over a 2-4 h period.  
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2.4 Conclusion 
Ligand 1 was developed based on a previously reported in vitro active ligand.27 The in 
vitro activity of 1 was assessed by optical melting and Surface Plasmon Resonance 
(SPR) techniques. Ligand 1 selectively binds to (CUG)12, stabilizes its hairpin structure
 
and inhibits (CUG)12･MBNL1 interaction. The polyamine side-chain, provides full 
aqueous solubility that was absent in the initially reported ligand 2. Ligand 1 penetrates 
the cellular as well as nuclear membrane. The bioactivity of 1 in model DM1 cells was 
studied by FISH technique using confocal microscopy and it was found to significantly 
reduce the number of ribonuclear foci. In splicing experiments, 1 partially rescued the IR 
mis-splicing. Moreover, we studied live DM1 model cells using time-lapse confocal 
microscopy. For the first time, we were able to observe uptake of a small molecular 
inhibitor of the (CUG)12･MBNL1 interaction by single live cells and further see its ability 
to disperse the foci over time. This approach is a powerful way to assess directly the 
effectiveness of small molecules targeted to CUG repeats. The positive results with 
compound 1 suggest that it is a good candidate for further development and therefore, 
toxicity and related studies are underway. 
 
(b) 
 
 
(d) 
 
Figure 2.14. Live cell microscopy demonstrates a direct evidence for MBNL1 foci dispersion with 1. a) Live 
DM1 model cells are treated with 1 (75 µM) at t = 0, immediately after the first image is taken. Fluoresence 
of 1, confirms its penetration to the nucleus. MBNL1 nuclear foci are gradually dispersing over time in two 
cells. Each box shows a 100 m   100 m area. b) Plot of fluorescence intensity of a representative GFP-
MBNL1 focus, corresponding to (a), shows dispersion over time. c) A single live cell shows stability of foci in 
a DM1 cell, in the absence of 1, over the period of 7 h. Each box shows a 100 m   100 m area. d) Plot of 
fluorescence intensity of a representative GFP-MBNL1 focus, corresponding to (c), shows no dispersion 
over time. 
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2.5 Materials and Methods 
MBNL1N, CUG0/960 Plasmid and RNAs. The expression vector pGEX-6p-1/MBNL1N 
was obtained from Maurice S. Swanson (University of Florida, College of Medicine). Wild 
type DMPK-CUG960, DMPK-CUG0 and GFP-MBNL1 mini-genes were obtained from the 
lab of Thomas Cooper (Baylor College of Medicine). The insulin receptor (IR) mini-gene 
was obtained from the lab of Nicholas Webster (University of California, San Diego).  
The MBNL1 used here is MBNL1N containing the four zinc finger motifs of MBNL1 and 
a hexa His tag (C-terminus). MBNL1N is known to bind RNA with a similar affinity as the 
full-length MBNL1 and is commonly used in such studies.48 All the oligonucleotides were 
purchased from Integrated DNA Technology and were HPLC purified. The sequences 
and modifications for RNA constructs used in this study are as follows: 
 (CUG)12 construct for optical melting experiments:  
5’–GCCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGGC–3’ 
(CUG)12 construct for SPR experiments:  
5’–GCCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGGC-TEG-biotin–3’ 
MBNL1N Protein Expression and Purification. Using BL21-CodonPlus(DE3)-RP 
competent cells (Stratagene), the expression of MBNL1N protein was induced with 1 
mM IPTG at OD600 0.6 in LB media with ampicillin for 2 h at 37 
oC. Bacterial cells were 
collected by centrifugation and were then resuspended in a lysis buffer containing 25 
mM Tris-Cl (pH = 8), 0.5 M NaCl, 10 mM imidazole, 2 mM BME, 5% glycerol, 0.1% Triton 
X-100, 2 mg mL-1 lysozyme, 0.1 mM PMSF, 1 µM pepstatin, and 1 µM leupeptin, and 
sonicated six times for 15 s each. The cell pellet was centrifuged, and the supernatant 
was collected and filtered through a 45 µm Millex filter. To purify MBNL1N, Ni-NTA 
agarose was incubated with the lysate for 1 h at 4 oC and washed with a washing buffer 
containing 25 mM Tris-Cl (pH = 8), 0.5 M NaCl, 20 mM imidazole and 0.1% Triton X-100, 
followed by elution with elution buffer of 25 mM Tris-Cl (pH = 8), 0.5 M NaCl, 250 mM 
imidazole and 0.1% Triton X-100. The eluate containing the GST fusion protein was 
dialyzed against 1X PBS buffer for using in SPR analysis. The molecular weight was 
confirmed by MALDI mass spectrometry and the concentration was determined by 
Bradford assay. 
Optical Melting Experiments. The melting temperature of the (CUG)12 was measured 
on a Shimadzu UV2450 spectrophotometer equipped with a temperature controller. The 
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path length of the cuvettes used was 1 cm. The absorbance of 3.3 µM (CUG)12 in 1X 
PBS buffer in the absence and presence of 3.3 and 9.9 µM of 1 was recorded at 260 nm 
with a slit width of 1 nm from 10 oC to 95 oC at a ramp rate of 0.5 oC min-1. Each profile 
for melting temperature analysis was generated by subtracting the absorbance of the 
solution of 1 in 1X PBS buffer from the (CUG)12/1 solution. Melting temperatures were 
determined by fitting the melting curve using Meltwin 3.5 software. 
Surface Plasmon Resonance (SPR) Analysis. All SPR experiments were conducted 
on a streptavidin coated sensor chip using a Biacore 3000 instrument. Streptavidin 
coated research grade sensor chips were preconditioned with three consecutive 1-min 
injections of 1 M NaCl/ 50 mM NaOH before the immobilization was started. 3’-biotin 
labeled (CUG)12 was captured on flow cell 2 (Response Unit, RU, between 100-1100). 
Flow cell 1 was used as a reference. Inhibition analysis was carried out in PBS 1X 
buffer, pH = 7.4, containing 0.05% Tween-20 and 0.2 mg mL-1 (7.4 µM or 580 µM 
nucleotides) bulk yeast t-RNA to confirm the specificity of inhibition. Various 
concentrations of 1 were passed over the immobilized RNA at a rate of 20 µL min-1 for 
300 s. After the initial 150 s, a solution of GST-MBNL1 protein, 650 nM, in the same 
buffer was flowed over the surface for 150 s. The reference-subtracted sensograms 
were obtained by subtracting the measured RU upon injection of PBS buffer from the 
sensograms. After the dissociation phase, the surface was regenerated, with a pulse of 
0.5% SDS and/or 100 mM NaOH, for a few times followed by a buffer wash to 
reestablish baseline. For inhibition studies, the resulting sensograms were set to the 
baseline at t = 150 s to offset the binding of 1 to the immobilized (CUG)12 surface. The 
peak RU at t = 150 s was recorded and converted to the percentage of (CUG)12 bound 
by MBNL1. All values normalized to that measured in the absence of 1. The data points 
were fit to a four parameter logistic curve to determine the apparent IC50 using the 
following equation by Kaleidagraph software: 
𝑌 =
𝑌     𝑌   
 + (
[𝟏]
𝐼𝐶  
) 
+ 𝑌    
where Y is the percentage of (CUG)12 bound by MBNL1, Ymax and Ymin are the maximum 
and minimum of this percentage and n is the Hill coefficient. Two or three separate SPR 
experiments on different sensor chips with different levels of (CUG)12 immobilization 
were carried out to verify that the values are not affected by surface RNA density. 
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FISH (Fluorescence In Situ Hybridization). A total of ca. 120,000 HeLa cells were 
seeded in each well of a 6-well plate on coverslips. After a day, the cells were 
transfected with 500 ng DMPKCUG0 or DMPKCUG960 plasmid and 500 ng GFP-
MBNL1 plasmid using Lipofectamine following the manufacturer’s protocol at cell 
confluence of 7080%.42 After 4 hours, the media was changed and 1 was added to 
each well at different concentrations (20, 50, 75 and 100 M). After two days, the cells 
were fixed with 4% PFA then washed five times with 1X PBS. Fixed cells were 
permeabilized with 0.5% triton X-100 in 1X PBS at room temperature for 5 min. Cells 
were prewashed with 30% formamide in 2X SSC for 10 min at room temperature. Cells 
were probed with FISH probe (1 ng L-1 of Cy3 CAG10 in 30% formamide, 2X SSC, 2 g 
mL-1 BSA, 66 g mL-1 yeast tRNA) for 2 h at 37 °C. Cells were then washed with 30% 
formamide in 2X SSC for 30 min at 37 °C, followed by washing with 1X SSC for 30 min 
at room temperature. The cells were washed twice with 1X PBS and then nuclei were 
stained with 1 M To-Pro-3 and washed twice. Cells were mounted onto glass sides with 
ProLong® Gold. Slides were imaged at RT by LSM 710, AxioObserver confocal 
microscopy equipment using a confocal single photon technique with a plan-Apochromat 
20x/0.8 M27 objective. Image analysis was performed by Axiovision interactive 
measurement. The following table indicates the excitation filters used in these 
experiments.  
Fluorophore Component Excitation wavelength (nm) 
Acridine Ligand 1 405 
GFP MBNL1 488 
Cy3 CUG960 555 
TO-PRO-3 Nucleus 639 
IR Splicing Assay. A total of ca. 120,000 cells were seeded in each well of a 6-well 
plate in DMEM supplemented with 10% FBS, 4.5 g L-1 glucose, L-glutamine and no 
antibiotics. After a day, at about 7080% confluence, the cells were transfected with 500 
ng DMPKCUG0 or DMPKCUG960 plasmid and 500 ng IR mini-gene plasmid using 
Lipofectamine 2000 and Opti-MEM reduced serum medium following the standard 
protocol.42, 49 The cells were incubated at 37 C. After 4 h, the transfection medium was 
replaced by the DMEM medium and the cells were treated with 1 at three different 
concentrations (50, 75, and 150 M). 
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After 48 h, cells were harvested and total RNA were isolated immediately using total 
RNA isolation kit and either stored at -80 C or 1 g of the RNA processed with reverse 
transcription step using iScriptTM cDNA synthesis kit, the reverse transcription product 
was cleaned using Quick Spin kit. Approximately 70 ng of cDNA was used in PCR, 31-35 
cycles (within a linear range) using PCR Master Mix kit following the standard protocol. 
The forward primer was 5’-GTA CCA GCT TGA ATG CTG CTC CT, and the reverse 
primer was 5’-CTC GAG CGT GGG CAC GCT. PCR products were separated on 8% 
PAGE gel in 1 X TBE, stained with EtBr in 15 min, de-stained with water in 15 min and 
observed under Molecular Imager. 
The gel image was analyzed using ImageJ and the data were plotted using 
Kaleidagraph. The p-values were calculated using two-tailed Student t test. 
Live Cell Imaging. A total of ca. 120,000 HeLa cells were grown in an Ibidi 35 mm 
Petri dish with a standard bottom, high walls and an imprinted 500 µm relocation grid. 
After a day, cell confluence reached to about 7080%, cells were tranfected with 500 ng 
DMPKCUG960 plasmid and 500 ng GFP-MBNL1 plasmid using Lipofectamine following 
standard protocol. After 4 h, media were changed and cells were incubated at 37 °C, 5% 
CO2. 24 h post-transfection, ligand 1 was added to final concentration of 75 M. Live-
cell, time-lapse images were taken before addition of 1 as well as at 2, 4 and 7 h time 
points at RT by a LSM 710, AxioObserver confocal microscopy equipment using a 
confocal single photon technique with a plan-Apochromat 20x/0.8 M27 objective. Image 
analysis was performed by Axiovision interactive measurement. For tracking the cells, 
DIC images were acquired simultaneously with the reflected light images using a TPMT 
module after setting the Köhler illumination with a fully opened condenser aperture (0.55 
NA). 
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2.6 Experimental Synthetic Procedures 
Figure 2.15. Synthesis of (6).  
N,N'-((Propane-1,3-diylbis(azanediyl))bis(propane-3,1-diyl))bis(2,2,2-trifluoro 
acetamide) (3). Title compound was synthesized from N,N'-bis(3-aminopropyl)propane-
1,3-diamine as described previously,33 in 77% yield, with minor changes. 1H NMR (500 
MHz, DMSO-d6) δ 9.61 (s, 2H), 8.75 (bs, 2H), 3.29 – 3.23 (m, 4H), 2.98 (t, J = 7.5 Hz, 
4H), 2.92 (t, J = 7.5 Hz, 4H), 1.91 (p, J = 7.8 Hz, 2H), 1.82 (p, J = 7.0 Hz, 4H); 13C NMR 
(125 MHz, DMSO-d6) δ 156.40, 117.08, 44.63, 44.02, 36.61, 25.22, 22.56; m/z LRMS 
(ESI) calculated for [M+H]+: 381.2; found 381.2. 
Di-tert-Butyl propane-1,3-diylbis((3-(2,2,2-trifluoroacetamido)propyl)carbamate) 
(4). Title compound was synthesized as described previously,33, 34 with minor changes. 
The product was purified via flash chromatography (SiO2; CH2Cl2:MeOH, 98:2 to 95:5) in 
85% yield. 1H NMR (500 MHz, DMSO-d6) δ 9.42 (bs, 2H), 3.18 – 3.07 (m, 12H), 1.71 – 
1.60 (m, 6H), 1.37 (s, 18H); m/z LRMS (ESI) calculated for [M+H]+: 581.3; found 581.3. 
Di-tert-Butyl propane-1,3-diylbis((3-aminopropyl)carbamate (5). Title compound 
was synthesized as described previously,33 with minor changes. The product was 
purified via flash chromatography (SiO2; CH2Cl2:MeOH:NH4OH, 80:19:1 to 67:30:2) to 
yield the pure product in 87% yield. 1H NMR (500 MHz, Chloroform-d) δ 3.28 (bs, 4H), 
3.16 (bs, 4H), 2.69 (t, J = 6.4 Hz, 4H), 1.79 – 1.71 (m, 2H), 1.64 (p, J = 6.8 Hz, 4H), 1.45 
(s, 18H); 13C NMR (125 MHz, Chloroform-d) δ 155.29, 79.06, 44.44, 38.96, 32.34, 31.73, 
28.17; m/z LRMS (ESI) calculated for [M+H]+: 389.3; found 389.3. 
3 
5 6 
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tert-Butyl (3-((3-acetamidopropyl)(tert-butoxycarbonyl)amino)propyl)(3-amino 
propyl) carbamate (6). Compound 5 (1.1 g, 2.83 mmol, 1 equiv.) was dissolved in THF 
(15 mL). A 0.5 M solution of 9-Borabicyclo(3.3.1)nonane (5.66 mL, 2.83 mmol, 1 equiv.) 
was added and the reaction was stirred at room temperature for 3 hours.35 Acetic 
anhydride (275 mg, 2.68 mmol, 0.95 equiv.) was added and the reaction was allowed to 
proceed at room temperature overnight. The reaction was quenched with water (10 mL) 
and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over 
magnesium sulfate and filtered through celite. The solution was concentrated by rotary 
evaporation, purified via flash chromatography (SiO2; CH2Cl2:MeOH:NH4OH, 94:5:0.5 to 
89:10:1) to afford 6 (1.154 g, 26%). 1H NMR (500 MHz, Chloroform-d) δ 3.32 – 3.10 (m, 
10H), 2.71 (t, J = 6.7 Hz, 2H), 1.98 (s, 3H), 1.82 (s, 2H), 1.78 – 1.72 (m, 2H), 1.69 – 1.64 
(m, 2H), 1.44 (s, 18H); m/z LRMS (ESI) calculated for [M+H]+: 431.3; found 431.3. 
 
Figure 2.16. Synthesis of 9-oxo-9,10-dihydroacridine-4-carboxylic acid (8).  
2,2'-Azanediyldibenzoic acid (7). Title compound was synthesized as described 
previously,36 in 91% yield, with minor changes in the work-up procedure. 1H NMR (500 
MHz, DMSO-d6) δ 7.91 (dd, J = 7.9, 1.3 Hz, 2H), 7.50 – 7.40 (m, 4H), 6.95 (ddd, J = 8.0, 
6.8, 1.5 Hz, 2H); 13C NMR (100 MHz, DMSO-d6) δ 168.41, 143.58, 133.38, 131.81, 
119.99, 117.56, 113.56; m/z LRMS (ESI) calculated for [M+H]+: 258.1; found 258.1. 
9-Oxo-9,10-dihydroacridine-4-carboxylic acid (8). Title compound was synthesized 
as described previously,36 in 95% yield, with minor changes in the work-up procedure. 1H 
NMR (400 MHz, DMSO-d6) δ 12.01 (bs, 1H), 8.53 (dd, J = 8.0, 1.5 Hz, 1H), 8.45 (dd, J = 
7.5, 1.6 Hz, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.83 – 7.73 (m, 2H), 7.41 – 7.29 (m, 2H); 13C 
NMR (126 MHz, DMSO-d6) δ 176.53, 169.14, 141.20, 139.92, 136.90, 134.11, 132.41, 
125.89, 122.32, 121.63, 120.60, 120.24, 118.63, 115.01 m/z LRMS (ESI) calculated for 
[M+H]+: 240.1; found 240.1. 
8 
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 Figure 2.17. Synthesis of (1).  
tert-Butyl (3-((3-acetamidopropyl)(tert-butoxycarbonyl)amino)propyl)(3-(9- 
Chloroacridine-4-carboxamido)propyl)carbamate (9). A round-bottom flask, equipped 
with a stir bar, was charged with 8 (600 mg, 2.5 mmol, 1 equiv.) and freshly distilled 
thionyl chloride (3 mL, 41 mmol, 16.4 equiv.). A catalytic amount of DMF was added and 
heated gently under reflux at 69 °C, stirring until homogeneous and then for 1 h. The 
excess thionyl chloride was distilled off and the last traces of it were removed 
azeotropically via co-evaporation with DCM (3 x 50 mL). It was left under vacuum 
(minimally) for 1 h to afford the crude intermediate as a yellow powder. The crude 
intermediate was dissolved in anhydrous DCM. Anhydrous triethylamine was added to 
the solution until the pH was 11 and it was cooled to 0 °C. Compound 6 (1.065 g, 2.75 
mmol, 1.1 equiv.) was added and the solution was stirred at 0 °C for 2 hours and slowly 
warmed to room temperature overnight. The solvent was removed by rotary evaporation 
and the crude mixture was purified via flash chromatography (SiO2; CH2Cl2:MeOH, 98:2 
to 95:5) to yield 9 as a yellow solid (586 mg, 60%); m/z LRMS (ESI) calculated for 
[M+H]+: 670.3; found 670.3. 
tert-Butyl(3-((3-acetamidopropyl)(tert-butoxycarbonyl)amino)propyl)(3-(9-((4-
((4,6-di-amino-1,3,5-triazin-2-yl)amino)butyl)amino)acridine-4-carboxamido)propyl) 
carbamate (10). A round-bottom flask, equipped with a stir bar, was charged with 9 (500 
mg, 0.576 mmol, 1 equiv.) and of N-(4-Aminobutyl)-[1,3,5]triazine-2,4,6-triamine (125 
9 
1 
10 
8 
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mg, 0.635 mmol, 1.1 equiv.). DIPEA (163 mg, 1.26 mmol, 2.2 equiv.) and anhydrous 
DMF (25 mL) were added. The solution was heated at 70 °C for 5 hours. The solvent 
was removed by rotary evaporation and the product was purified via flash 
chromatography (Basic Alumina; DCM:Methanol:NH4OH, from 95:4.9:0.1 to 90:9.5:0.5) 
to yield 10 as a yellow solid (377 mg, 0.317 mmol, 55%); m/z LRMS (ESI) calculated for 
[M+H]+: 831.5; found 831.5. 
N-(3-((3-((3-Acetamidopropyl)amino)propyl)amino)propyl)-9-((4-((4,6-diamino-
1,3,5-triazin-2-yl)amino)butyl)amino)acridine-4-carboxamide (1). A round-bottom 
flask, equipped with a stir bar, was charged with 10 (310mg, 0.261 mmol, 1equiv.). TFA 
(30 mL) and anhydrous DCM (70 mL) were added and stirred at room temperature for 6 
h. The solvents were removed to yield 1 as a yellow solid (437 mg, 0.261 mmol, 100%). 
1H NMR (500 MHz, Deuterium Oxide) δ 8.33 (d, J = 8.6 Hz, 1H), 8.16 (dd, J = 13.0, 8.0 
Hz, 2H), 7.90 – 7.84 (m, 2H), 7.58 (d, J = 8.5 Hz, 1H), 7.46 (t, J = 7.9 Hz, 2H), 4.02 (t, J 
= 6.7 Hz, 2H), 3.56 (t, J = 7.0 Hz, 2H), 3.29 – 3.10 (m, 10H), 3.06 – 3.03 (m, 2H), 2.14 – 
2.06 (m, 4H), 1.96 (s, 3H), 1.93 – 1.85 (m, 4H), 1.70 – 1.63 (m, 2H); 13C NMR (125 MHz, 
Deuterium Oxide) δ 174.89, 168.78, 165.12, 163.37, 163.09, 162.80, 162.52, 159.99, 
159.45, 158.02, 156.64, 136.13, 134.88, 120.06, 119.18, 118.71, 117.74, 115.41, 113.09, 
48.84, 45.74, 45.38, 44.74, 40.38, 37.07, 36.16, 31.59, 25.78, 24.87, 22.89, 21.91; m/z 
HRMS (ESI) calculated for [M+H]+: 631.3945; found 631.3944. 
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Chapter 3.  
The Bivalent Ligand Approach Leads to a 
Bioactive Inhibitor of MBNL1·CUGexp Complex  
3.1 Abstract 
An expanded CUG repeat (CUGexp) is the causative agent of myotonic dystrophy type 
1 (DM1) by sequestering muscleblind-like 1 protein (MBNL1), a regulator of alternative 
splicing. Inhibition of the pathologic 
MBNL1·CUGexp interaction by 
targeting aberrant CUGexp is the 
most reliable approach in DM1 
drug discovery efforts thus far. 
Herein, we present the design, synthesis and in vitro and cell-based evaluation of a 
small library of dimeric ligands based on a ligand that was previously reported to be 
active in an in vitro assay. This library includes 10 dimeric ligands that differ in length, 
composition and attachment point of the linking chain. From the results of in vitro 
assays, we propose that the potency of dimeric ligands depends on the composition 
more than the length of spacer. Oligoamino spacers give a greater gain in affinity to 
CUGexp as well as greater inhibition potency of MBNL1·CUGexp interaction. The most 
potent in vitro ligands were further evaluated in a DM1 cell model. The optimized 
bivalent ligand was an aqueous-soluble and cell permeable ligand that displayed almost 
complete dispersion of CUGexp foci. For direct proof of its bioactivity, we evaluated its 
activity by tracking a live DM1 cell model. This ligand was able to disperse MBNL1 from 
CUGexp foci in individual live DM1 model cells using time-lapse confocal fluorescence 
microscopy. 
3.2 Introduction 
Previously, ligand 1 was reported as a modest (CUG)12·MBNL1 inhibitor (IC50 = 46 µM) 
in an in vitro assay.1 However, this ligand had two shortcomings: Modest inhibition 
potency and more importantly, cell impermeability.  
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Considering the repeating nature of CUGexp, one approach to increase the affinity of 
this ligand to CUGexp is the generation of multivalent ligands.2, 3 The multivalent effect 
has been previously proven useful to increase the binding affinity of ligands toward a 
wide variety of multivalent targets including CUGexp.4-12 Another advantage of multivalent 
ligands is their potential to become cell-permeable, with appropriate spacers. 
Development of a bioactive multivalent ligand has some obstacles such as large size 
and molecular weight.12 This is a serious drawback in terms of drugability. For example, 
previously Hoechst 33528 tetramer and pentamers have been developed as inhibitors 
for this interaction but were found insoluble and cell-impermeable.13 Therefore this 
strategy is limited mostly to dimeric ligands with moderate molecular weights. The 
increase in affinity, attributed to dimeric ligands, arises from the thermodynamic 
advantage inherent in a cooperative binding system.3, 14 In other words, the overall 
entropy of the ligand·CUGexp complex is significantly lowered by having the second 
binding module localized in the vicinity of its respective binding site, upon binding of the 
first module.2 
The possibility of gaining increased selectivity and potency through the use of dimeric 
ligands is an attractive pathway that is becoming more prevalent in drug discovery 
efforts.15-20 For almost all cases, due to entropic and enthalpic costs of bivalent binding, 
the bivalent effect is less than ideal, i.e., square binding constant.2 On one hand, 
conformational rigidity can cause spatial mismatch and diminish the binding enthalpy of 
the second module. On the other hand, conformational flexibility can cause high 
enthropic cost for the binding of the second module. Therefore, both rigidity and flexibility 
can potentially diminish the bivalent effect. So it is essential to have the right spacer to 
maximize the bivalent effect. To accomplish this goal, without a structural knowledge of 
the binding mode, a small library of dimeric ligands was considered necessary. 
Therefore, we pursued the rational design of a small library of dimeric ligands based on 
1.  
For the dimeric ligands to be cell-permeable, the composition of the spacers 
incorporated into the dimeric ligands play an important role. A successful combination of 
bivalent effect and drugability can yield an optimized dimeric ligand with increased 
potency and cell-permeability. 
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3.3 Results and Discussion  
Rational Design and Synthesis of dimeric ligands: The design of a dimeric ligand 
requires the following selections: (1) a monomeric ligand with a modest affinity and 
selectivity for CUGexp (2) an appropriate handle, that would not interfere with the 
ligand·CUGexp interaction, for the attachment of the spacer to the monomeric ligand, and 
(3) an appropriate spacer to connect the two monomers so that each module can bind to 
CUGexp. From the previous studies in our lab, it was determined that 1 is a modest 
inhibitor for (CUG)12·MBNL1 (IC50 = 46 µM) with over 50 fold selectivity for (CUG)4 
relative to a random duplex.1 The covalent linkage of 1 to a spacer required attachment 
of a handle to it. The three possible sites for covalent modification of 1 were the acridine 
ring, the triaminotriazine recognition unit or the linking chain between these two 
components. Modification of the recognition unit is not favored due to possible 
interruption of hydrogen binding to UU mismatches. However, various bis-acridine 
intercalators spanning 2 or more base pairs, have been synthesized and studied 
before.21-25 The most expeditious synthetic approach utilized an acridine ring containing 
a carboxylic acid group to connect two units through a spacer. Positioning the carboxylic 
acid handle in either position 1 or 3 in the acridine ring is not synthetically feasible 
because the synthetic route yields an inseparable mixture of both.26 The remaining two 
positions of the acridine ring, i.e., positions 2 and 4, are synthetically attractive points for 
the preparation of dimeric ligands because by positioning the spacer and triaminotriazine 
recognition units on the same (2-carboxamido derivatives) or the opposite (4-
carboxamido derivatives) sides of the acridine unit, the dimeric complex likely requires a 
non-threading or threading mechanism of binding, respectively, which increases the 
diversity of our library. It was found that the chloro- and methoxy-groups in 1 could be 
replaced with a 2- or 4-carboxamido group (see 2 and 3 in Figure 3.1, respectively) 
without reducing its affinity for CUG repeat or its inhibition potency of the MBNL1·CUG 
complex. 
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Figure 3.1. Library of synthesized dimeric ligands 4-13  
Terminal diamine compounds were selected as the spacers for the synthesis of 
dimeric ligands, as they possess the desired functionality to form a stable amide bond to 
the carboxylic acid handle on the acridine ring.27, 28 A rigid spacer can result in an ’all or 
nothing’ effect;29 whereby an appropriately designed rigid spacer increases the 
concentration of the second binding module at the UU mismatch site and an 
inappropriate spacer diminishes the binding of the second module. Without structural 
data for the binding mode, the spacer should be flexible enough to allow bivalent 
binding.  
The polarity of the spacer is another important consideration when designing the 
dimeric ligands because solubility issues may arise from the inclusion of a 
polymethylene chain. The original monomeric ligand is not aqueous soluble, so 
polyamide and polyalkyl chains were ruled out as potential spacers because they can 
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become increasingly hydrophobic with increasing length. Thus, heteroatom-rich spacers, 
oligoamino or oligoether terminal diamines with various lengths from 10 to 21 atoms, 
were designed. Oligoethers consisted of oligoethylene or oligopropylene glycols. 
Oligoamino linkers can introduce positive charge to the dimeric ligand and increase its 
affinity to the polyphosphate backbone.30 Spacers were designed so that they span two 
central GC base-pairs according to the nearest site exclusion principle and the two 
binding modules (triaminotriazine rings) could potentially bind to consecutive CUG sites. 
Although the binding mode was not firmly established for 1,31 it was designed to act as a 
“stacked intercalator” with the acridine and triaminotriazine rings π-stacked whereas the 
intercalator sits between the GC base pair and the U-triaminotriazine-U base triplet.1 
Two series of dimeric ligands at distinct attachment points were synthesized as 
shown in Figure 3.2 which shows the general route for synthesis of the dimeric ligands. 
Spacers were either commercially available or synthesized as shown in Schemes 3.1-
3.8 (See the Experimental Synthetic Procedures). 
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a
Reagents and conditions: (a) SOCl2, DMF (Cat.), 70 °C 2 h; (b) DCM, NEt3, 0 °C to RT, 15 h; 60-78%; (c) 
DMF, DIPEA, 80 °C, 6 h; 55-75%; (d) CF3COOH, DCM, RT, 6 h, 100%. 
Figure 3.2. General synthetic scheme for dimeric ligands 
Optical Melting Experiments. It has been proposed that MBNL1 displays a 
preference for single stranded (ss) CUGexp, and, thus, destabilizes the double stranded 
(ds) CUGexp upon binding.32, 33 If this model is correct, any ligand that stabilizes the ds 
form of CUGexp may prove a more effective inhibitor of the MBNL1·CUGexp interaction. 
The increase in (CUG)12 melting temperature upon ligand binding correlates with the 
(CUG)12 stem loop stability, therefore we studied the effect of ligands on the Tm of 
(CUG)12. Ligands 4, 5 and 6 were not fully soluble in the reaction condition; therefore we 
could not get any ∆Tm for them. We carried out thermal denaturation study of (CUG)12, in 
the presence of 1 equivalent of other ligands. Monophasic melting curves were obtained; 
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∆Tm values are shown in table 3.1. For the monomeric ligands, 2, ∆Tm was 1.8 °C. For 
two of oligoether-spacer containing dimeric ligands, 7 and 8, ∆Tm was 2.7 and 1.8 °C 
respectively, close to that of the monomeric ligand, suggesting these ligands are binding 
to (CUG)12 only with one of their binding modules. This can be explained by the possible 
coil-like conformation of oligoethylene glycol spacers,34 which prevents the desired 
distance between binding modules. Oligopropylene glycol spacer in 6 was designed to 
prevent this coil-like conformation however it happened to be aqueous insoluble. Three 
oligoamino-spacer containing dimeric ligands, 9, 10 and 11, had a higher ∆Tm of 9.3, 9.6 
and 8.4 °C, respectively, suggesting a bivalent binding to (CUG)12 and a greater 
stabilization of the ds form of (CUG)12. This finding suggests that 9, 10 and 11, unlike 7 
and 8, have the right type of spacer to bind to (CUG)12 by two binding modules and 
stabilize the ds form of (CUG)12 to a greater extent relative to the corresponding 
monomer. This finding shows the importance of the composition of the spacer is greater, 
rather than the number of atoms. Oligoethylene glycol spacers with similar numbers of 
atoms to oligoamino spacers failed to give the dimeric ligands the same ∆Tm value. 
Although this is an encouraging result, ∆Tm is considered a qualitative parameter. 
Table 3.1. ∆Tm value of (CUG)12 
upon adding ligand in a 1:1 ratio. 
Ligand Solution ∆Tm(°C) 
2 5% DMSO 1.8 ± 0.6 
7 5% DMSO 2.7 ± 0.4 
4 Insoluble ______ 
12 5% DMSO N.D. 
13 5% DMSO N.D. 
5 Insoluble ______ 
8 5% DMSO 1.8 ± 0.2 
6 Insoluble ______ 
9 Aqueous 9.3 ± 0.6 
10 Aqueous 9.6 ± 1.3 
11 Aqueous 8.4 ± 2.1 
Steady State Fluorescence Studies. To measure the binding affinity of the ligands 
to CUG repeat, a steady state fluorescence titration method with TAMRA-(CUG)6 was 
utilized. It is known that guanosine quenches the TAMRA fluorescence through 
photoinduced electron transfer.35, 36 Therefore, it is possible that binding of a ligand to 
the UU mismatch close to 5’-TAMRA makes a structural change that can lead to 
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quenching of the 5’-TAMRA by the 3’-G in 5’-TAMRA-(CUG)6 -3’. Ligands were titrated 
into TAMRA-(CUG)6 solution. Upon increasing the ligand concentration, TAMRA 
fluorescence intensity gradually decreased as a result of fluorophore quenching by the 
bound ligand. A plot of normalized fluorescence intensity versus increased 
concentrations of each ligand yielded a binding isotherm and KD value (Figure 3.3) which 
show a trend similar to the ∆Tm. 
Two of the dimeric ligands with oligoether-type spacers were evaluated. Ligand 12 
gave a KD close to the monomeric ligand 2 and 7 showed only 3-fold decrease in KD. 
Whereas dimeric ligands with oligoamino-type spacer, 11, 10 and 9, show 14, 17 and 
206 fold decrease in KD, respectively. Although 9 and 10 have the same atom numbers, 
the greater binding affinity of 9 might be because of the electrostatic interaction of the 
correctly positioned amino group in the spacer with the polyphosphate backbone of 
TAMRA-(CUG)6.
30 
(a) (b) 
 
 
Ligand KD(µM) 
7 23 ± 3 
12 75 ± 10 
2 66 ± 1 
9 0.32 ± 0.02 
10 3.8 ± 0.3 
11 4.8 ± 0.7 
Figure 3.3. a) Fluorescence titrations of TAMRA-(CUG)6 with ligands. Comparison of normalized 
fluorescence intensity change of TAMRA-(CUG)6 in the presence of increasing concentrations of ligands. 
TAMRA was excited at 560 nm and its emission was recorded at 590 nm. Error bars represent mean ± s.d. 
of three replicates. b) KD was derived by fitting the Fluorescence intensities at different concentrations of 
ligands into the following equation:  =
        
  (
  
[ ]
) 
+    
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Inhibition of MBNL1·CUG Interaction Using a SPR-Based Biosensor. Because 
SPR technique is particularly well suited for quantifying the binding of proteins to a target 
on the SPR chip, we developed a simple SPR-based method to directly measure 
MBNL1 complexation of (CUG)12 in real time under equilibrium condition and in a label-
free format. Further, we were able to quantify the inhibition potency of ligands. To rule 
out non-specific inhibition due to aggregation and non-selective RNA binding the assays 
were performed in the presence of Tween-20 and excessive competitor t-RNA.37 Thus, 
biotinylated (CUG)12 was immobilized on a streptavidin coated SPR sensor chip and 
incubated with different concentrations of each ligand to reach a steady state response 
units (RU) over 150 s. The response to the binding of each ligand was negligible in 
comparison to protein binding so the direct contribution of each ligand could be ignored. 
Successive injections of a 0.65 µM solution of MBNL1 containing the same 
concentration of each ligand as in the pre-incubation, led to varying responses 
depending on the concentration of each ligand. Because the SPR signal directly reflects 
the binding of MBNL1 to the biotinylated (CUG)12, the differences in the response curves 
are a direct result of inhibition by each ligand. The maximum RU at 150 s was recorded 
for each concentration of ligands and converted to the fraction of (CUG)12 bound by 
MBNL1, all values normalized to that measured in the absence of each ligand. Fitting the 
data points in the plot of %(CUG)12 bound by MBNL1 versus increasing concentrations 
of each ligand (Figure 3.4a) gave an apparent IC50 value for each ligand (Figure 3.4b).  
Normalized IC50 values can be calculated by dividing the actual IC50 by the number 
of binding modules it has. The ratio between normalized IC50 values of monomeric and 
dimeric ligand is called bivalent effect. The IC50 values (Figure 3.4) show that more than 
the spacer length, its composition is critical for an optimal bivalent effect. The dimeric 
ligands with oligoether-type spacer, 13, 8, 12 and 7, show a small bivalent effect of 3, 4, 
5 and 8, respectively, whereas dimeric ligands with oligoamino-type spacer, 9, 10, 11, 
show a large bivalent effect of 24, 29 and 133, respectively. 
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(a) (b) 
 
 
Ligand IC50 (µM) Bivalent effect 
7 18 ± 1 8 
12 28 ± 12 5 
2 293 ± 19 N.A. 
9 1.1 ± 0.1 133 
13 43 ± 4 3 
8 37 ± 6 4 
10 6 ± 3 24 
11 5 ± 2 29 
Figure 3.4. a) Fitting the response unit data in the plot of % (CUG)12 bound by MBNL1 versus increasing 
concentrations of each ligand to a dose-response curve by SPR assay. b) IC50 values and bivalent effects 
were derived. Error bars represent mean ± s.d. of three replicates. 
These in vitro experiments demonstrate that 9 can bind to (CUG)12, stabilize the 
hairpin structure and inhibit the (CUG)12･MBNL1 interaction, selectively. It is noteworthy 
that all of the in vitro experiments above were carried out with (CUG)12 in 1X PBS buffer. 
This particular buffer was chosen because it is the closest of common buffers to 
physiological conditions. It is also a more challenging buffer for small molecule inhibitors 
because it increases the (CUG)12･MBNL1 stability. 
Ligand 9 is active in nuclear foci dispersion in CUG repeat-transfected cells. 
After successful in-vitro studies, we sought to study the most potent dimeric ligands, 9, in 
cell-based assays. Two other dimeric ligands, 5 and 11, and the corresponding 
monomeric ligand, 2, were studies for a comparison. Spermine, which has a similar 
structure to the spacer in 9, was studies as a negative control. We studied cytotoxicity of 
9 as well as 2 in HeLa cells and both showed IC50 values higher than 100 µM by 
Sulforhodamine B in 24 hours. The cellular permeability of 9 as well as 2, 5 and 11 was 
tested by fluorescence microscopy tracking the fluorescence of acridine ring in the 
ligands. We found that 9 and 5 are cell-permeable whereas 2 and 11 are not (Figure 3.5, 
column 2). 
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(a) TO-Pro-3/ Nucleus Acridine/ Ligand Cy3-(CAG)10/ CUG
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Figure 3.5. a) Confocal fluorescent images show CUG
exp
 foci in DM1 model cells are present in rows 2-6, no 
ligand treatment, treated with spermine (negative control), 2, 9 and 5, respectively. CUG
exp
 foci are not 
present in negative control cells, row 1, as well as row 7 where DM1 cell model is treated with 9, for 48 h. b) 
Plot of CUG
exp
 foci-containing cell fraction at various concentrations of ligands. These data are gathered 
from scoring over 100 cells. The error bars represent mean ± standard error of at least three independent 
experiments. 
CUG960-trasfected HeLa cells were used as our DM1 model cells. They were treated with 
three different concentrations, 20, 35 and 50 µM, of each ligand for 36 h followed by 
Fluorescence in situ hybridization (FISH) study with Cy3-CAG10 probe. This probe 
targets CUG960 nuclear foci and its fluorescence was tracked by confocal fluorescence 
microscopy. We found 2, 5 and 11, and our negative control, Spermine, show no 
significant foci dispersion in any concentration; however we observed partial foci 
+
 9
 (
3
5
µ
M
) 
    
 
(b) 
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dispersion for 9 at 20 µM and 35 µM and full foci dispersion for 9 at 50 µM concentration 
(Figure 3.5a, column 3). This study of the foci-containing fixed cells was a statistical 
comparison and represents an indirect measurement of the foci dispersion by ligands. 
Figure 3.6. HeLa cells transfected with CUG0 served as our negative control cell. 
TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
120 0 (0%) 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
32 8 (25%) 
Figure 3.7. HeLa cells transfected with CUG960 served as our DM1 cell model. 
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Figure 3.8. DM1 cell model treated with Spermine (negative control compound), 50 µM.  
 
 
 
 
 
TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
64 17 (26.5%) 
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Total number of cells Number and percentage of foci containing cells 
51 8 (15.7%) 
Figure 3.9. DM1 cell model treated with 2, 20 µM. 
 
 
 
 
TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
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Total number of cells Number and percentage of foci containing cells 
67 11 (16.4%) 
Figure 3.10. DM1 cell model treated with 2, 35 µM. 
 
 
 
 
TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
58 12 (20.7%) 
Figure 3.11. DM1 cell model treated with 2, 50 µM. 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
43 7 (16.3%) 
Figure 3.12. DM1 cell model treated with 5, 20 µM. 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
27 5 (18.5%) 
Figure 3.13. DM1 cell model treated with 5, 35 µM. 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
32 8 (25%) 
Figure 3.14. DM1 cell model treated with 11, 20 µM. 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
38 7 (18.4%) 
Figure 3.15. DM1 cell model treated with 11, 35 µM. 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
15 3 (20%) 
Figure 3.16. DM1 cell model treated with 11, 50 µM. 
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Total number of cells Number and percentage of foci containing cells 
35 3 (8.6%) 
Figure 3.17. DM1 cell model treated with 9, 20 µM. 
 
 
 
 
TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
38 2 (5.3%) 
Figure 3.18. DM1 cell model treated with 9, 35 µM.. 
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TO-Pro-3/ Nucleus Acridine/ Ligand 
  
Cy3-(CAG)10/ CUG
exp
 Merged 3 channels 
  
Total number of cells Number and percentage of foci containing cells 
32 0 (0%) 
Figure 3.19. DM1 cell model treated with 9, 50 µM. 
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Ligand 9 is active in MBNL1 foci dispersion in Live DM1 cell microscopy. FISH 
experiment was performed on fixed cells which compared ligand-treated cells with 
untreated ones, indirectly. Because the effect of 9 is an indirect measurement of its 
activity, we sought to study its activity, directly in a single live DM1 model cell. Live cells 
were tracked in a Petri dish with an imprinted 500 μm grid, to relocate the cell following 
the incubation interval, and incubated with 9 at 50 µM at t = 0 and monitored by confocal 
microscopy at several time points (Figures 3.21 and 3.22). The first observation at time 
point, t = 0, was made immediately before addition of 9 and MBNL1 nuclear foci were 
clearly present (Figure 3.20a, t = 0). The ability to monitor the location of 9 was made 
possible by the inherent fluorescence of the acridine unit. Over time, 9 penetrated the 
cellular and nuclear membrane and the MBNL1 foci gradually dispersed o the nucleus 
(Figure 3.20a, t = 3, 6 and 10 h). To validate that foci are dispersed over the entire 
nucleus a Z-stacked image, containing 1 μm-apart slices from the whole DM1 model cell, 
was obtained which confirmed almost all the foci are dispersed over the entire nucleus at 
t = 10 h, upon treatment with 9 at 50 µM (Figure 3.23). As a negative control, to rule out 
the possibility of spontaneous MBNL1 foci dispersion over time, DM1 model cell without 
ligand treatment was studied the same way. The stability of foci was confirmed by the 
presence of foci in all the time points (Figure 3.20b). It is noteworthy that the increase in 
cell size and number of MBNL1 foci is caused by natural growth of live cells and 
continuous expression of GFP-MBNL1 in real time. To compare MBNL1 nuclear foci in 
untreated cells with 9-treated cells a Z-stacked image, containing 1 μm apart slices, from 
the whole cell was obtained which confirmed that several number of foci are present at 
different slices of the untreated cell (Figure 3.24). 
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Figure 3.20. Live cell microscopy demonstrates a direct evidence for MBNL1 foci dispersion with 9. a) Live 
DM1 model cells are treated with 9 (50 µM) at t = 0, immediately after the first image is taken. Fluoresence 
of 9, confirms its penetration to the nucleus. MBNL1 nuclear foci are gradually dispersing over time in two 
cells. b) Two live cell shows stability of foci in a DM1 cell, in the absence of 9, over the period of 10 h. Each 
box shows 120 µM X 120 µM. 
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 Acridine/ Ligand GFP/ MBNL1 Merged channels/ DIC 
t 
=
 0
 
   
t 
=
 3
 h
 
   
t 
=
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 h
 
   
t 
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0
 h
 
   
Figure 3.21. Merged channels of two DM1 cells treated with 9 (50 µM), corresponding to two cells in Figure 
3.20a are combined with the DIC channel to show the absolute position of each individual cell. Each box 
shows 200 µM X 200 µM. 
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 Acridine/ Ligand GFP/ MBNL1 Merged channels/ DIC 
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Figure 3.22. Merged channels of two untreated DM1 cells, corresponding to Figure 3.20b are combined with 
the DIC channel to show the absolute position of each individual cell. Each box shows 200 µM X 200 µM. 
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1 2 3 
4 5 6 
7 8 9 
10 11 12 
Figure 3.23. Z-stacked image of two DM1 cells treated with 9 (50 µM) at t = 10 h, corresponding to two cells 
in the last row of figure 3.20a. It contains 12 Slices,1 µM apart from each other. Almost all MBNL1 foci are 
dispersed throughout the nuclei at t = 10 h. Each box shows 120 µM X 120 µM. 
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1 2 3 
4 5 6 
7 8 9 
10 11 12 
Figure 3.24. Z-stacked image of two untreated DM1 cells at t = 10 h, corresponding to two cells in the last 
row of figure 3.20b. It contains 12 Slices,1 µM apart from each other. Many MBNL1 foci are present in the 
nuclei at t = 10 h. Each box shows 120 µM X 120 µM. 
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3.4 Conclusion 
To improve the potency and drugability of a previously reported hit molecule we 
applied a dimeric ligand approach to target CUG repeat. Limited by the absence of 
structural data on the ligand･CUGexp complex, we designed and synthesized a small 
library of dimeric ligands that could potentially bind to consecutive CUG sites. This small 
library consisting of 10 dimeric ligands varied in composition, length and attachment 
point of spacer. These ligands were assessed for their binding potency to (CUG)12 as 
well as inhibition potency of (CUG)12·MBNL1 interaction. We found the bivalent effect 
depends more on the composition of the spacer rather than the length of it. Dimeric 
ligands with oligoamino spacers were the most potent ones, whereas the dimeric ligands 
containing oligoether spacers, with the same or similar number of atoms, improved the 
binding and inhibition potency to a much lesser extent. Moreover, short oligoamino 
spacers made the dimeric ligands aqueous soluble whereas those containing oligoether 
spacers were aqueous insoluble. Among four dimeric ligands containing oligoamino 
spacers 9 was the most potent ligand by in vitro assays. In cell-based assays 9 was low-
cytotoxic (IC50> 75 µM) and bioactive at 35 µM. To obtain a direct evidence of its 
bioactivity, we studied 9 by time-lapse confocal fluorescence microscopy and observed a 
gradual MBNL1 foci dispersion in individual live DM1 model cells at 50 µM over 10 h. To 
validate that foci are dispersed over the entire nucleus a Z-stacked image, containing 1 
μm-apart slices from the whole DM1 model cell, was obtained which confirmed almost all 
the foci are dispersed over the entire nucleus at t = 10 h, upon treatment with 9 at 50 
µM. The positive results with 9 suggest that it is the optimized dimeric ligand and a good 
candidate for further lead development. 
 3.5 Materials and Methods 
MBNL1N, CUG0/960 Plasmid and RNAs. The expression vector pGEX-6p-
1/MBNL1N was obtained from Maurice S. Swanson (University of Florida, College of 
Medicine). Wild type DMPK-CUG960, DMPK-CUG0 and GFP-MBNL1 mini-genes were 
obtained from the lab of Thomas Cooper (Baylor College of Medicine). The insulin 
receptor (IR) mini-gene was obtained from the lab of Nicholas Webster (University of 
California, San Diego).  
The MBNL1 used here is MBNL1N containing the four zinc finger motifs of MBNL1 
and a hexa His tag (C-terminus). MBNL1N is known to bind RNA with a similar affinity as 
 95 
 
the full-length MBNL1 and is commonly used is such studies.38 All the oligonucleotides 
were purchased from Integrated DNA Technology and were HPLC purified. The 
sequences and modifications for RNA constructs used in this study are as follows: 
 (CUG)12 construct for optical melting experiments:  
5’–GCCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGGC–3’ 
(CUG)12 construct for SPR experiments:  
5’–GCCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGGC-TEG-biotin–3’ 
MBNL1N Protein Expression and Purification. Using BL21-CodonPlus(DE3)-RP 
competent cells (Stratagene), the expression of MBNL1N protein was induced with 1 
mM IPTG at OD600 0.6 in LB media with ampicillin for 2 h at 37 
oC. Bacterial cells were 
collected by centrifugation and were then resuspended in a lysis buffer containing 25 
mM Tris-Cl (pH = 8), 0.5 M NaCl, 10 mM imidazole, 2 mM BME, 5% glycerol, 0.1% 
Triton X-100, 2 mg mL-1 lysozyme, 0.1 mM PMSF, 1 µM pepstatin, and 1 µM leupeptin, 
and sonicated six times for 15 s each. The cell pellet was centrifuged, and the 
supernatant was collected and filtered through a 45 µm Millex filter. To purify MBNL1N, 
Ni-NTA agarose was incubated with the lysate for 1 h at 4 oC and washed with a 
washing buffer containing 25 mM Tris-Cl (pH=8), 0.5 M NaCl, 20 mM imidazole and 
0.1% Triton X-100, followed by elution with elution buffer of 25 mM Tris-Cl (pH = 8), 0.5 
M NaCl, 250 mM imidazole and 0.1% Triton X-100. The eluate containing the GST 
fusion protein was dialyzed against 1X PBS buffer for using in SPR analysis. The 
molecular weight was confirmed by MALDI mass spectrometry and the concentration 
was determined by Bradford assay. 
Optical Melting Experiments. The melting temperature of the (CUG)12 was 
measured on a Shimadzu UV2450 spectrophotometer equipped with a temperature 
controller. The path length of the cuvettes used was 1 cm. The absorbance of 3.3 µM 
(CUG)12 in 1X PBS buffer in the absence and presence of 3.3 µM of each was recorded 
at 260 nm with a slit width of 1 nm from 10 oC to 95 oC at a ramp rate of 0.5 oC min-1. 
Each profile for melting temperature analysis was generated by subtracting the 
absorbance of the solution of each ligand in 1X PBS buffer from the (CUG)12/ligand 
solution. Melting temperatures were determined by fitting the melting curve using 
Meltwin 3.5 software. 
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Surface Plasmon Resonance (SPR) Analysis. All SPR experiments were 
conducted on a streptavidin coated sensor chip using a Biacore 3000 instrument. 
Streptavidin coated research grade sensor chips were preconditioned with three 
consecutive 1-min injections of 1 M NaCl/ 50 mM NaOH before the immobilization was 
started. 3’-biotin labeled (CUG)12 was captured on flow cell 2 (Response Unit, RU, 
between 100-1100). Flow cell 1 was used as a reference. Inhibition analysis was carried 
out in PBS 1X buffer, pH = 7.4, containing 0.05% Tween-20 and 0.2 mg/mL (7.4 µM or 
580 µM nucleotides) bulk yeast t-RNA to confirm the specificity of inhibition. Various 
concentrations of each ligand were passed over the immobilized RNA at a rate of 20 µL 
min-1 for 300 s. After the initial 150 s, a solution of GST-MBNL1 protein, 650 nM, in the 
same buffer was flowed over the surface for 150 s. The reference-subtracted 
sensograms were recorded. After the dissociation phase, the surface was regenerated, 
with a pulse of 0.5% SDS and/or 100 mM NaOH, for a few times followed by a buffer 
wash to reestablish baseline. The measured RU upon injection of PBS buffer was 
subtracted from the sensograms. For inhibition studies, the resulting sensograms were 
set to the baseline at t = 150 s to offset the binding of each ligand to the immobilized 
(CUG)12 surface. The peak RU at t = 150 s was recorded and converted to the 
percentage of (CUG)12 bound by MBNL1. All values normalized to that measured in the 
absence of each ligand. The data points were fit to a four parameter logistic curve to 
determine the apparent IC50 using the following equation by Kaleidagraph software: 
𝑌 =
𝑌     𝑌   
 + (
[      ]
𝐼𝐶  
) 
+ 𝑌    
where Y is the percentage of (CUG)12 bound by MBNL1, Ymax and Ymin are the maximum 
and minimum of this percentage and n is the Hill coefficient. Two or three separate SPR 
experiments on different sensor chips with different levels of (CUG)12 immobilization 
were carried out to verify that the values are not affected by surface RNA density.  
Steady State Fluorescence-based Binding Assays. To determine the equilibrium 
parameters for binding of ligands to CUGexp, we followed quenching of TAMRA in 
TAMRA-(CUG)6 at various ligand concentrations. TAMRA-(CUG)6 was excited at 560 
nm and its emission was recorded at 590 nm. Stoichiometric titrations were carried out 
at 20 oC in PBS, 1X buffer. The baseline fluorescence was recorded before addition of 
20 nM TAMRA-(CUG)6. Increase in the fluorescence was recorded and attributed to the 
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fluorescence of TAMRA-(CUG)6. Upon addition of each aliquot of each ligand, the 
fluorescence signal was allowed to equilibrate. Titration was continued at a series of 
increasing final concentrations of the ligand until the fluorescence was completely 
quenched. Fluorescence intensities at different concentrations of ligands were fit to the 
following equation using Kaleidagraph software: 
 =
        
 + (
  
[ ]
) 
+    
KD is the dissociation binding constant, [L] is the ligand concentration, n is the Hill 
coefficient and F0 and Fmax are the fluorescence intensity of free and fully bound RNA, 
respectively. In the control experiment, ligands had no effect on the fluorescence 
intensity of the free TAMRA fluorophore. 
FISH (Fluorescence In Situ Hybridization). A total of ca. 120,000 HeLa cells were 
seeded in each well of a 6-well plate on coverslips. After a day, the cells were 
transfected with 500 ng DMPKCUG0 or DMPKCUG960 plasmid using Lipofectamine 
following the manufacturer’s protocol at cell confluence of 7080%.39 After 4 hours, the 
media were changed and each ligand was added to each well at different concentrations 
(20, 35 and 50 M). After two days, the cells were fixed with 4% PFA then washed five 
times with 1x PBS. Fixed cells were permeabilized with 0.5% triton X-100 in 1x PBS at 
room temperature for 5 min. Cells were prewashed with 30% formamide in 2x SSC for 
10 min at room temperature. Cells were probed with FISH probe (1 ng L-1 of Cy3 CAG10 
in 30% formamide, 2x SSC, 2 g mL-1 BSA, 66 g mL-1 yeast tRNA) for 2 h at 37 °C. 
Cells were then washed with 30% formamide in 2x SSC for 30 min at 37 °C, followed by 
washing with 1x SSC for 30 min at room temperature. The cells were washed twice with 
1x PBS and then nuclei were stained with 1 M To-Pro-3 and washed twice. Cells were 
mounted onto glass sides with ProLong® Gold. Slides were imaged at RT by LSM 710, 
AxioObserver confocal microscopy equipment using a confocal single photon technique 
with a plan-Apochromat 20x/0.8 M27 objective. Image analysis was performed by 
Axiovision interactive measurement. The following table indicates the excitation filters 
used in these experiments.  
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Fluorophore Component Excitation wavelength (nm) 
Acridine Ligands 405 
Cy3 CUG960 555 
TO-PRO-3 Nucleus 639 
Live Cell Imaging. A total of ca. 120,000 HeLa cells were grown in an Ibidi 35 mm 
Petri dish with a standard bottom, high walls and an imprinted 500 µm relocation grid. 
After a day, cell confluence reached to about 7080%, cells were tranfected with 500 g 
DMPKCUG960 plasmid and 500 ng GFP-MBNL1 plasmid using Lipofectamine following 
standard protocol. After 4 h, media were changed and cells were incubated at 37 °C, 5% 
CO2. 24 h post-transfection, ligand 9 was added to final concentration of 50 M. Live-
cell, time-lapse images were taken before addition of 9 as well as at 3, 6 and 10 h time 
points at RT by a LSM 710, AxioObserver confocal microscopy equipment using a 
confocal single photon technique with a plan-Apochromat 20x/0.8 M27 objective. Image 
analysis was performed by Axiovision interactive measurement. For tracking the cells, 
DIC images were acquired simultaneously with the reflected light images using a TPMT 
module after setting the Köhler illumination with a fully opened condenser aperture (0.55 
NA). 
Instrumentation and Chemicals. All reagents were purchased from commercial 
suppliers and used without further purification. Anhydrous solvents were obtained from 
an anhydrous solvent dispensing system. For all reactions employing anhydrous 
solvents, glassware was oven-dried, cooled under vacuum, and then purged and 
conducted under dry nitrogen. Purified compounds were further dried under high 
vacuum (0.01–0.05 Torr) or lyophilized using a Labconco lyophilizer. Yields refer to 
purified and spectroscopically pure compounds. NMR spectra were recorded at 23 °C on 
either Varian Unity 500 or Varian Unity Inova 500NB, operating at 500 MHz and 125 
MHz for 1H and 13C acquisitions, respectively. NMR spectra were processed using 
MestReNova software. Chemical shifts are reported in ppm and referenced to the 
corresponding residual nuclei in the following deuterated solvents: CDCl3 (7.26 ppm 
1H, 
77.16 ppm 13C); DMSO (2.50 ppm 1H, 39.52 ppm 13C); D2O (4.79 ppm 
1H); CD3OD (3.31 
ppm 1H, 50.41 ppm 13C). Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q 
(quartet), p (pentet), sext (sextet), dd (doublet of doublets), td (triplet of doublets), dt 
(doublet of triplets), m (multiplet), b (broad). Integration is provided and coupling 
constants, J, are reported in Hertz (Hz). ESI mass spectra were recorded using the 
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Quattro or ZMD mass spectrometer. High resolution mass spectra (HRMS) were 
obtained at the University of Illinois mass spectrometry facility. All compounds described 
herein gave NMR and mass spectral data in accord with their structures. Ligand 1 gave 
a HRMS within 1 ppm of calculated values. 
3.6 Experimental Synthetic Procedures  
Scheme 3.1. Synthesis of N
2
-(4-Aminobutyl)-1,3,5-triazine-2,4,6-triamine
a 
 
a
Reagents and conditions: (a) 130 °C, 80%. 
N2-(4-Aminobutyl)-1,3,5-triazine-2,4,6-triamine (28). Title compound was 
synthesized as described previously in 80% yield,1 with minor changes in the work-up 
procedure. 1H NMR (500 MHz, DMSO-d6) δ 6.40 (t, J = 5.6 Hz, 1H), 6.05 (s, 2H), 5.88 
(s, 2H), 3.14 (q, J = 6.3 Hz, 2H), 2.56 – 2.51 (m, 2H), 1.44 (p, J = 7.1 Hz, 2H), 1.37 – 
1.31 (m, 2H); m/z LRMS (ESI) calculated for [M+H]+: 198.1; found 198.1. 
Scheme 3.2. Synthesis of 9-Oxo-9,10-dihydroacridine-4-carboxylic acid
a
 
 
a
Reagents and conditions: (a) Cu, Cu2O, K2CO3, DMF, Reflux, 24 h, 91%; (b) PPA, 120 °C, 95%; (c) Cu, 
Cu2O, K2CO3, 2-ethoxyethanol, 130 °C, 70%; (d) PPA, 120 °C, 95%. 
 
,2'-Azanediyldibenzoic acid (41). Title compound was synthesized as described 
previously in 91% yield,40 with minor changes in the work-up procedure. 1H NMR (500 
MHz, DMSO-d6) δ 7.91 (dd, J = 7.9, 1.3 Hz, 2H), 7.50 – 7.40 (m, 4H), 6.92 – 6.97 (m, 
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2H); 13C NMR (100 MHz, DMSO-d6) δ 168.41, 143.58, 133.38, 131.81, 119.99, 117.56, 
113.56; m/z LRMS (ESI) calculated for [M+H]+: 258.1; found 258.1. 
9-Oxo-9,10-dihydroacridine-4-carboxylic acid (14). Title compound was 
synthesized as described previously in 95% yield,40 with minor changes in the work-up 
procedure. 1H NMR (400 MHz, DMSO-d6) δ 12.01 (s, 1H), 8.53 (dd, J = 8.0, 1.5 Hz, 1H), 
8.45 (dd, J = 7.5, 1.6 Hz, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.83 – 7.73 (m, 3H), 7.41 – 7.29 
(m, 3H); 13C NMR (125 MHz, DMSO- d6) δ 176.53, 169.14, 141.20, 139.92, 136.90, 
134.11, 132.41, 125.89, 122.32, 121.63, 120.60, 120.24, 118.63, 115.01; m/z LRMS 
(ESI) calculated for [M+H]+: 240.1; found 240.1. 
2-((4-Carboxyphenyl)amino)benzoic acid (42). Title compound was synthesized 
as described previously in 70% yield,41 with minor changes in the work-up procedure. 1H 
NMR (500 MHz, DMSO-d6) δ 9.87 (s, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 8.7 Hz, 
2H), 7.51 – 7.45 (m, 2H), 7.27 (d, J = 8.7 Hz, 2H), 6.96 – 6.91 (m, 1H); m/z LRMS (ESI) 
calculated for [M+H]+: 258.1; found 258.1. 
9-Oxo-9,10-dihydroacridine-2-carboxylic acid (15). Title compound was 
synthesized as described previously in 95% yield,42 with minor changes in the work-up 
procedure. 1H NMR (400 MHz, DMSO-d6) δ 12.90 (s, 1H), 12.06 (s, 1H), 8.83 (d, J = 2.0 
Hz, 1H), 8.26 – 8.18 (m, 2H), 7.75 – 7.82 (m, 1H), 7.56 – 7.61 (m, 2H), 7.36 – 7.27 (m, 
1H); 13C NMR (125 MHz, DMSO-d6) δ 177.00, 167.41, 143.13, 140.90, 134.12, 133.88, 
133.62, 128.39, 126.10, 121.76, 120.85, 119.69, 117.69, 117.38; m/z LRMS (ESI) 
calculated for [M+H]+: 240.1; found 240.1. 
Scheme 3.3. Synthesis of N,N’-Bis(3-aminopropyl)-1,8-octanediamine
a
 
 
a
Reagents and conditions: (a) 2 equiv. acrylonitrile, EtOH, 0 °C to RT, 48 h, 83%; (b) Boc2O, NEt3, MeOH, 0 
°C to RT, 24 h; (c) H2, Ra-Ni, Pd/C, LiOH, dioxane, H2O, 24 h, 65%. 
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N,N’-Bis(2-cyanoethyl)-1,8-octanediamine (39). 1,8-octanediamine (1.8 g, 12.5 
mmol, 1 equiv.) was dissolved in ethanol. Acrylonitrile (1.33 g, 25 mmol, 2 equiv.) was 
added dropwise to the solution and stirred for 48 h at room temperature to yield the 
product in 83% yield. 1H NMR (500 MHz, Chloroform-d) δ 2.93 (td, J = 6.6, 2.2 Hz, 4H), 
2.66 – 2.59 (m, 4H), 2.52 (td, J = 6.6, 2.2 Hz, 4H), 1.48 (s, 4H), 1.31 (s, 8H); 13C NMR 
(125 MHz, Chloroform-d) δ 118.87, 49.36, 45.27, 30.16, 29.54, 27.28, 18.90; m/z LRMS 
(ESI) calculated for [M+H]+: 251.2; found 251.2. 
1,17-Diazido-3,6,9,12,15-pentaoxaheptadecane (40). Compound 39 (3.13 g, 12.5 
mmol, 1 equiv.) was treated with Di-tert-butyl dicarbonate (10.91 g, 50 mmol, 4 equiv.) 
and triethylamine (5.06 g, 50 mmol, 4 equiv.) in methanol at room temperature for 24 h 
to give 40 in 85% yield. m/z LRMS (ESI) calculated for [M+H]+: 333.2; found 333.2. 
N,N′-Bis(3-aminopropyl)-Bis(t-butylcarbamate)-1,8-octanediamine (33). 
Compound 40 was hydrogenated in the presence of Pd and Raney nickel and LiOH in a 
water/ dioxane mixture for 24 h at 100 atm to give the product in 65% yield. m/z LRMS 
(ESI) calculated for [M+H]+: 281.2; found 281.2. 
Scheme 3.4. Synthesis of N,N'-Bis(3-aminopropyl)-1,3-propanediamine
a
 
 
a
Reagents and conditions: (a) H2O, ACN, 80 °C, 24 h, 77%; (b) Boc2O, NEt3, 0 °C to RT, 24 h, 85%; (c) 0.6 
M NaOH/MeOH, RT, 24 h, 87%. 
3,6,9,12,15-Pentaoxaheptadecane-1,17-diyl bis(4-methylbenzenesulfonate) (44). 
N,N′-Bis(3-aminopropyl)-1,3-propanediamine was dissolved in acetonitrile. 
Ethyltrifluoroacetate and water were added dropwise at room temperature and then 
stirred at 82ºC for 24 h to give 44 in 77% yield.43, 44 1H NMR (500 MHz, Chloroform-d) δ 
7.79 (d, J = 8.3 Hz, 4H), 7.34 (d, J = 8.1 Hz, 4H), 4.15 (t, J = 5 Hz, 4H), 3.69 – 3.67 (m, 
4H), 3.64 – 3.56 (m, 16H), 2.44 (s, 6H); m/z LRMS (ESI) calculated for [M+H]+: 591.2; 
found 591.2. 
1,17-Diazido-3,6,9,12,15-pentaoxaheptadecane (45). Compound 44 was treated 
with NEt3 and slow addition of Di-tert-butyl dicarbonate at 0 ºC. The solution was stirred 
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at RT for 24 h and worked up as described,43, 44 to yield the product in 85% yield. 1H 
NMR (500 MHz, Chloroform-d) δ 3.69 – 3.65 (m, 20H), 3.42 – 3.36 (m, 4H); 13C NMR 
(126 MHz, Chloroform-d) δ 70.85, 70.82, 70.78, 70.73, 70.18, 50.83; m/z LRMS (ESI) 
calculated for [M+H]+: 333.2; found 333.2. 
3,6,9,12,15-Pentaoxaheptadecane-1,17-diamine (35). Compound 45 was stirred in 
a methanolic sodium hydroxide solution to deprotect the terminal trifluoroacetyl groups 
and give 35 in 87% yield. 43, 44 1H NMR (500 MHz, Chloroform-d) δ 3.67 – 3.60 (m, 20H), 
3.50 (t, J = 5.2 Hz, 4H), 2.85 (t, J = 5.2 Hz, 4H); 13C NMR (125 MHz, Chloroform-d) δ 
73.69, 70.77, 70.76, 70.73, 70.45, 42.01; m/z LRMS (ESI) calculated for [M+H]+: 281.2; 
found 281.2. 
Scheme 3.5. Synthesis of hexaethylene glycol diamine
a
 
 
a
Reagents and conditions: (a) TsCl, CH2Cl2, DMAP, NEt3, 0 °C to RT, 24 h, 77%; (b) NaN3, DMF, 80 °C, 24 
h, 85%; (c) H2, Pd/C, CH3OH, 87%. 
Hexaethylene glycol 1,20-ditosylate (46). Hexaethylene glycol (0.705 g, 2.5 mmol, 
1 equiv.), DMAP (60 mg, 0.5 mmol, 0.2 equiv.) and NEt3 (3.5 mL, 24 mmol, 10 equiv.) 
were dissolved in anhydrous DCM (50 mL) and cooled to 0°C. Tosyl Chloride (1.605 g, 
10 mmol, 4 equiv.) was added and stirred for 24 h at room temperature to give 46 in 
77% yield.45 1H NMR (500 MHz, DMSO-d6) δ 9.61 (s, 2H), 8.75 (s, 2H), 3.26 (q, J = 6.5 
Hz, 4H), 2.98 (t, J = 7.5, 4H), 2.94 – 2.88 (m, 4H), 1.91 (p, J = 7.8 Hz, 2H), 1.82 (p, J = 
7.0 Hz, 4H); 13C NMR (125 MHz, DMSO-d6) δ 156.40, 117.08, 44.63, 44.02, 36.61, 
25.22, 22.56; m/z LRMS (ESI) calculated for [M+H]+: 381.2; found 381.2. 
Hexaethylene glycol 1,20-diazide (47). Excess sodium azide (663 mg, 10.2 mmol, 
10.2 equiv.) was combined with 46 (1 g, 1.7 mmol, 1 equiv.), dissolved in anhydrous 
DMF (15 mL) and stirred at 80°C for 24 h to yield hexaethylene glycol diazide. The 
product was purified via flash chromatography (SiO2; CH2Cl2:MeOH, 98:2 to 95:5) in 
85% yield.45 1H NMR (500 MHz, DMSO-d6) δ 9.41 (bs, 2H), 3.18 – 3.08 (m, 12H), 1.72 – 
1.62 (m, 6H), 1.40 – 1.35 (m, 18H); m/z LRMS (ESI) calculated for [M+H]+: 581.3; found 
581.3. 
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Hexaethylene glycol 1,20-diamine (36). Compound 47 was dissolved in methanol 
and hydrogenated in the presence of 5% Pd/C for 24h to yield hexaethylene glycol 
diamine. The product was purified via flash chromatography (SiO2; 
CH2Cl2:MeOH:NH4OH, 80:19:1 to 67:30:2) to give the pure product in 87% yield. 
1H 
NMR (500 MHz, Chloroform-d) δ 3.28 (bs, 4H), 3.16 (bs, 4H), 2.69 (t, J = 6.4 Hz, 4H), 
1.81 – 1.70 (m, 2H), 1.64 (p, J = 6.8 Hz, 4H), 1.45 (s, 18H); 13C NMR (126 MHz, 
Chloroform-d) δ 155.29, 79.06, 44.44, 43.68, 38.96, 32.34, 31.73, 28.17; m/z LRMS 
(ESI) calculated for [M+H]+: 389.3; found 389.3. 
Scheme 3.6. Synthesis of 37
a
 
 
a
Reagents and conditions: (a) DCM, 0 °C to RT, 24 h (b) Boc2O, NEt3, , Boc2O, 0 °C to RT, 48 h; (c) 
methanol, NaOH, RT, 48 h, 34% overall. 
N,N'-(((azanediylbis(ethane-2,1-diyl))bis(azanediyl))bis(ethane-2,1-
diyl))bis(2,2,2-trifluoroacetamide) (48). Tetraethylenepentamine (5 g, 26.4 mmol, 1 
equiv.) was dissolved in DCM (100 mL) and cooled to 0 °C. Ethyl trifluoroacetate (7.5 g, 
52.8 mol, 2 equiv.) was added dropwise and the reaction was stirred for 30 min at 0 °C 
and then for 24 h at RT and worked up as described previously.46 m/z LRMS (ESI) 
calculated for [M+H]+: 382.2; found 382.2. 
Di-tert-Butyl (((tert-butoxycarbonyl)azanediyl)bis(ethane-2,1-diyl))bis((2-(2,2,2-
trifluoroacetamido)ethyl)carbamate) (49). Without isolation, TEA (14.6 mL, 105.6 
mmol, 4 equiv.) was added to the previous reaction mixture. A solution of Boc2O (23 g, 
105.6 mmol, 4 equiv.) in DCM (30 mL) was added dropwise and then then the reaction 
mixture was stirred for 48 h. The mixture was washed with NaHCO3 and water, tried over 
sodium sulfate. The solution was concentrated by rotary evaporation and worked up.46 
m/z LRMS (ESI) calculated for [M+H]+: 682.3; found 682.3. 
Di-tert-Butyl(((tert-butoxycarbonyl)azanediyl)bis(ethane-2,1-diyl))bis((2-amino 
ethyl)carbamate) (37). Methanol (200 mL) was and NaOH (8 g) was added to 49 and 
the reaction mixture was stirred for 48 h. The reaction mixture was concentrated by 
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rotary evaporation, dissolved in chloroform and NaOH, and filtered through celite. The 
filtrate was washed with water and the organic layers dried over sodium sulfate and 
concentrated. The solvent was removed by rotary evaporation and the crude mixture 
was purified via flash chromatography (SiO2; CH2Cl2:MeOH:NH4OH, 90:10:0 to 90:10:1) 
to yield the product in 33.8% overall yield. m/z LRMS (ESI) calculated for [M+H]+: 490.4; 
found 490.4. 
Scheme 3.7. Synthesis of 38
a
 
 
a
Reagents and conditions: (a) DCM, methanol, RT, 24 h (b) Boc2O, DCM, NEt3, 0 °C to RT, 3 h; (c) NaOH, 
methanol, RT, 24 h, 14% overall. 
N,N'-((Ethane-1,2-diylbis(azanediyl))bis(ethane-2,1-diyl))bis(2,2,2-trifluoro 
acetamide) (50). Triethylenepropylamine (5 g, 34.1 mmol, 1 equiv.) was dissolved in 
DCM (20 mL) and methanol (10 mL). A solution of Ethyl trifluoroacetate (10.2 g, 71.8 
mmol, 2.1 equiv.) in DCM (50 mL) as added dropwise over 1 h at 0 °C. This was stirred 
at RT for 3 h and worked up as described previously;47 m/z LRMS (ESI) calculated for 
[M+H]+: 339.1; found 339.1. 
Di-tert-butyl ethane-1,2-diylbis((2-(2,2,2-trifluoroacetamido)ethyl)carbamate) 
(51). Without purification, a solution of Boc2O (25 g, 114.5 mmol, 3.36 equiv.) in DCM 
(20 mL) was added dropwise over a half hour. Triethylamine (16.1 mL, 114. 5 mmol, 
3.36 equiv.) was added and the reaction was sitrred overnight. The solvent was then 
evaporated to 150 mL, washed with saturated NaHCO3, sodium citrate (5%), and water. 
The organic layer was dried over sodium sulfate, filtered, and concentrated. m/z LRMS 
(ESI) calculated for [M+H]+: 539.2; found 529.2. 
Di-tert-butyl ethane-1,2-diylbis((2-aminoethyl)carbamate) (38). Without 
purification, 51 was dissolved in methanol. NaOH (1 M) was added to the the solution 
and the reaction was stirred overnight. The reaction mixture was concnetnrated by rotary 
evaporation, dissolved in chloroform, dried over sodium sulfate, filtered thorugh celite, 
and concentrated. The crude mixture was purified via flash chromatography (SiO2; 
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CH2Cl2:MeOH 95:5) to yeild the pure product in 35.5% yield overall. m/z LRMS (ESI) 
calculated for [M+H]+: 347.3; found 347.3. 
Scheme 3.8. Synthesis of pentapropyleneglycol diamine
a
 
 
a
Reagents and conditions: (a) TsOH (cat.), toluene, 110 °C, 24 h, 96%; (b) BH3-THF, 90 °C, 4 days, 61%; 
(c) acrylonitrile, NaH, 15-crown-5, 0 °C, 30 min, 94%; (d) BH3-THF, 90 °C 24 h, 90%. 
 
General synthetic procedure for compounds 18-27. A round-bottom flask, 
equipped with a stir bar, was charged with 14 or 15 (1 equiv.) and freshly distilled thionyl 
chloride (16.4 equiv.). A catalytic amount of DMF was added and heated gently under 
reflux at 70 °C, stirring until homogeneous and then for 1 h. The excess thionyl chloride 
was distilled off and the last traces of it were removed azeotropically via co-evaporation 
with DCM (3 x 50 mL). It was left under vacuum (minimally) for 1 h to afford the crude 
intermediate as a yellow powder. The crude intermediate was dissolved in anhydrous 
DCM. Anhydrous triethylamine was added to the solution until the pH was 11 and it was 
cooled to 0 °C. Corresponding diamines 33-43 (0.45 equiv.) was added and the solution 
was stirred at 0 °C for 2 hours and slowly warmed to room temperature overnight. The 
solvent was removed by rotary evaporation and the crude mixture was purified via flash 
chromatography (SiO2; CH2Cl2:MeOH, generally from 98:2 to 95:5) to yield 18-27 as a 
yellow solid. 
General synthetic procedure for compounds 4, 6-8, 12,13, 29-32. A round-bottom 
flask, equipped with a stir bar, was charged with one of compounds 18-27 (1 equiv.) and 
N-(4-Aminobutyl)-[1,3,5]triazine-2,4,6-triamine (1.1 equiv.). DIPEA (2.2 equiv.) and 
anhydrous DMF (25 mL) were added. The solution was heated at 70 °C for 5 hours. The 
solvent was removed by rotary evaporation and the product purified via flash 
chromatography (Basic Alumina; DCM:Methanol:NH4OH, generally from 95:4.9:0.1 to 
90:9.5:0.5) to yield the corresponding compound, 4, 6-8, 12,13,29-32 as a yellow solid. 
General synthetic procedure for compounds 5, 9-11. A round-bottom flask, 
equipped with a stir bar, was charged with one of compounds 18-27 (1 equiv.). TFA (30 
52 
d 
53 
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mL) and anhydrous DCM (70 mL) were added and stirred at room temperature for 2 h. 
The solvents were removed to yield compounds 5, 9-11 as a yellow solid in 100% yield. 
9-Chloro-N-methylacridine-2-carboxamide (16). 1H NMR (500 MHz, chloroform-d) 
δ 8.79 (d, J = 1.6 Hz, 1H), 8.40 (d, J = 8.6 Hz, 1H), 8.24 – 8.19 (m, 2H), 8.14 (dd, J = 
9.0, 1.8 Hz, 1H), 7.86 – 7.83 (m, 1H), 7.69 – 7.62 (m, 1H), 6.56 (bs, 1H), 3.13 (d, J = 4.8 
Hz, 3H); m/z LRMS (ESI) calculated for [M+H]+: 271.1; found 271.1; m/z LRMS (ESI) 
calculated for [M+H]+: 271.1; found 271.1. Yield = 75% 
9-((4-((4,6-Diamino-1,3,5-triazin-2-yl)amino)butyl)amino)-N-methylacridine-2-
carboxamide (2). 1H NMR (500 MHz, methanol-d4) δ 8.91 (s, 1H), 8.33 (d, J = 8.6 Hz, 
1H), 8.02 (dd, J = 9.1, 1.9 Hz, 1H), 7.85 (t, J = 7.6 Hz, 2H), 7.75 – 7.68 (m, 1H), 7.42 – 
7.35 (m, 1H), 4.03 (t, J = 7.2 Hz, 2H), 3.37 – 3.33 (m, 2H), 3.00 (s, 3H), 1.93 (p, J = 7.4 
Hz, 2H), 1.70 (p, J = 7.2 Hz, 2H); m/z HRMS (ESI) calculated for [M+H]+: 432.2260; 
found 432.2267; Yield = 70% 
9-Chloro-N-methylacridine-4-carboxamide (17). 1H NMR (500 MHz, Chloroform-d) 
δ 11.33 (s, 1H), 8.90 (d, J = 6.9 Hz, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.26 (d, J = 8.3 Hz, 
1H), 8.02 – 7.95 (m, 1H), 7.76 (t, J = 7.4 Hz, 1H), 7.65 – 7.55 (m, 2H), 3.19 (d, J = 4.7 
Hz, 3H); m/z LRMS (ESI) calculated for [M+H]+: 271.1; found 271.1. m/z LRMS (ESI) 
calculated for [M+H]+: 271.1; found 271.1; Yield = 78% 
9-((4-((4,6-Diamino-1,3,5-triazin-2-yl)amino)butyl)amino)-N-methylacridine-4-
carboxamide (3). 1H NMR (400 MHz, DMSO-d6) δ 8.54 (d, J = 8.2 Hz, 2H), 8.41 (d, J = 
8.3 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.79 – 7.73 (m, 1H), 7.42 (q, J = 8.8 Hz, 2H), 6.54 
(t, J = 5.5 Hz, 1H), 6.14 (s, 2H), 6.00 (s, 2H), 3.89 (t, J = 6.5 Hz, 2H), 3.17 (q, J = 6.3 Hz, 
2H), 3.01 (d, J = 4.2 Hz, 3H), 1.79 (p, J = 7.6 Hz, 2H), 1.52 (p, J = 7.2 Hz, 2H); m/z 
LRMS (ESI) calculated for [M+H]+: 432.2; found 432.2. m/z LRMS (ESI) calculated for 
[M+H]+: 432.2; found 432.2. Yield = 80% 
N,N'-(Piperazine-1,4-diylbis(propane-3,1-diyl))bis(9-chloroacridine-2-
carboxamide) (18). m/z LRMS (ESI) calculated for [M+H]+: 679.2 ; found 679.2. Yield= 
65% 
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N,N'-(Piperazine-1,4-diylbis(propane-3,1-diyl))bis(9-((4-((4,6-diamino-1,3,5-
triazin-2-yl)amino)butyl)amino)acridine-2-carboxamide) (4). m/z LRMS (ESI) 
calculated for [M+H]+: 1001.6 ; found 1001.6. Yield = 61% 
Di-tert-butyloctane-1,8-diylbis((3-(9-chloroacridine-2-carboxamido)propyl) 
carbamate) (19). 1H NMR (500 MHz, Chloroform-d) δ 9.08 (s, 2H), 8.52 – 8.42 (m, 4H), 
8.35 (s, 4H), 7.87 (s, 2H), 7.68 (s, 2H), 3.53 (s, 4H), 3.44 (s, 4H), 3.18 (s, 4H), 1.81 (s, 
4H), 1.56 (s, 4H), 1.52 (s, 18H), 1.32 (s, 8H); m/z LRMS (ESI) calculated for [M+H]+: 
937.4; found 937.4. Yield = 65% 
Di-tert-butyloctane-1,8-diylbis((3-(9-((4-((4,6-diamino-1,3,5-triazin-2-yl)amino) 
butyl)amino)acridine-2-carboxamido)propyl)carbamate) (29). 1H NMR (500 MHz, 
Methanol-d4) δ 8.90 (s, 2H), 8.29 (d, J = 8.6 Hz, 2H), 8.04 (d, J = 8.6 Hz, 2H), 7.84 (s, 
4H), 7.73 – 7.66 (m, 2H), 7.40 – 7.33 (m, 2H), 4.01 (t, J = 7.0 Hz, 4H), 3.45 (t, J = 6.7 
Hz, 4H), 3.35 (s, 8H), 3.17 (s, 4H), 1.94 – 1.84 (m, 8H), 1.68 (p, J = 7.0 Hz, 4H), 1.49 (s, 
4H), 1.43 (s, 18H), 1.26 (s, 8H); m/z LRMS (ESI) calculated for [M+H]+: 1259.7; found 
1259.7. Yield = 61% 
N,N'-((Octane-1,8-diylbis(azanediyl))bis(propane-3,1-diyl))bis(9-((4-((4,6-
diamino-1,3,5-triazin-2-yl)amino)butyl)amino)acridine-2-carboxamide) (5). 1H NMR 
(500 MHz, Deuterium Oxide) δ 8.62 (s, 2H), 8.10 – 8.07 (m, 4H), 7.90 – 7.85 (m, 2H), 
7.51 (s, 2H), 7.50 – 7.43 (m, 4H), 3.98 (t, J = 6.2 Hz, 4H), 3.56 (t, J = 6.6 Hz, 4H), 3.19 
(t, J = 6.1 Hz, 4H), 3.15 – 3.11 (m, 4H), 3.07 – 3.03 (m, 4H), 2.05 (q, J = 6.9 Hz, 4H), 
1.91 – 1.85 (m, 4H), 1.73 – 1.68 (m, 4H), 1.66 – 1.61 (m, 4H), 1.41 – 1.34 (m, 8H); m/z 
LRMS (ESI) calculated for [M+H]+: 1059.6; found 1059.6. Yield = 100% 
N,N'-(4,8,12,16-Tetraoxanonadecane-1,19-diyl)bis(9-chloroacridine-4-
carboxamide) (20). 1H NMR (500 MHz, Chloroform-d) δ 9.00 (d, J = 6.9 Hz, 2H), 8.58 
(dd, J = 8.7, 1.4 Hz, 2H), 8.41 (d, J = 8.7 Hz, 2H), 8.14 (d, J = 8.7 Hz, 2H), 7.89 – 7.84 
(m, 2H), 7.76 – 7.71 (m, 2H), 7.71 – 7.65 (m, 2H), 3.76 (q, J = 6.8 Hz, 4H), 3.66 (t, J = 
6.3 Hz, 4H), 3.55 (t, J = 6.4 Hz, 4H), 3.46 (t, J = 6.4 Hz, 4H), 3.41 (t, J = 6.4 Hz, 4H), 
2.08 (p, J = 6.5 Hz, 4H), 1.83 (p, J = 6.4 Hz, 4H), 1.76 (p, J = 6.4 Hz, 2H); m/z LRMS 
(ESI) calculated for [M+H]+: 785.3; found 785.3. Yield = 62% 
N,N'-(4,8,12,16-Tetraoxanonadecane-1,19-diyl)bis(9-((4-((4,6-diamino-1,3,5-
triazin-2-yl)amino)butyl)amino)acridine-4-carboxamide) (6). 1H NMR (500 MHz, 
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DMSO-d6) δ 8.59 (s, 2H), 8.52 (d, J = 7.6 Hz, 2H), 8.39 (d, J = 7.2 Hz, 2H), 7.87 (s, 2H), 
7.71 (s, 2H), 7.55 (s, 2H), 7.38 (p, J = 7.6 Hz, 4H), 6.46 (t, J = 5.7 Hz, 2H), 6.08 (s, 4H), 
5.94 (s, 4H), 3.85 (t, J = 6.3 Hz, 4H), 3.53 (t, J = 5.7 Hz, 8H), 2.46 – 3.38 (m, 3H), 3.31 
(t, J = 6.4 Hz, 2H), 3.26 (t, J = 6.4 Hz, 2H), 3.16 (q, J = 6.4 Hz, 3H), 1.89 (p, J = 6.2 Hz, 
4H), 1.81 – 1.73 (m, 4H), 1.67 (p, J = 6.4 Hz, 4H), 1.58 (p, J = 6.4 Hz, 2H), 1.55 – 1.46 
(m, 4H); m/z LRMS (ESI) calculated for [M+H]+: 1007.6; found 1007.6. Yield = 60% 
N,N'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(9-chloroacridine-2-
carboxamide) (21). 1H NMR (500 MHz, DMSO-d6) δ 9.03 – 8.96 (m, 2H), 8.84 (s, 2H), 
8.34 (d, J = 8.7 Hz, 2H), 8.24 (dd, J = 9.1, 1.8 Hz, 2H), 8.20 – 8.12 (m, 4H), 7.95 – 7.90 
(m, 2H), 7.79 – 7.72 (m, 2H), 3.65 (d, J = 8.6 Hz, 8H), 3.51 (q, J = 5.3 Hz, 4H); 13C NMR 
(125 MHz, DMSO- d6) δ 176.86, 165.62, 142.45, 140.77, 133.70, 132.02, 126.79, 
126.03, 125.70, 121.55, 120.72, 119.54, 117.51, 117.27, 69.57, 68.94; m/z LRMS (ESI) 
calculated for [M+H]+: 627.2; found 627.2. Yield = 66% 
N,N'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(9-((4-((4,6-diamino-1,3,5-
triazin-2-yl)amino)butyl)amino)acridine-2-carboxamide) (7). 1H NMR (400 MHz, 
Methanol-d4) δ 8.73 (s, 2H), 8.11 (d, J = 8.6 Hz, 2H), 7.91 (dd, J = 9.1, 1.6 Hz, 2H), 7.69 
(dd, J = 21.1, 8.7 Hz, 4H), 7.63 – 7.56 (m, 2H), 7.29 – 7.20 (m, 2H), 3.82 (t, J = 7.1 Hz, 
4H), 3.74 (d, J = 5.5 Hz, 8H), 3.64 (t, J = 5.2 Hz, 4H), 3.28 (d, J = 6.7 Hz, 4H), 1.81 (p, J 
= 7.5 Hz, 4H), 1.66 – 1.59 (m, 4H); m/z LRMS (ESI) calculated for [M+H]+: 949.5; found 
949.5. Yield = 61% 
N,N'-(3,6,9,12,15-Pentaoxaheptadecane-1,17-diyl)bis(9-chloroacridine-4-
carboxamide) (22). 1H NMR (500 MHz, Chloroform-d) δ 8.88 (dd, J = 9.5, 1.4 Hz, 2H), 
8.41 (dd, J = 9.7, 1.6, 2H), 8.22 (d, J = 8.7 Hz, 2H), 8.05 (d, J = 8.6 Hz, 2H), 7.76 (t, J = 
9.7 Hz, 2H), 7.62 (t, J = 7.1 Hz, 2H), 7.55 (t, J = 7.5 Hz, 2H), 3.85 (d, J = 4.9 Hz, 4H), 
3.83 – 3.79 (m, 4H), 3.76 – 3.73 (m, 4H), 3.72 – 3.68 (m, 4H), 3.62 – 3.58 (m, 4H), 3.55 
– 3.51 (m, 4H); 13C NMR (125 MHz, Chloroform-d) δ 165.36, 146.99, 146.02, 142.74, 
135.50, 131.49, 129.35, 128.64, 128.42, 127.47, 126.46, 124.51, 124.26, 123.57, 70.80, 
70.68, 70.58, 70.42, 70.22, 39.76; m/z LRMS (ESI) calculated for [M+H]+: 759.2; found 
759.2. Yield = 70% 
N,N'-(3,6,9,12,15-Pentaoxaheptadecane-1,17-diyl)bis(9-((4-((4,6-diamino-1,3,5-
triazin-2-yl)amino)butyl)amino)acridine-4-carboxamide) (8). 1H NMR (500 MHz, 
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DMSO-d6) δ 8.60 (dd, J = 7.1, 1.1 Hz, 2H), 8.56 – 8.51 (m, 2H), 8.39 (d, J = 9.1 Hz, 2H), 
7.92 (d, J = 8.6 Hz, 2H), 7.75 – 7.68 (m, 2H), 7.53 (t, J = 5.5 Hz, 2H), 7.41 (dd, J = 8.6, 
7.3 Hz, 2H), 7.39 – 7.35 (m, 2H), 6.42 (t, J = 5.7 Hz, 2H), 6.02 (bs, 4H), 5.88 (bs, 4H), 
3.85 (q, J = 6.5 Hz, 4H), 3.69 – 3.64 (m, 4H), 3.64 – 3.61 (m, 8H), 3.58 – 3.55 (m, 4H), 
3.47 – 3.43 (m, 4H), 3.39 – 3.35 (m, 3H), 3.14 (q, J = 6.5 Hz, 4H), 1.76 (p, J = 7.5 Hz, 
4H), 1.49 (p, J = 6.9 Hz, 4H); m/z LRMS (ESI) calculated for [M+H]+: 1081.6; found 
1081.6. Yield = 65% 
Di-tert-butylpropane-1,3-diylbis((3-(9-chloroacridine-4-carboxamido)propyl) 
carbamate) (23). 1H NMR (500 MHz, Chloroform-d) δ 9.00 (s, 2H), 8.36 (d, J = 14.0 Hz, 
4H), 8.27 (s, 2H), 8.20 (d, J = 16.2 Hz, 4H), 7.80 (t, J = 7.4, 2H), 7.62 (t, J = 6.2, 2H), 
3.54 (s, 4H), 3.45 (s, 4H), 3.23 (s, 4H), 1.89 – 1.81 (m, 6H), 1.52 (s, 18H); 13C NMR (125 
MHz, Chloroform-d) δ 149.56, 149.23, 132.76, 131.12, 130.12, 129.75, 128.54, 127.13, 
124.59, 124.33, 123.26, 44.94, 43.54, 36.14, 28.52, 27.87, 27.63; m/z LRMS (ESI) 
calculated for [M+H]+: 867.3; found 867.3. Yield = 60% 
Di-tert-butylpropane-1,3-diylbis((3-(9-((4-((4,6-diamino-1,3,5-triazin-2-yl)amino) 
butyl)amino)acridine-4-carboxamido)propyl)carbamate) (30). 1H NMR (500 MHz, 
Methanol-d4) δ 8.60 (s, 2H), 8.37 (d, J = 8.5 Hz, 2H), 8.20 (d, J = 8.5 Hz, 2H), 7.86 (d, J 
= 54.6 Hz, 2H), 7.63 (t, J = 7.1 Hz, 2H), 7.38 – 7.32 (m, 2H), 7.32 – 7.27 (m, 2H), 3.82 
(s, 4H), 3.49 (t, J = 6.2 Hz, 4H), 3.35 (s, 4H), 3.27 (t, J = 6.8 Hz, 4H), 3.19 (s, 4H), 1.88 
(s, 1H), 1.84 – 1.75 (m, 4H), 1.59 (p, J = 7.1, 6.7 Hz, 17H), 1.34 (s, 4H); m/z LRMS (ESI) 
calculated for [M+H]+: 1189.7; found 1189.7. Yield = 55% 
N,N'-((Propane-1,3-diylbis(azanediyl))bis(propane-3,1-diyl))bis(9-((4-((4,6-
diamino-1,3,5-triazin-2-yl)amino)butyl)amino)acridine-4-carboxamide) (9). 1H NMR 
(500 MHz, Deuterium Oxide) δ 8.34 (d, J = 8.3 Hz, 1H), 8.17 (d, J = 8.3 Hz, 1H), 8.11 (d, 
J = 7.4 Hz, 1H), 7.78 (t, J = 7.7 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.47 – 7.38 (m, 2H), 
4.07 (t, J = 6.8 Hz, 2H), 3.58 (t, J = 6.7 Hz, 2H), 3.36 – 3.31 (m, 2H), 3.26 (t, J = 5.9 Hz, 
6H), 2.31 (p, J = 7.9, 7.5 Hz, 1H), 2.14 – 2.08 (m, 2H), 1.94 (p, J = 7.2 Hz, 3H), 1.68 (q, 
J = 6.5, 5.7 Hz, 3H); m/z LRMS (ESI) calculated for [M+H]+: 989.6; found 989.6. Yield = 
100% 
 110 
 
Di-tert-butyl(((tert-butoxycarbonyl)azanediyl)bis(ethane-2,1-diyl))bis((2-(9-
chloroacridine-4-carboxamido)ethyl)carbamate) (24). m/z LRMS (ESI) calculated for 
[M+H]+: 968.4; found 968.4. Yield = 60% 
Di-tert-butyl (((tert-butoxycarbonyl)azanediyl)bis(ethane-2,1-diyl))bis((2-(9-((4-
((4,6-diamino-1,3,5-triazin-2-yl)amino)butyl)amino)acridine-4-carboxamido)ethyl) 
carbamate) (31). m/z LRMS (ESI) calculated for [M+H]+: 1290.7; found 1290.7. Yield = 
58% 
N,N'-(((Azanediylbis(ethane-2,1-diyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(9-
((4-((4,6-diamino-1,3,5-triazin-2-yl)amino)butyl)amino)acridine-4-carboxamide) (10). 
1H NMR (500 MHz, Deuterium Oxide) δ 8.23 (d, J = 8.5 Hz, 2H), 8.09 (d, J = 7.4 Hz, 
2H), 7.99 (d, J = 8.6 Hz, 2H), 7.65 (t, J = 7.7 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.36 (t, J 
= 7.9 Hz, 2H), 7.28 (s, 2H), 3.88 (t, J = 6.7 Hz, 3H), 3.76 (t, J = 5.4 Hz, 3H), 3.52 (s, 4H), 
3.37 (t, J = 5.5 Hz, 3H), 3.13 (t, J = 6.1 Hz, 3H), 1.79 (p, J = 6.9 Hz, 3H), 1.56 – 1.50 (m, 
3H). m/z LRMS (ESI) calculated for [M+H]+: 990.6; found 990.6. Yield = 100% 
Di-tert-butylethane-1,2-diylbis((2-(9-chloroacridine-4-carboxamido)ethyl) 
carbamate) (25). m/z LRMS (ESI) calculated for [M+H]+: 825.3; found 825.3. Yield = 
62% 
Di-tert-butylethane-1,2-diylbis((2-(9-((4-((4,6-diamino-1,3,5-triazin-2-yl)amino) 
butyl)amino)acridine-4-carboxamido)ethyl)carbamate) (32). m/z LRMS (ESI) 
calculated for [M+H]+: 1147.6; found 1147.6. Yield = 57% 
N,N'-((Ethane-1,2-diylbis(azanediyl))bis(ethane-2,1-diyl))bis(9-((4-((4,6-diamino-
1,3,5-triazin-2-yl)amino)butyl)amino)acridine-4-carboxamide) (11). 1H NMR (500 
MHz, Deuterium Oxide) δ 8.18 (d, J = 8.6 Hz, 2H), 8.07 (d, J = 7.2 Hz, 2H), 8.05 – 8.01 
(m, 2H), 7.67 (t, J = 7.5 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.34 (s, 2H), 7.29 (t, J = 8.0 
Hz, 2H), 3.95 (s, 4H), 3.83 (s, 4H), 3.73 (s, 4H), 3.50 (s, 4H), 3.21 (s, 4H), 1.86 (s, 4H), 
1.61 (s, 4H); 13C NMR (125 MHz, Deuterium Oxide) δ 170.11, 163.32, 163.03, 162.75, 
162.47, 159.99, 159.26, 157.58, 156.52, 119.95, 118.19, 117.63, 115.30, 112.98, 48.85, 
48.65, 43.81, 40.32, 36.56, 26.06, 24.93; m/z LRMS (ESI) calculated for [M+H]+: 947.5; 
found 947.5. Yield = 100% 
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N,N'-(((Oxybis(ethane-2,1-diyl))bis(oxy))bis(propane-3,1-diyl))bis(9-
chloroacridine-2-carboxamide) (26). 1H NMR (500 MHz, Chloroform-d) δ 8.76 (s, 2H), 
8.24 (d, J = 8.6 Hz, 2H), 8.15 – 8.09 (m, 4H), 8.07 (d, J = 9.1 Hz, 2H), 7.77 – 7.69 (m, 
4H), 7.54 (t, J = 7.6 Hz, 2H), 3.65 – 3.56 (m, 12H), 3.52 – 3.48 (m, 4H), 1.89 (p, J = 5.7 
Hz, 4H); m/z LRMS (ESI) calculated for [M+H]+: 699.2; found 699.2. Yield = 70% 
N,N'-(((Oxybis(ethane-2,1-diyl))bis(oxy))bis(propane-3,1-diyl))bis(9-((4-((4,6-
diamino-1,3,5-triazin-2-yl)amino)butyl)amino)acridine-2-carboxamide) (12). 1H NMR 
(500 MHz, Methanol-d4) δ 8.75 (s, 2H), 8.15 (d, J = 8.6 Hz, 2H), 7.97 – 7.91 (m, 2H), 
7.79 – 7.70 (m, 4H), 7.65 – 7.58 (m, 2H), 7.31 – 7.24 (m, 2H), 3.86 (t, J = 7.1 Hz, 4H), 
3.66 – 3.62 (m, 4H), 3.59 – 3.55 (m, 8H), 3.52 (t, J = 6.8 Hz, 4H), 3.32 – 3.27 (m, 4H), 
1.91 – 1.86 (m, 4H), 1.86 – 1.80 (m, 4H), 1.64 (p, J = 6.9 Hz, 4H); m/z LRMS (ESI) 
calculated for [M+H]+: 1021.5; found 1021.5. Yield = 66% 
N,N'-(3,6,9,12,15-Pentaoxaheptadecane-1,17-diyl)bis(9-chloroacridine-2-
carboxamide) (27). 1H NMR (500 MHz, Chloroform-d) δ 8.89 (s, 2H), 8.39 – 8.15 (m, 
8H), 7.88 – 7.82 (m, 2H), 7.66 – 7.61 (m, 2H), 3.75 (s, 8H), 3.66 (d, J = 5.3 Hz, 4H), 3.63 
(d, J = 5.4 Hz, 4H), 3.61 – 3.58 (m, 4H), 3.55 – 3.51 (m, 4H); m/z LRMS (ESI) calculated 
for [M+H]+: 759.2; found 759.2. Yield = 65% 
N,N'-(3,6,9,12,15-Pentaoxaheptadecane-1,17-diyl)bis(9-((4-((4,6-diamino-1,3,5-
triazin-2-yl)amino)butyl)amino)acridine-2-carboxamide) (13). 1H NMR (500 MHz, 
Methanol-d4) δ 8.82 (s, 2H), 8.22 (d, J = 8.7 Hz, 2H), 8.03 – 7.96 (m, 2H), 7.79 (s, 4H), 
7.66 (q, J = 8.4, 7.7 Hz, 2H), 7.36 – 7.28 (m, 2H), 3.91 (t, J = 7.2 Hz, 4H), 3.66 (t, J = 5.0 
Hz, 4H), 3.64 – 3.60 (m, 4H), 3.60 – 3.57 (m, 4H), 3.57 – 3.54 (m, 4H), 3.52 – 3.51 (m, 
4H), 3.48 – 3.47 (m, 4H), 3.30 – 3.22 (m, 4H), 1.86 (p, J = 7.6 Hz, 4H), 1.65 (p, J = 7.0 
Hz, 4H); m/z LRMS (ESI) calculated for [M+H]+: 1081.6; found 1081.6. Yield = 60%. 
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Chapter 4.
2
  
Single Molecule Study of the CUG Repeat･MBNL1 
Interaction and its Inhibition by Small Molecules  
4.1 Abstract 
Effective drug discovery and optimization can be accelerated by techniques capable 
of deconvoluting the complexities often present in targeted biological systems. We report 
a single-molecule approach to 
study the binding of an alternative 
splicing regulator, muscleblind-
like 1 protein (MBNL1), to 
(CUG)n=4,6 and the effect of small 
molecules on this interaction. 
Expanded CUG repeats (CUGexp) are the causative agent of myotonic dystrophy type 1 
by sequestering MBNL1. MBNL1 is able to bind to the (CUG)n･inhibitor complex 
indicating that the inhibition is not a straight forward competitive process. A simple 
ligand, highly selective for CUGexp was used to design a new dimeric ligand that binds to 
(CUG)n almost 50-fold more tightly and is more effective in destabilizing MBNL1･(CUG)4. 
The single-molecule method and the analysis framework might be extended to the study 
of other biomolecular interactions. 
4.2 Introduction 
Myotonic dystrophy type 1 (DM1) is a triplet-repeat disease originating from a 
progressive expansion of the CTG repeat (CTGexp) in the 3’-untranslated region of the 
DMPK gene.1 The CTGexp produces a toxic RNA transcript (CUGexp) that does not exit 
the nucleus but associates with proteins. One of these proteins, MBNL1, is an important 
regulator of alternative splicing.2 Sequestration of MBNL1 in nuclear foci leads to 
multiple misspliced pre-mRNAs, incorrect protein levels, and ultimately the signs and 
                                                 
2
 This Chapter is a manuscript under review at Nucleic Acids Research. It is a collaborative 
project with Maria Spies lab at University of Iowa. 
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symptoms of the disease.3 In a mouse model of DM1 a morpholino antisense 
oligonucleotide (ASO) 1, a 2’-O-(2-methoxyethyl) ASO4 and a D-amino acid hexapeptide 
(ABP1)5 reversed this process, rescued the missplicing and reversed the phenotype in 
mice thereby validating CUGexp as a therapeutic target. Because no drugs are currently 
available to treat DM1, there is intense interest in finding small molecules that may 
function in a manner similar to the morpholino antisense oligonucleotides, but avoid the 
limitations inherent in the antisense therapeutic approach.6 Pentamidine,7 
benzo[g]quinolone heterocycle derivatives,8 a Hoechst derivative (H1),9 and modularly 
assembled Hoechst 3325810 are examples of bioactive CUGexp binders that are able to 
restore MBNL1 function in DM1 cell and animal models.  
Central to the discovery of new and improved therapeutic agents for DM1 is 
understanding how small molecules bind CUGexp and the mechanism by which they 
block the MBNL1 binding. Previously, we and others analyzed the MBNL1･CUGexp･
inhibitor system using a competitive inhibition model and have employed bulk solution 
techniques to analyze the equilibrium binding. However, these bulk solution methods 
usually require large sample volumes and have low sensitivity. Most importantly, these 
techniques do not provide the kinetic information that can be vital for accelerating drug 
discovery and development11 and sometimes do not give a full thermodynamic picture. 
Surface-based biosensors provide kinetic information, directly in real time with a fast 
response and high sensitivity, by measuring the interaction between an immobilized 
macromolecule and its soluble binding partner. The localized SPR (LSPR) technique, in 
particular, is developing rapidly into a powerful method.12 Nonetheless, the SPR 
techniques are model-dependent and can have difficulties distinguishing different 
analytes, for example a protein from an inhibitor.13 
The lack of a suitable method for studying the MBNL1･CUGexp interaction and its 
inhibition by small molecules means that the overall complexation process remains 
largely unexplored. The same holds true for many other systems where it is desirable to 
disrupt off-pathway protein･RNA interactions without affecting the biologically important 
function of the protein. To aid our drug discovery program and provide a potentially 
general approach to studying RNA･protein inhibition, we developed a single-molecule 
method to analyze the MBNL1･CUGexp･inhibitor system. The major advantage of our 
model-independent approach is the ability to detect and measure the individual binding 
events in real time under equilibrium conditions.14 Analyzing the distributions of bound 
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and free states gives the most reliable on and off rates and a full picture of the inhibition 
process.15, 16 
Herein, we describe the use of total internal reflection fluorescence (TIRF) microscopy 
to study, at the single-molecule level, the inhibition of MBNL1 binding to CUG repeat by 
known small molecule inhibitor 1 (Figure 4.1). The synthesis of dimeric inhibitor ligand 2, 
based on structure 1, is described and evaluated using the TIRF method. Ligand 2 was 
shown to be bioactive in DM1 cell models (data will be published elsewhere). Both 
compounds are found to bind RNA at the same time as MBNL1 indicating that the 
inhibition of MBNL1･CUGexp interaction does not follow a simple competitive mechanism. 
Rather than competitive steric blocking of the MBNL1 complexation site on CUG repeat, 
it appears the ligands are accelerating the dissociation of the protein. 
4.3 Results  
Design and Synthesis of Small Molecules. Our previous studies validated 3 (Figure 
4.1) as a selective CUG binder, which was able to inhibit the MBNL1･CUG interaction 
with an apparent IC50 = 52 ± 20 µM.
17 Because the ultimate RNA target is CUGexp, a 
logical way to increase the selectivity and potency of this lead compound is to utilize the 
multivalent effect.18 Disney and coworkers successfully applied this approach to the 
Hoechst 33258 ligand, which was known to bind CUG with modest selectivity.19 Because 
the rationally designed ligand 3 already exhibited a high affinity to (CUG)4 and showed 
excellent selectivity, we initially pursued a dimeric ligand. 
The covalent linkage of ligand 3 to itself or other compounds required a functional 
derivative. The three possible sites for covalent modification of 3 are the acridine ring, 
the triaminotriazine recognition unit or the linking chain. The most expeditious synthetic 
approach utilized an acridine ring containing a carboxylic acid group to interconnect two 
ligands. It was found that the chloro- and methoxy-groups in 3 could be replaced with a 
2- or 4-carboxamido group (see 1 and 4 in Figure 4.1, respectively) without altering its 
affinity for CUG or its inhibition of the MBNL1･CUG complex. Limited by the absence of 
structural data on the ligand･CUGexp complex, we designed and synthesized a small 
library of dimeric ligands that could potentially bind to consecutive CUG sites. This study, 
which will be published elsewhere, led us to 2 as the optimized dimeric ligand used in 
the current study (Figure 4.1).  
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Ligand 2 was designed to target two consecutive UU mismatches, with the N,N'-bis(3-
aminopropyl)-1,3-propanediamine linker spanning two central GC base-pairs. Although 
the binding mode was not firmly established for 3, it was designed to act as a “stacked 
intercalator” with the acridine and triaminotriazine rings π-stacked while the intercalator 
sits between the GC base pair and the U-triaminotriazine-U base triplet.17 A recent 
combined experimental and computational study provides support for that binding model 
in the major groove of the CUG RNA.20 By positioning the linking chain and 
triaminotriazine recognition units on opposite sides of the acridine unit, the bivalent 
complex likely requires a threading mechanism for binding.21 This design element was 
intentional with the goal of increasing the binding affinity through a higher residence 
time.22, 23 
Establishing a TIRFM-based Assay to Monitor the MBNL1･(CUG)n Interaction.
3 To 
investigate binding of MBNL1 to (CUG)n and the effect of 1 and our bioactive dimeric 
ligand, 2, on MBNL1･(CUG)n interaction, we developed a TIRFM–based single-molecule 
binding assay.28, 29 A stem-loop containing two CUG pairs separated by a tetraloop, 
(CUG)4, was used as an RNA substrate to analyze the MBNL1 binding. This RNA 
construct has been previously established as the shortest CUG repeat to which MBNL1 
                                                 
3
 The single molecule study has been performed in Maria Spies lab at University of Illinois (2011-
12) and University of Iowa (2012-13). 
 
Figure 4.1. Compounds 1-4 used in this study. 
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binds with a similar affinity as to the long CUG repeats.30 The predicted stem-loop 
structure of (CUG)4 has been confirmed by melting studies (Tm = 60.6 ± 0.6).
30, 31 
Therefore, (CUG)4 is the shortest validated CUG repeat model. Moreover, it contains 
only one MBNL1 binding site per RNA molecule, which simplifies analysis of the 
association/dissociation events. Validation of the single site binding is described in the 
next section below.  
 
Figure 4.2. Single-molecule analysis of MBNL1 binding to (CUG)4. a. (CUG)4 was immobilized on a PEG-
coated surface of the slide via biotin-neutravidin interaction. The experiment was carried out in two steps. (1) 
Positions of (CUG)4 molecules on the slide were triangulated by exciting Cy5 label of (CUG)4 with a red laser. 
(2) MBNL1･(CUG)4 interaction was monitored using green TIR illumination. Upon binding to (CUG)4, Cy3 
label on MBNL1 is excited as it is sequestered within the evanescent field. b. Representative Cy3 (green) and 
Cy5 (red) fluorescence intensity trajectories from an individual (CUG)4 molecule. Arrows 1 and 2 depict 
periods of red and green excitation, respectively. ON and OFF events are indicated on the right. 
We followed the binding of Cy3 labeled MBNL1 to, and its dissociation from, individual 
(CUG)4 RNA molecules. Biotinylated and Cy5-labeled (CUG)4 was immobilized on a 
PEG-coated surface of the TIRFM flow chamber via biotin-neutravidin interaction (Figure 
4.2a, left). First, locations of the surface-tethered(CUG)4 molecules were identified by 
illuminating the slide with red laser (641 nm), which selectively excited the Cy5 
fluorophore present on (CUG)4. Then, the laser was switched to green (532 nm) to 
monitor binding of Cy3 labeled MBNL1 to (CUG)4 (Figure 4.2a, right). We followed 
MBNL1･(CUG)4 interaction in real time, with a time resolution of 100 ms. In this 
experimental scheme, the surface-tethered (CUG)4 and Cy3 labeled MBNL1 are at 
equilibrium during the length of the measurement. TIR-generated evanescent field 
excites only the Cy3 labeled MBNL1 molecules that reside near the surface longer than 
2 frames of the camera, which only occurs when MBNL1 is bound to the surface-
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tethered (CUG)4. This mode of excitation eliminates the background fluorescence of 
Cy3-MBNL1 in solution and thereby allows monitoring MBNL1･(CUG)4 interactions over 
a broad range of MBNL1 concentrations.  
Each event of MBNL1 binding to the surface-tethered (CUG)4 was observed as the 
appearance of a Cy3 signal at the location where (CUG)4 resided. Conversely, 
dissociation of MBNL1 from (CUG)4 resulted in the disappearance of the Cy3 signal. 
Fluorescence trajectories (Figure 4.2b) showed multiple events of two-state (ON and 
OFF) association and dissociation. The presence of only two states indicates that each 
observed event corresponded to binding of a single MBNL1 to a single (CUG)4. To 
confirm that potential non-specific interaction of MBNL1 with the surface does not 
interfere with our analysis, we substituted Cy5-labeled (CUG)4 with Cy5-labeled 
streptavidin. Only a few fluorescence trajectories showing both Cy5 and Cy3 signals 
were observed in the presence of 300 pM Cy3-MBNL1 (about 5% of what was observed 
in the presence of Cy5-labeled (CUG)4) confirming that the vast majority of binding 
events described above resulted from specific MBNL1･(CUG)4 interaction. Analysis of 
the Cy3-MBNL1･(CUG)4 interaction in the presence of unlabeled MBNL1 confirmed that 
MBNL1 binding properties were not affected by the Cy3 conjugation (Figure 4.11). 
 
Figure 4.3. a. Distributions of all ON (left) and OFF (right) event durations detected in the 50 trajectories of 
individual (CUG)4 molecules are fit to single exponentials to yield k-1 ([MBNL1] = 50 pM) and von ([MBNL1] = 
200 pM), respectively. b. Effect of MBNL1 concentration on the k-1 and von of the observed events is shown. 
k-1 (dissociation rate constant) was independent of [MBNL1], suggesting the absence of functional 
cooperation between monomers. Initially, von (association rate) increased with increasing [MBNL1]. It was 
saturated at the MBNL1 concentrations above 200 pM. 
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The Cy3 (green laser excitation) regions of the trajectories were fit to a two-state 
model using QuB software,32 yielding dwell times in the OFF (dissociated) and ON 
(bound) states (Figure 4.4). We determined kinetic parameters of MBNL1 binding to the 
surface-tethered (CUG)4 by globally analyzing distributions of ON and OFF dwell times 
in the presence of different concentrations of MBNL1 protein. All protein concentrations 
(50, 100, 150, 200, 300 and 400 pM) were used to determine the dissociation rate 
constant, whereas the association rate constant was determined using only 50 – 200 pM 
range of concentrations, which gave a linear dependence of the observed association 
rate on MBNL1 concentration. 
 
Figure 4.4. Representative trajectories with two-state fitting. Single-molecule trajectories were fit using QuB 
to reveal the binding and dissociation of MBNL1 to (CUG)4. The data was collected in the standard buffer in 
the presence of 0 pM, 100 pM and 200 pM MBNL and were globally fit by HMM using QuB software. For 
representative trajectories fit idealized states (red line) are shown superimposed on the actual Cy3 intensity 
trajectories (light blue). The trajectories in which (CUG)4 molecules showed either abnormally high Cy5 
intensity or more than two-step bleaching were omitted from analysis.  
Figure 4.3a and 4.3b show individually fit ON and OFF time distributions obtained in 
the presence of 50 pM and 200 pM MBNL1, respectively. Global analyses of the dwell 
distributions yielded the dissociation rate constant for MBNL1･(CUG)4 complex, k-1 = 
100 pM MBNL1
200 pM MBNL1
0 pM MBNL1
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1.44 ± 0.3 s-1, and association rate constant, k1 = (4.6 ± 0.2) x 10
8 s-1 M-1, from which we 
calculated the equilibrium dissociation constant, KD1 = k-1/k1 = 3.1 ± 0.1 nM. The system 
was set up by Dr. Masayoshi Honda, a postdoctoral researcher in Maria Spies lab. 
Stoichiometry of the MBNL1･(CUG)n Interaction. Biotinylated (CUG)12 can 
simultaneously accommodate multiple Cy3 labeled MBNL1 molecules. Its Cy3 
trajectories contained 5 states characterized by different Cy3 intensities (Figure 4.5a). 
An intensity histogram showed that there are three major Cy3 intensity populations 
consistent with the binding of one (around 196 a.u.), two (around 332 a.u.), and three 
(around 458 a.u.) MBNL1 proteins to the (CUG)12. A small fourth peak (around 632 a.u.) 
may represent more than one Cy3 label present on a fraction of MBNL1 molecules (Cy3 
labeling efficiency of MBNL1 was 110%). Stoichiometry determination assay using SPR 
confirmed a stoichiometric ratio of MBNL1:(CUG)12 close to 3:1 (Figure 4.12).  
Figure 4.5. Each (CUG)4 can accommodate a single MBNL1 protein, whereas three MBNL1 proteins can be 
simultaneously bound to (CUG)12. a. Schematic representation of (CUG)12 (left), b. Schematic 
representation of (CUG)4. Representative fluorescence intensity trajectories for (MBNL1)3･(CUG)12 (a) and 
MBNL1･(CUG)4 (b) are shown in the middle (light green line shows the raw data collected at 100 ms time 
resolution, dark green line shows intensity averaged for 9 data points). The fluorescence intensity histogram 
compiled from the trajectory is shown on the right (aqua) and is fit to 5 Gaussian peaks (black lines), 
corresponding to stepwise increase in (CUG)12 occupancy by MBNL1 (a) whereas only a single 1:1 binding 
state is observed for MBNL1･(CUG)4 (b). 
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Revealing the Mechanism of the MBNL1･(CUG)n Interaction Inhibition by 1 and 2. 
We then carried out MBNL1･(CUG)4 binding studies in the presence of increasing 
concentrations of 1 and 2. Before starting the recording, the Cy3 labeled MBNL1 and the 
ligands were incubated for at least 5 minutes in the TIRFM reaction chamber to ensure 
that all components of the system are at equilibrium. The difference in the dwell time 
distributions for the MBNL1･(CUG)4 complex in the absence and presence of 1 and 2, 
and therefore the difference in the apparent koff of the MBNL1･(CUG)4 complex, 
suggested that both 1 and 2 do not act as simple competitive inhibitors, which should 
only affect the on-rate (Figures 4.6-4.9). 
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Figure 4.6. Representative global fitting of off-event dwell time for 1 at different concentrations. 
 179 
 
Figure 4.7. Representative global fitting of on-event dwell time for 1 at different concentrations. 
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Figure 4.8. Representative global fitting of off-event dwell time for 2 at different concentrations. 
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Figure 4.9. Representative global fitting of on-event dwell time for 2 at different concentrations.  
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 Based on the proposed modes of (CUG)4 binding by the ligand and MBNL1, it is 
possible that both can coexist on the same (CUG)4 molecule: whereas the ligand is 
expected to interact with the U-U mismatch,17 MBNL1 specifically binds to consecutive 
GC nucleotides.33 The observed inhibition likely stems from different affinity of the 
MBNL1 protein for naked and ligand-bound (CUG)4. Most of this effect originates from 
increased off-rate of (CUG)4･MBNL1･ligand complex compared to (CUG)4･MBNL1. This 
situation can be described by a closed scheme of linked equilibria (Table 1a). 
Assumptions derived from our experimental design and conditions allowed us to 
globally fit distributions of the time intervals between binding events, obtained at a range 
of ligand concentrations, to the equation 1. 
,
 
is the equilibrium dissociation constant for ligand (1 or 2) 
binding to (CUG)4. Free and ligand-bound RNA exist in equilibrium defined by  and 
ligand concentration. All single-molecule TIRFM studies were carried out under 
conditions where the concentration of the inhibitor was much greater than was the 
concentration of surface-tethered RNA. Hence, it can be safely assumed that the total 
concentration of ligand equals the concentration of free ligand and is designated as [I] 
below. The second assumption is that only a small fraction of the protein is in the RNA･P 
or RNA･I･P complex because its concentration in the microscope flow cell is significantly 
lower than the expected KD1 or KD3. The binding kinetics can be then deduced from the 
ON time distributions analyzed using the open scheme shown in Table 4.1b where the 
forward flux through the two manifolds will be determine by this ratio: 
 
Equation 1 assumes a simplified open scheme (see Table 4.1b) and contains a double 
exponential 
𝑌 = 𝐶𝑜 𝑠𝑡  [    exp( 𝑘  [MBNL1]  𝑡) + [I]  exp( 𝑘  [MBNL1]  𝑡)]               ( ) 
where the decay constants correspond to kinetic association constants for MBNL1 
binding to (CUG)4, k1, and (CUG)4･I complex, k3, respectively. The two exponentials are 
weighted by the abundance of each manifold under given conditions, which are defined 
by the equilibrium between free and ligand-bound (CUG)4. The experiments were carried 
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out in the presence of 0, 4, 20, 100 and 200 µM of ligand 1 or in the presence of 0, 0.5, 
1, 2, 4, 6 and 8 µM of ligand 2. 
The closed scheme in Table 4.1a was used to analyze the ON time distributions. 
These distributions were globally fit to equation (2). 
𝑌 = 𝐶𝑜 𝑠𝑡  [    exp( (𝑘   𝑘  [I])  𝑡) + [I]  exp( (𝑘   𝑘  )  𝑡)]                 (2) 
Const×KD2 is the weight of manifold (1) whereas Const×[I] is the weight of manifold (2) 
adjusted by the number of observed events. These analyses yielded KD2, k4 and (k-3−k-4). 
Parameters k-3 and k-4 are linked as (k-3−k-4) and therefore cannot be determined 
individually by fitting but can be calculated from the linked equilibria as 𝑘  =
(       )       
             
. The results are summarized in Table 4.1.4  
Indicative of its function as a bivalent inhibitor, the binding affinity of 2 for (CUG)4 was 
almost 50-fold higher that of 1. Because neither 1 nor 2 behave as typical competitive 
inhibitors, but instead allow formation of the (CUG)4･MBNL1･ligand complex, the 
traditionally defined KI is replaced by KD2, which represents the affinity of the ligand for 
(CUG)4. We can, however, define an apparent IC50 as the concentration of ligand at 
which 50% of MBNL1 is free. It is notable, however, that this apparent IC50 depends on 
the concentration of the MBNL1 and (CUG)4 (Figure 4.10) making each inhibitor to be 
effective in a relatively narrow concentration range. 
Because of the kinetic scheme, which includes two pathways, we cannot use the 
traditional definition of KI. We can, however, define the apparent IC50 as a concentration 
of the ligand at which 50% of MBNL1 is free. 
 
 
 
 
 
 
 
                                                 
4
 The single molecule data was collected by Dr. Masayoshi Honda, a postdoctoral researcher in 
Maria Spies lab. The analysis platform was developed by Professor Maria Spies (University of 
Iowa). 
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Table 4.1. Parameters from global fitting of the dwell-time distributions to the closed (a) and open (b) 
schemes of linked equilibria describing state interconversion in the (CUG)4･MBNL1･ligand system. 
ki is assoc. rate const. and k-i is dissoc. rate const. KDi = k-i/ki is equilibrium dissoc. const. for the respective 
step in the Scheme. I = Inhibitor (1 or 2). 
Unless indicated, the errors shown are standard errors from fitting the data.
  
* Errors were calculated as:  
 
 
Manifold 1 
Parameter Significance Value 
k1, s
-1 
M
-1
 
Rate constant for MBNL1 associating to naked (CUG)4 (4.6 ± 0.2) x 10
8
 
k-1, s
-1
 
Rate constant for MBNL1 dissociating from naked (CUG)4 1.44 ± 0.3 
KD1 = k-1/k1, nM
 
Affinity of MBNL1 for (CUG)4 3.1 ± 0.1 
Manifold 2 
Parameter
 
Significance Value for 2 Value for 1 
 
Affinity of ligand for (CUG)4 0.45 ± 0.02 22 ± 3 
 
 4.9  0.3 2.7  0.1 
 
Rate constant for MBNL1 dissociating from 
(CUG)4･MBNL1･I 
5.4 ± 0.3 2.9 ± 0.1 
 
Rate constant for MBNL1 associating to (CUG)4･I (2.7 ± 0.2) × 10
8
 (2.8 ± 0.2) × 
10
8
 
 
Affinity of MBNL1 for ligand-bound (CUG)4 20 ± 2* 10.2 ± 0.8* 
 
Affinity of MBNL1 for ligand-bound relative to 
naked (CUG)4 
0.16 ± 0.01 0.30 ± 0.06 
 
Rate constant for ligand dissociating from 
(CUG)4･MBNL1･I complex 
0.55 ± 0.03 0.12 ± 0.01 
 
Rate constant for ligand associating to (CUG)4･
MBNL1 
(1.93 ± 0.03) × 
10
5
 
(1.7 ± 0.7)×10
3
 
 
Affinity of ligand for MBNL1-bound (CUG)4 2.9 ± 0.2* 71 ± 27* 
 
KD2, mM
k-3 - k-4( ), s
-1
k-3, s
-1
k+3, s
-1M -1
nM
k
k
KD ,
3
3
3


1
3
D
D
K
K
k-4, s
-1
k+4, s
-1M -1
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Apparent ; MBNL1 protein and (CUG)4 are shown as P and RNA, respectively. 
Total protein concentration Ptotaléë
ù
û= P
FREEé
ë
ù
û+ RNA ×P[ ]+ RNA × I ×P[ ] = P; 
Total RNA RNAtotaléë
ù
û= RNA
FREEé
ë
ù
û+ RNA × I[ ]+ RNA ×P[ ]+ RNA × I ×P[ ] = R. 
We need to express IC50 in terms of known concentrations and equilibrium dissociation 
constants: 
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Equation (8) relates the apparent IC50 to the absolute concentrations of protein and 
RNA and to equilibrium dissociation constants. It is obvious that the amount of ligand 
required to observe half of the protein in the free form will greatly depend on actual 
concentrations of ligand and RNA. Thus, it will be potent under relatively narrow set of 
conditions.  
 
Figure 4.10. Apparent IC50 values for 1 and 2 at [MBNL1] = 5 and 50 nM. The concentration of ligand 
required to observe half of MBNL1 in the free form, IC50, depends on actual concentrations of MBNL1 and 
(CUG)4. 
At micromolar concentrations, many small molecules self-associate into colloidal 
aggregates that non-specifically inhibit protein activity. Aggregate-based inhibition is 
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sensitive to detergent,34 therefore we confirmed that the inhibition by 2 was not affected 
by the presence of Triton X-100, eliminating the possibility of ligand aggregation.  
To ensure that the observed inhibition mode does indeed steam from the (CUG)4･
MBNL1･ligand complex formation and not an experimental artifact, we analyzed the 
(CUG)4･MBNL1 binding in the presence of the unlabeled MBNL1 protein, which should 
act a competitive inhibitor of Cy3-MBNL1 binding to the immobilized (CUG)4. Addition of 
unlabeled MBNL1 had no effect on k-1 for the (CUG)4･MBNL1 complex; in contrast k1 
decreased proportionally to the fraction of Cy3-MBNL1 (Figure 4.11). Not only did this 
control experiment confirmed that we can clearly distinguish the different modes of 
inhibition, but also that Cy3-labeling does not interfere with (CUG)4･MBNL1 interaction. 
 
Figure 4.11. Unlabeled MBNL1 acts as a competitive inhibitor. (a) Schematic representation of competitive 
inhibition. (b and c) k-1 is unaffected by addition of unlabeled MBNL1 whereas apparent k+1 is decreased. (d) 
k+1 is linearly dependent on [Cy3-MBNL1]/ ([unlabeled MBNL1] +[Cy3-MBNL1]) ratio. 
 
a 
c d 
b 
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Binding Affinity and MBNL1 Inhibition Potency of Ligand 2 are Nearly 100-fold 
That of 1 in Bulk Experiments. To provide a more conventional confirmation of single-
molecule results, we used SPR to study the inhibition of MBNL1 binding to (CUG)4 and 
(CUG)12. To distinguish binding of ligands from MBNL1 to the immobilized RNA 
constructs, the injection of MBNL1 was preceded by ligand injection. The experiments 
were done in the presence of a large excess of competitor tRNA (1 µM yeast tRNA) to 
confirm the specificity of ligands for CUG repeat. The maximum RU upon MBNL1 
injection at various concentrations of each inhibitor was recorded. These values were 
normalized and plotted versus increasing concentration of each ligand to yield a binding 
isotherm. Apparent IC50 values against (CUG)4 and (CUG)12 for 1 were 174 ± 12 µM and 
293 ± 19 µM, respectively, whereas for 2, the values were 1.3 ± 0.2 µM, and 1.1 ± 0.1 
µM, respectively (Figure 4.13). Biotinylated RNA constructs were immobilized on a 
streptavidin coated surface. The immobilization density for most of the experiments was 
kept under 100 RU. For the stoichiometry study of MBNL1 binding to (CUG)12, 1100 RU 
of (CUG)12 was immobilized. Stoichiometry of MBNL1 binding to CUG12 was obtained 
by measuring the steady state binding response from the injection of a highly 
concentrated MBNL1 solution (12 µM) for 120 s. Although the RU is still not fully reached 
the maximum steady state, we could approximately derive the stoichiometry ratio for 
MBNL1 binding to (CUG)12 using this equation: 𝑅 = (
    
  
)(
   
   
) 
RL is the density of immobilized (CUG)12, ligand, on the chip surface; Rmax is the 
maximum binding response for MBNL1 binding; Sm is the binding stoichiometry; MWL is 
the molecular weight of (CUG)12, 13293 Da, and MWA is the molecular weight of GST-
MBNL1 analyte, 60489 Da. Analysis of the steady-state SPR response unit (RU) yielded 
a binding stoichiometry of almost 3:1 for MBNL1 binding to (CUG)12, which implies that 
one (CUG)12 can bind to three MBNL1 proteins. 
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Figure 4.12. Representative sensogram for stoichiometric study of MBNL1･(CUG)12 interaction. (a) The 
arrows show the starting point of (CUG)12 immobilization and MBNL1 injection. The sensogram suggests 
stoichiometric ratio of 3:1 for MBNL1:(CUG)12 binding as shown schematically in (b). 
RU change in the sensogram was observed upon addition of inhibitors 1 and 2 as 
well as MBNL1, indicating binding to the biotinylated CUG repeats. Therefore, for the 
inhibition studies at different concentrations of small molecules, simultaneous injection of 
both MBNL1 and inhibitors made the analysis impossible. This limitation results from the 
fact that the RU signal would have to be deconvoluted to determine whether the binding 
is from MBNL1 or the small molecule. To circumvent this problem, we set up an 
experiment in which injection of the small molecule preceded the injection of MBNL1. 
This way, by pre-incubation of the surface with small molecule, we were able to reach 
the plateau binding level of the small molecule. Then, while keeping the small molecule 
concentration the same, the second injection gave rise only to the MBNL1 binding. With 
the assumption that ligand does not dissociate significantly under these conditions, the 
proportion of MBNL1 binding that is inhibited at any concentration of small molecule 
could be determined. The highest RU was measured at the point that the injection was 
stopped. This is end point of the association phase and start of the dissociation phase. 
This RU is an indication of MBNL1 binding level, therefore the higher the inhibitor 
concentration, the lower this would be point. 
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Fig 4.13 (cont. on next page) 
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Figure 4.13. Representative Sensograms from SPR studies and fitting data to dose-response curves. 
Biotinylated (CUG)4 is the immobilized ligand in (a) and (c). Biotinylated (CUG)12 is the immobilized ligand in 
(b) and (d). Varying concentration of 1 and 2 are injected from t = -120 s to either t = 120 s (a, b and c) or t = 
240 s (d). GST-MBNL1, 0.65 µM, is injected from t = 0 s to either t = 120 s (a, b and c) or t = 240 s (d). 
Baseline for the curves was set to RU = 0 at t = 0. (e) Inhibition of MBNL1 binding to (CUG)4 in the presence 
of varying concentrations of 1 and 2. (f) Inhibition of MBNL1 binding to (CUG)12 in the presence of varying 
concentrations of 1 and 2. Error bars represent mean ± s.d. of three replicates. 
For each ligand the fact that apparent IC50 values for inhibition of MBNL1 binding to 
either (CUG)4 and (CUG)12 are close, supports the previous findings that both these 
constructs are acceptable models for CUG repeat.30 Normalized IC50 values can be 
calculated by multiplying the actual IC50 by the number of binding modules it has. The 
ratio between normalized IC50 values is the bivalent effect, which is almost 120-fold for 2. 
This improvement in inhibition confirms the inhibition result obtained by single molecule 
TIRF microscopy, however, by this method, we were unable to measure how the binding 
kinetic change in the presence of inhibitors or reveal the inhibition mode of the ligands. 
This is due to the fact that this technique doesn’t allow us to differentiate binding of 
inhibitor from MBNL1. Therefore at any concentration of inhibitor, whether in association 
or dissociation phase, we are detecting association and dissociation of both MBNL1 and 
small molecules to the immobilized RNA construct. This deficiency is overcome in the 
single molecular TIRFM experiments by only MBNL1 with Cy3 which enables us to 
detect binding and unbinding of an individual MBNL1 protein.  
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 Due to non-competitive inhibition mechanism, IC50 values should depend on the 
concentration of immobilized (CUG)n on the SPR sensor chip, which is not measurable. 
Nonetheless, obtaining smaller IC50 value for 2, compared to 1, is in agreement with the 
single-molecule results. To verify that 1 and 2 don’t bind to MBNL1 protein we carried 
out Isothermal Titration Calorimetry experiments. ITC titration curves show no 
measureable interaction between the ligands and MBNL1 protein (Figure 4.14). 
Figure 4.14. ITC binding isotherms and titration curves of 1 (a) and 2 (b) to MBNL1.solution. No 
measureable binding is observed.  
To measure the binding constants of 1 and 2 to CUG repeat by another bulk approach, a 
steady state fluorescence titration method with TAMRA-(CUG)6 was utilized. It is known 
that guanosine quenches the TAMRA fluorescence through photoinduced electron 
transfer.35, 36 Therefore, it is possible that binding of a ligand to the UU mismatch close to 
5’-TAMRA makes a structural change that can lead to quenching of the 5’-TAMRA by the 
3’-G in 5’-TAMRA-(CUG)6 -3’. Ligands 1 and 2 were titrated into TAMRA-(CUG)6 
solution.  
a b 
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Figure 4.15. Fluorescence titrations of TAMRA-(CUG)6 with 1 and 2. Comparison of normalized 
fluorescence intensity change of TAMRA-(CUG)6 in the presence of increasing concentrations of 1 and 2. 
TAMRA was excited at 560 nm and its emission was recorded at 590 nm. Error bars represent mean ± s.d. 
of three replicates. 
Upon increasing the ligand concentration, TAMRA fluorescence intensity gradually 
decreased as a result of fluorophore quenching by the bound ligand. A plot of normalized 
fluorescence intensity versus increased concentrations of each ligand yielded a binding 
isotherm with KD of 66 ± 2 µM and 318 ± 15 nM for 1 and 2, respectively (Figure 4.15). 
These KD values are similar to what we derived from the single-molecule study (Table 1). 
Figure 4.16. Schematic representation of steady-state fluorescence titrations of TAMRA-(CUG)6 with 1 and 
2. 
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4.4 Discussion 
RNA is emerging as an attractive drug target because of its central role in transcription, 
translation, and an ever-growing number of key cellular processes.37 Most traditional 
RNA targeted drug discovery has focused on antibiotics and anti-HIV drug candidates.38 
However non-coding RNA as a drug target has recently gained significant attention.39 In 
many diseases, such as DM1, targeting RNA is the most appropriate option as the RNA 
is the causative agent of the pathology, whereas the protein function should not be 
altered.40 Despite their potential health benefits, the development of small molecules that 
specifically target RNA is still in its infancy. Previous studies, including our own, have 
identified small molecule inhibitors of the MBNL1･CUGexp interaction. In each case it was 
assumed that the identified small molecule acts as a conventional competitive inhibitor. 
To further develop this approach to drug discovery, it is vital to establish the exact 
mechanism of the inhibition and ideally to provide a full kinetic and thermodynamic 
picture of the process.11 Thus, we undertook the first study of its kind to provide a full 
description of the mechanism by which a protein･RNA interaction is inhibited at the 
single molecule level. 
We developed and employed a TIRFM-based single molecule analysis to study the 
interaction of MBNL1, a key regulatory protein in alternative splicing process, and 
(CUG)4, a validated model of CUG
exp as well as the inhibition of this interaction by the 
small molecule RNA binding ligands. Our analysis revealed the affinity of MBNL1 for 
(CUG)4 to be 3.1 ± 0.1 nM, whereas using EMSA we,
17 and others30 reported KD values 
of 26 ± 4 nM and 170 ± 20 nM, respectively. This was not surprising because the single-
molecule measurements were carried out under true equilibrium conditions, whereas 
EMSA can underestimate affinity because the short-lived complexes may dissociate 
while being resolved. Additionally, only productive (native) interactions between (CUG)4 
and MBNL1 molecules were detected by the single-molecule measurements thereby 
canceling out any possible errors resulting from heterogeneity of MBNL1 or (CUG)4.  
Single-molecule analyses of the MBNL1･(CUG)4 interaction in the presence of two 
inhibitors allowed us to determine the affinities of the two tested ligands for (CUG)4 as 
well as how they affect MBNL1･(CUG)4 complex formation. Notably, the equilibrium 
dissociation constants for the ligand･(CUG)n binding determined in bulk and at the 
single-molecule level were very similar. Converging of the binding affinity of the 1･
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(CUG)n and 2･(CUG)n complexes (n = 4 or 6) measured by the fluorescence and single-
molecule methods to the same value validated the single-molecule method. Our single-
molecule analysis was model-independent and suggested an inhibition mode that has 
not been considered previously: instead of competing for the same binding site the 
ligands and MBNL1 can form a ternary complex on (CUG)4. 
 
Figure 4.17. Schematic representation of proposed non-competitve MBNL1･CUGexp inhibition by 2. 
In the more physiologically relevant buffer used in this study, ligand 1 was a relatively 
weak inhibitor, which bound to (CUG)4 with a low affinity (i.e., KD = 22 ± 3 µM). Moreover, 
it allowed MBNL1 to bind to the 1･(CUG)4 complex with a very high affinity (KD = 10.2 ± 
0.8 nM). This interesting finding prompted us to design more effective small molecules. 
We pursued a bivalent ligand with the idea that it would: (1) bind to CUGexp with a higher 
affinity and ideally weaken the MBNL1 interaction with ligand･CUGexp, (2) exhibit a 
longer occupancy time and increase the RNA ds stabilization, if MBNL1 indeed binds 
preferentially to the ss form of RNA as has been suggested,41, 42 and (3) bind a longer 
segment of RNA to achieve more effective coverage and steric blocking of CUGexp. 
To reach the drug development goals outlined above, we designed a library of dimeric 
ligands and found 2 to be the most potent inhibitor of CUG repeat･MBNL1 interaction. 
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The affinity of 2 for (CUG)4 was measured by the single-molecule method to be KD = 450 
± 20 nM, a value that is almost 50-fold lower than that measured for 1. Despite this large 
increase in affinity, MBNL1 can still bind to the 2･(CUG)4 complex. This unexpected 
observation of a non-competitive inhibition mode for both 1 and 2 is the key finding of 
this study. Its implication for drug design is obvious. The 2･(CUG)4 complex reduces the 
MBNL1 affinity only 6-fold relative to naked (CUG)4 and 2-fold relative to that measured 
for the 1･(CUG)4 complex. Thus, tight binding is an insufficient criterion for effective 
inhibition because it may shift the overall equilibrium into manifold 2 of Table 4.1a (i.e., 
low KD2) without necessarily affecting MBNL1 binding. Highly effective inhibition will 
result from agents that exhibit both tight and selective binding to CUGexp (low KD2) and 
high KD3 values.  
Another significant result is that the apparent IC50 values for the ligands depend 
markedly on both (CUG)4 and MBNL1 concentrations (Figure 4.10). Thus, the CUG
exp 
length and cellular copy number and the MBNL1 concentration will determine the drug 
effectiveness. Because the CUG repeat continues to expand over the patient’s life, an 
ideal therapeutic agent should be able to inhibit binding of MBNL1 to CUGexp over a 
broad range of nuclear CUGexp copy number and repeat lengths. By single molecule and 
bulk methods (Figures 4.10, 4.13 and Table 4.1) we found that, given the same 
concentration of MBNL1, 2 effectively inhibits (CUG)n･MBNL1 (n= 4 or 12) interaction to 
a greater extent than 1 and over a broader range of (CUG)n concentrations, a trend that 
can be further improved in the future ligands.  
4.5 Conclusion 
This study revealed that inhibition of (CUG)4･MBNL1 interaction by small molecules 
does not occur by a simple competitive mechanism. These findings aided in the design 
of a more potent (CUG)4･MBNL1 inhibitor and are guiding our current optimization 
efforts. More generally, the increasingly frequent discovery of key roles for RNA outside 
its established role in protein synthesis suggests new opportunities for RNA-targeted 
therapeutics. Indeed, RNA is now a validated, yet underutilized drug target, with less off-
pathway binding. As the development of inhibitors for protein･RNA interactions becomes 
more widespread, we believe the inhibition model revealed in this study will need to be 
considered. It is likely that the dynamic and versatile structure of RNA allows it to form 
ternary ligand･protein･RNA complexes, although with lower stability.43 Finally, the single-
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molecule methodology described herein may prove to be a powerful method to unravel 
the inhibition mechanism for any biomacromolecular interaction. 
 
 
Figure 4.18. Schematic representation of four states in equilibrium in the proposed non-competitve MBNL1･
CUG
exp
 inhibition by ligands. 
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4.6 Materials and Methods 
Instrumentation and Chemicals. All reagents were purchased from commercial 
suppliers and were used without further purification. Anhydrous solvents were obtained 
from an anhydrous solvent dispensing system. For all reactions employing anhydrous 
solvents, glassware was oven-dried, cooled under vacuum, and then purged with dry 
nitrogen; all reactions were conducted under dry nitrogen. Purified compounds were 
further dried under high vacuum (0.01–0.05 Torr) or lyophilized using a Labconco 
lyophilizer. Yields refer to purified and spectroscopically pure compounds. NMR spectra 
were recorded at 23 °C on either Varian Unity 500 or Varian Unity Inova 500NB, 
operating at 500 MHz and 125 MHz for 1H and 13C acquisitions, respectively. NMR 
spectra were processed using MestReNova software. Chemical shifts are reported in 
ppm and referenced to the corresponding residual nuclei in the following deuterated 
solvents: CDCl3 (7.26 ppm 
1H, 77.16 ppm 13C); DMSO (2.50 ppm 1H, 39.52 ppm 13C); 
D2O (4.79 ppm 
1H); CD3OD (3.31 ppm 
1H, 50.41 ppm 13C). Multiplicities are indicated by 
s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), sext (sextet), dd (doublet of 
doublets), ddd (doublet of doublet of doublets), td (triplet of doublets), dt (doublet of 
triplets), m (multiplet), b (broad). Integration is provided and coupling constants, J, are 
reported in Hertz (Hz). ESI mass spectra were recorded using the Quattro or ZMD mass 
spectrometer. High resolution mass spectra (HRMS) were obtained at the University of 
Illinois mass spectrometry facility. All compounds described herein gave NMR and mass 
spectral data in accord with their structures. Ligands 1 and 2 gave a HRMS within 5 ppm 
of calculated values. 
MBNL1N Plasmid and RNA. The expression vector pGEX-6p-1/MBNL1N was 
obtained from Maurice S. Swanson (University of Florida, College of Medicine, 
Gainesville, FL, USA) 44. MBNL1N is comprised of the four zinc finger motifs of MBNL1. 
It contains a 6xHis tag at the C-terminus and the GST tag at the N-terminus. MBNL1N 
binds RNA with similar affinity as the full-length MBNL1. It is referred to as MBNL1 
throughout this paper for the sake of simplicity. All the oligonucleotides were purchased 
from Integrated DNA Technology and were HPLC purified. The sequences and 
modifications for RNA constructs used in each study are shown in the respective 
material section. 
MBNL1N Protein Expression and Purification. Using BL21-CodonPlus(DE3)-RP 
competent cells (Stratagene), the expression of MBNL1N protein was induced with 1mM 
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IPTG at OD600 0.6 in LB media with ampicillin for 2 h at 37 
oC. Bacterial cells were 
collected by centrifugation and were then resuspended in a lysis buffer containing 25 
mM Tris-Cl (pH = 8), 0.5 M NaCl, 10 mM imidazole, 2 mM BME, 5% glycerol, 0.1% 
Triton X-100, 2 mg/mL lysozyme, 0.1 mM PMSF, 1 µM pepstatin, and 1 µM leupeptin, 
and sonicated six times for 15 s each. The cell pellet was centrifuged, and the clarified 
lysate was collected and filtered through a 45 µm Millex Filter (Millipore). To purify 
MBNL1N, Ni-NTA agarose (QIAGEN) was incubated with the lysate for 1 h at 4 oC and 
washed with a washing buffer containing 25 mM Tris-Cl (pH = 8), 0.5 M NaCl, 20 mM 
imidazole and 0.1% Triton X-100, followed by elution with elution buffer of 25 mM Tris-Cl 
(pH = 8), 0.5 M NaCl, 250 mM imidazole and 0.1% Triton X-100. The eluate containing 
the GST fusion 6xHis-MBNL1N was dialyzed against PBS, 1X buffer for using in SPR 
analysis. The molecular weight was confirmed by MALDI mass spectrometry and the 
concentration was determined by Bradford assay. 
Preparation of Cy3-MBNL1 Protein for TIRFM Study. The GST fusion protein was 
incubated with Glutathione Sepharose 4B (GE Healthcare) for 1 h at 4 oC. After washing 
with a buffer containing 25 mM Tris-Cl (pH = 8), 300 mM NaCl, 5 mM BME and 0.1% 
Triton X-100, the beads were collected and incubated with PreScission Protease (GE 
Healthcare) overnight at 4 oC. After being cleaved from the beads, the protein was 
collected in the flow-through of the column. Fluorescent labeling of MBNL1 was 
performed by coupling Cy3 mono-reactive NHS esters (GE Healthcare) to the N-terminal 
amine group at pH = 7.0.45-47 MBNL1 was mixed with a 12.5-fold molar excess of the 
Cy3 mono-reactive NHS ester in potassium phosphate buffer (62 mM K2HPO4, 38 mM 
KH2PO4, pH = 7.05, 100 mM NaCl, 1 mM DTT) for 10 min at room temperature. The 
reaction mixture was incubated for 12 h at 4 °C. The labeling reaction was terminated by 
the addition of 50 mM Tris-HCl, pH = 7.5. Cy3-labeled MBNL1 was separated from the 
free dye using PD SpinTrap G-25 column (GE healthcare). The ratio of dye incorporated 
per protein molecule was determined to be 1.1 mol Cy3 per 1 mol MBNL1. The 
sequences and modifications for RNA constructs used in this study: 
(CUG)4 construct: 5’- Cy5-GCUGCUGUUCGCUGCUG-TEG-Biotin – 3’ 
(CUG)12 construct:  
5’- GCCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGGC-TEG-Biotin – 3’ 
Steady State Fluorescence-Based Binding Assays. To determine the equilibrium 
parameters for binding of 1 and 2 to CUGexp, we followed quenching of TAMRA in 
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TAMRA-(CUG)6 at various ligand concentrations. The assays were performed using a 
Cary Eclipse Fluorescence Spectrophotometer (Varian). TAMRA-(CUG)6 was excited at 
560 nm and its emission was recorded at 590 nm. Stoichiometric titrations were carried 
out at 20 oC in PBS, 1X buffer. The baseline fluorescence was recorded before addition 
of 20 nM TAMRA-(CUG)6. Increase in the fluorescence was recorded and attributed to 
the fluorescence of TAMRA-(CUG)6. Upon addition of each aliquot of 1 or 2, the 
fluorescence signal was allowed to equilibrate, recorded over 5 min, and averaged. 
Titration was continued at a series of increasing final concentrations of the ligand until 
the fluorescence was completely quenched. Fluorescence intensities at different 
concentrations of 1 (1.95. 3.91, 7.81, 15.6, 31.4, 62.8, 94.2, 125.6, 157, 500 and 1000 
µM) and 2 (39, 90, 210, 300, 390, 480, 570, 660, 750, 840 and 1250 nM) were fit to the 
following equation using Kaleidagraph software: 
 =
        
 + (
  
[ ]
) 
+    
KD is the dissociation binding constant, [L] is the ligand concentration, n is the Hill 
coefficient and F0 and Fmax are the fluorescence intensity of free and fully bound RNA, 
respectively. In the control experiment, ligands 1 and 2 had no effect on the fluorescence 
intensity of the free TAMRA fluorophore. The sequences and modifications for (CUG)6 
RNA construct used in this study: 5’- TAMRA-CUGCUGCUGCUGCUGCUG – 3’ 
Reaction Conditions for the Single Molecule Assay. Biotinylated (CUG)4 or (CUG)12 
were immobilized on a quartz surface, which was coated with polyethylene glycol in 
order to eliminate nonspecific surface adsorption of proteins. The immobilization was 
mediated by biotin-neutravidin interaction between biotinylated Cy5-labeled (CUG)4, 
neutravidin and biotinylated polymer (PEG, MW = 5,000). Standard PBS buffer 
contained the oxygen scavenging system consisting of 1 mg/mL glucose oxidase, D-
glucose (0.4%, w/v), 2-mercaptoethanol (1%, v/v) and 0.04 mg/mL catalase. 
Immobilization of 50 pM of each oligonucleotide allowed for detection of 100–600 
individual molecules per slide. Cy3 labeled MNBL1 was then added and incubated for 5 
min at 25°C in the standard PBS, 1X buffer in the absence or presence of the indicated 
concentrations of 1 and 2. Sample excitation and data recording were initiated after all 
components of the MBNL1･(CUG)4･inhibitor system were allowed to equilibrate in the 
TIRFM sample chamber. The presence of ligands had no effect on the fluorescence 
intensity of the Cy3 labeled MBNL1.  
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Figure 4.19. Schematic representation of TIRF set-up used in the MBNL1･CUGexp inhibition study by 
ligands (courtesy of Dr. Masayoshi Honda). 
Single Molecule Data Acquisition and Analysis. TIRFM was used to excite 
fluorophores present near the surface, within the evanescent field. Cy3 fluorescence 
was excited by a DPSS laser (532 nm, 75 mW), while diode laser (641 nm, 100 mW) 
was used for direct Cy5 excitation. The fluorescence signals originated from the Cy3 and 
Cy5 dyes were collected by a water immersion 60x objective, separated by a 630 nm 
dichroic mirror, passed through a 550 nm long-pass filter to block out laser scattering 
and detected by EMCCD camera with a time resolution of 100 ms. Single molecule 
fluorescence trajectories were extracted from the recorded video file by IDL software. 
The collected trajectories were visualized using an in-house MATLAB program and were 
validated for the presence of the Cy5 signal by visual inspection of the acquired data. 
The Cy3 excitation regions of all individual trajectories were fit to the two-state model 
using the QuB software. This fitting generated the dwell times in the bound (ON) and 
free (OFF) states of the immobilized RNA molecules, which were binned and plotted as 
the histograms. The resulting ON and OFF event distributions were globally fit to 
exponential decay functions or to models described by equations (1) and (2) using Prism 
4.0 software to obtain the kinetic parameters. 
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Figure 4.20. Schematic representation of TIRF microscopy set-up used to localize Cy5-labeled (CUG)4 and 
Cy3-labeled MNBL1 (courtesy of Dr. Masayoshi Honda). 
Surface Plasmon Resonance (SPR) Analysis. All SPR experiments were 
conducted on a streptavidin coated sensor chip using a Biacore 3000 instrument. 
Streptavidin coated research grade sensor chips were preconditioned with three 
consecutive 1-minute injections of 1 M NaCl/ 50 mM NaOH before the immobilization 
was started. 3’-biotin labeled RNA (CUG4 or CUG12) was captured on flow cell 2 
(Response Unit, RU, between 100-1100). Flow cell 1 was used as a reference. Inhibition 
analysis was carried out in PBS, 1X buffer, pH = 7.4, containing 0.05% Tween-20 and 
0.2 mg/mL (7.4 µM or 580 µM nucleotides) bulk yeast t-RNA to confirm the specificity of 
inhibition. Various concentrations of 1 and 2 were flowed at a rate of 20 µL/min for 240 s 
over the immobilized RNA. After the initial 120 s, a solution of GST-MBNL1 protein, 600 
nM, in the same buffer was also flowed over the surface for the rest of time, 120 s. The 
reference-subtracted sensograms were recorded.  
After the dissociation phase, the surface was regenerated, with a pulse of 0.5% SDS 
and/or 100 mM NaOH, for a few times followed by buffer wash to re-establish baseline. 
RU upon the injection of PBS buffer was subtracted from sensograms. For inhibition 
studies, the resulting sensograms were baselined at t = 120 s to offset the binding of 
small molecule to the immobilized RNA surface. The peak RU (t = 120 s) was recorded. 
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Two or three separate SPR experiments on different sensor chips with different levels of 
RNA immobilization were performed to verify that the values are not affected by surface 
RNA density. The sequences and modifications for RNA constructs used in this study: 
(CUG)4 construct: 5’- GCUGCUGUUCGCUGCUG-TEG-Biotin - 3’ 
(CUG)12 construct:  
5’- GCCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGGC-TEG-Biotin – 3’ 
Isothermal Titration Calorimetry. ITC measurements were performed at 25 °C on a 
MicroCal VP-ITC (MicroCal). Experiment consisted of titrating 10 µL of a 5 µM ligand 
from a 280 µL syringe (rotating at 300 rpm), for a total of 28 injections, into a sample cell 
containing 1.42 mL of a 0.2 µM MBNL1N solution. The duration of the injection was set 
to 24 s, and the delay between injections was 300 s. The initial delay before the first 
injection was 60 s. To derive the heat associated with each injection, the area under 
each isotherm (microcalories per second versus seconds) was determined by integration 
by the graphing program Origin 5.0 (MicroCal). The stock solution of 1 and 2 were 10mM 
in DMSO and water, respectively. The buffer solution for ITC experiments was 1X PBS, 
pH 7.0. 5% DMSO was added to the buffer for experiments with 1 to balance the 
residual DMSO in the ligand solution. 
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4.7 Experimental Synthetic Procedures 
 
Figure 4.21. Synthesis of 9-((4-((4,6-Diamino-1,3,5-triazin-2-yl)amino)butyl)amino)-N-methylacridine-2-
carboxamide (1). 
N2-(4-Aminobutyl)-1,3,5-triazine-2,4,6-triamine (5). Title compound was prepared as 
described previously,17 in 80% yield. 1H NMR (500 MHz, DMSO-d6) δ 6.40 (t, J = 5.6 Hz, 
1H), 6.05 (s, 2H), 5.88 (s, 2H), 3.14 (q, J = 6.3 Hz, 2H), 2.54 – 2.52 (m, 2H), 1.44 (p, J = 
7.1 Hz, 2H), 1.37 – 1.31 (m, 2H). 
2-((4-Carboxyphenyl)amino)benzoic acid (6). Title compound was prepared as 
described previously,24 with minor changes in the work-up procedure, in 70% yield. 1H 
NMR (500 MHz, DMSO-d6) δ 9.87 (bs, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 8.7 Hz, 
5 
5 
8 7 
6 
9 
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2H), 7.50 – 7.46 (m, 2H), 7.27 (d, J = 8.7 Hz, 2H), 6.96 – 6.91 (m, 1H).; m/z LRMS (ESI) 
calculated for [M+H]+: 258.1; found 258.1. 
9-Oxo-9,10-dihydroacridine-2-carboxylic acid (7). Title compound was prepared as 
described previously,25 with minor changes in the work-up procedure, in 95% yield. 1H 
NMR (400 MHz, DMSO-d6) δ 12.90 (bs, 1H), 12.06 (s, 1H), 8.83 (d, J = 2.0 Hz, 1H), 8.22 
(ddd, J = 17.7, 8.4, 1.6 Hz, 2H), 7.8 – 7.76 (m, 1H), 7.6 – 7.57 (m, 2H), 7.36 – 7.27 (m, 
1H); 13C NMR (125 MHz, DMSO-d6) δ 177.00, 167.41, 143.13, 140.90, 134.12, 133.88, 
133.62, 128.38, 126.10, 121.76, 120.85, 119.69, 117.69, 117.38; m/z LRMS (ESI) 
calculated for [M+H]+: 240.1; found 240.1. 
9-Chloro-N-methylacridine-2-carboxamide (9). A round-bottom flask, equipped with a 
stir bar, was charged with 7 (375 mg, 1.6 mmol, 1 equiv.) and freshly distilled thionyl 
chloride (2 mL, 27.5 mmol , 17.2 equiv.). A catalytic amount of DMF was added and the 
solution was heated gently under reflux at 69 ºC, stirring until homogeneous and then for 
1 h. The excess thionyl chloride was distilled off and the last traces were removed 
azeotropically via coevaporation with DCM (3 x 50 mL). The mixture was left under 
vacuum (minimally) for 1 hr to afford the crude intermediate, 8, as a yellow powder. 1H 
NMR (500 MHz, chloroform-d) δ 9.48 (d, J = 1.5 Hz, 1H), 9.25 (d, J = 9.2 Hz, 1H), 9.16 
(d, J = 8.8 Hz, 1H), 8.72 – 8.62 (m, 2H), 8.37 – 8.30 (m, 1H), 8.06 – 7.99 (m, 1H); m/z 
LRMS (ESI) calculated for [M+H]+: 276.0; found 276.0. The crude intermediate, without 
further purification, was dissolved in anhydrous DCM. Anhydrous triethylamine was 
added to the solution until the pH = 11 and it was cooled to 0 ºC. A 2M solution of 
methylamine in methanol (0.9 mL, 1.8 mmol, 1.1 equiv.) was added and the solution was 
stirred at 0 ºC for 2 h and then slowly warmed to room temperature overnight. The 
solvent was removed by rotary evaporation and the crude mixture was purified via flash 
chromatography (SiO2; CH2Cl2:MeOH, 98:2 to 95:5) to yield 9 as a yellow solid (325 mg, 
1.2 mmol, 75%). 1H NMR (500 MHz, chloroform-d) δ 8.79 (d, J = 1.6 Hz, 1H), 8.40 (d, J 
= 8.6 Hz, 1H), 8.24 – 8.19 (m, 2H), 8.14 (dd, J = 9.0, 1.8 Hz, 1H), 7.86 – 7.83 (m, 1H), 
7.69 – 7.62 (m, 1H), 6.56 (bs, 1H), 3.13 (d, J = 4.8 Hz, 3H); m/z LRMS (ESI) calculated 
for [M+H]+: 271.1; found 271.1. 
9-((4-((4,6-Diamino-1,3,5-triazin-2-yl)amino)butyl)amino)-N-methylacridine-2-
carbox-amide (1). A round-bottom flask, equipped with a stir bar, was charged with 9 
(290 mg, 1.07 mmol, 1 equiv.) and 5 (233 mg, 1.18 mmol, 1.1 equiv.). DIPEA (305 mg, 
2.36 mmol, 2.2 equiv.) and anhydrous DMF (20 mL) were added. The solution was 
heated at 70 ºC for 5 h. The solvent was removed by rotary evaporation and the product 
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was purified via flash chromatography (basic alumina; DCM:methanol:NH4OH, 
95:4.9:0.1 to 85:14:1) to yield a yellow solid (377 mg, 0.76 mmol, 71%). 1H NMR (500 
MHz, methanol-d4) δ 8.91 (s, 1H), 8.33 (d, J = 8.6 Hz, 1H), 8.02 (dd, J = 9.1, 1.9 Hz, 1H), 
7.85 (t, J = 7.6 Hz, 2H), 7.75 – 7.68 (m, 1H), 7.42 – 7.35 (m, 1H), 4.03 (t, J = 7.2 Hz, 
2H), 3.37 – 3.33 (m, 2H), 3.00 (s, 3H), 1.93 (p, J = 7.4 Hz, 2H), 1.70 (p, J = 7.2 Hz, 2H); 
m/z HRMS (ESI) calculated for [M+H]+: 432.2260; found 432.2267. 
 
Figure 4.22. Synthesis of Di-tert-Butyl propane-1,3-diylbis((3-aminopropyl)carbamate (12). 
N,N'-((Propane-1,3-diylbis(azanediyl))bis(propane-3,1-diyl))bis(2,2,2-trifluoro 
acetamide) (10). The title compound was prepared from N1,N1'-(propane-1,3-
diyl)bis(propane-1,3-diamine) as described previously,4 with minor changes, in 77% 
yield. 1H NMR (500 MHz, DMSO-d6) δ 9.61 (s, 2H), 8.75 (bs, 2H), 3.26 (q, J = 6.5 Hz, 
4H), 3.02 – 2.95 (m, 4H), 2.94 – 2.88 (m, 4H), 1.91 (p, J = 7.8 Hz, 2H), 1.82 (p, J = 7.0 
Hz, 4H); 13C NMR (125 MHz, DMSO-d6) δ 156.40, 117.08, 44.63, 44.02, 36.61, 25.22, 
22.56; m/z LRMS (ESI) calculated for [M+H]+: 381.2; found 381.2. 
Di-tert-Butyl propane-1,3-diylbis((3-(2,2,2-trifluoroacetamido)propyl)carbamate) 
(11). The title compound was prepared as described previously,4 with minor changes. 
The product was purified via flash chromatography (SiO2; CH2Cl2:MeOH, 98:2 to 95:5) to 
afford S7 in 85% yield. 1H NMR (500 MHz, DMSO-d6) δ 9.42 (bs, 2H), 3.18 – 3.07 (m, 
12H), 1.71 – 1.60 (m, 6H), 1.37 (s, 18H); m/z LRMS (ESI) calculated for [M+H]+: 581.3; 
found 581.3. 
10 
11 
12 
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Di-tert-Butyl propane-1,3-diylbis((3-aminopropyl)carbamate (12). The title compound 
was prepared as described previously,26 with minor changes. The product was purified 
via flash chromatography (SiO2; CH2Cl2:MeOH:NH4OH, 80:19:1 to 67:30:2) to afford S8 
in 80% yield. 1H NMR (500 MHz, chloroform-d) δ 3.28 (s, 4H), 3.16 (s, 4H), 2.69 (t, J = 
6.4 Hz, 4H), 1.75 (s, 2H), 1.64 (p, J = 6.8 Hz, 4H), 1.45 (s, 18H); 13C NMR (126 MHz, 
chloroform-d) δ 155.29, 79.06, 44.44, 43.68, 38.96, 32.34, 31.73, 28.17; m/z LRMS 
(ESI) calculated for [M+H]+: 389.3; found 389.3.  
 
13 
14 
12 
15 
5 
16 
 208 
 
2,2'-Iminodibenzoic (13). A round-bottom flask, equipped with a stir bar, was charged 
with 2-bromobenzoic acid (3.00 g, 14.9 mmol, 1 equiv.), anthranilic acid (2.25 g, 16.4 
mmol, 1.1 equiv.), K2CO3 (6.00 g, 44 mmol, 2.95 equiv.), Cu (0.20 g, 2.9 mmol, 0.2 
equiv.) and Cu2O (0.22 g, 1.45 mmol, 0.1 equiv.). To this mixture, anhydrous DMF (50 
mL) was added and it was stirred at reflux at 130 ºC for 16 h. The work-up procedure 
was carried out as reported previously,27 to yield 2,2'-iminodibenzoic acid in 91% yield as 
a light green solid. 1H NMR (400 MHz, DMSO-d6) δ 13.06 (bs, 1H), 10.85 (bs, 1H), 7.91 
(s, 2H), 7.46 (s, 4H), 6.95 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 168.41, 143.58, 
133.38, 131.81, 119.99, 117.56, 113.56; m/z LRMS (ESI) calculated for [M+H]+: 258.1; 
found 258.1. 
9-Oxo-9,10-dihydroacridine-4-carboxylic acid (14). The title compound was prepared 
as described previously,25 with minor changes in the work-up procedure, in 95% yield. 1H 
NMR (500 MHz, DMSO-d6) δ 11.96 (s, 1H), 8.53 (dd, J = 8.0, 1.5 Hz, 1H), 8.45 (dd, J = 
7.5, 1.7 Hz, 1H), 8.24 (d, J = 8.1 Hz, 1H), 7.82 – 7.73 (m, 2H), 7.39 – 7.30 (m, 2H); 13C 
NMR (125 MHz, DMSO-d6) δ 176.53, 169.14, 141.20, 139.92, 136.90, 134.11, 132.41, 
125.89, 122.32, 121.63, 120.60, 120.24, 118.63, 115.01; m/z LRMS (ESI) calculated for 
[M+H]+: 240.1; found 240.1. 
Di-tert-Butylpropane-1,3-diylbis((3-(9-chloroacridine-4-carboxamido)propyl) 
carbamate) (15). A round-bottom flask equipped with a stir bar was charged with 14 
(600 mg, 2.5 mmol, 1 equiv.) and freshly distilled thionyl chloride (3 mL, 41 mmol , 16.4 
equiv.). A catalytic amount of DMF was added and heated gently under reflux at 69 ºC, 
stirring until homogeneous and then for 1 h. The excess thionyl chloride was distilled off 
and the last traces removed azeotropically via coevaporation with DCM (3 x 50 mL). It 
was left under vacuum for (minimally) 1 h to afford the crude intermediate as a yellow 
powder. The crude intermediate was dissolved in anhydrous DCM. Anhydrous 
triethylamine was added to the solution until the pH was 11 and it was cooled to 0 ºC. 12 
(437 mg, 1.125 mmol, 0.45 equiv.) was added and the solution was stirred at 0 ºC for 2 h 
and slowly warmed to room temperature overnight. The solvent was removed by rotary 
evaporation and the crude mixture was purified via flash chromatography (SiO2; 
CH2Cl2:MeOH, 98:2 to 95:5) to yield a yellow solid (586 mg, 0.675 mmol, 60%). 
1H NMR 
(500 MHz, chloroform-d) δ 9.00 (s, 2H), 8.36 (d, J = 14.0 Hz, 4H), 8.27 (s, 2H), 8.20 (d, J 
= 16.2 Hz, 4H), 7.80 (s, 2H), 7.65 – 7.60 (m, 2H), 3.54 (s, 4H), 3.46 (d, J = 12.0 Hz, 4H), 
3.23 (s, 4H), 1.86 (dd, J = 14.5, 7.5 Hz, 6H), 1.52 (s, 18H); 13C NMR (125 MHz, 
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chloroform-d) δ 166.30, 156.65, 149.56, 149.23, 142.50, 132.76, 131.12, 130.12, 
129.75, 128.54, 127.13, 124.59, 124.33, 123.26, 80.31, 44.94, 43.54, 36.14, 28.52, 
27.87, 27.63; m/z LRMS (ESI) calculated for [M+H]+: 867.3; found 867.3. 
Di-tert-Butylpropane-1,3-diylbis((3-(9-((4-((4,6-diamino-1,3,5-triazin-2-yl)amino) 
butyl)amino)acridine-4-carboxamido)propyl)carbamate) (16). A round-bottom flask, 
equipped with a stir bar, was charged with 15 (500 mg, 0.576 mmol, 1 equiv.) and N2-(4-
Aminobutyl)-1,3,5-triazine-2,4,6-triamine (250 mg, 1.27 mmol, 2.2 equiv.). DIPEA (327 
mg, 2.53 mmol, 4.4 equiv.) and anhydrous DMF (25 mL) were added. The solution was 
heated at 70 ºC for 5 h. The solvent was removed by rotary evaporation and the product 
purified via flash chromatography (basic alumina; DCM:methanol:NH4OH, from 
95:4.9:0.1 to 90:9.5:0.5) to yield a yellow solid (377 mg, 0.317 mmol, 55%).1H NMR (500 
MHz, methanol-d4) δ 8.60 (s, 2H), 8.37 (d, J = 8.5 Hz, 2H), 8.20 (d, J = 8.5 Hz, 2H), 7.96 
– 7.76 (m, 2H), 7.63 (s, 2H), 7.37 – 7.27 (m, 4H), 3.82 (s, 4H), 3.49 (s, 4H), 3.35 (s, 4H), 
3.27 (t, J = 6.8 Hz, 4H), 3.19 (s, 4H), 1.94 – 1.76 (m, 10H), 1.59 (d, J = 7.0 Hz, 4H), 1.34 
(d, J = 35.9 Hz, 18H); m/z LRMS (ESI) calculated for [M+H]+: 1189.7; found 1189.7. 
N,N'-((Propane-1,3-diylbis(azanediyl))bis(propane-3,1-diyl))bis(9-((4-((4,6-diamino-
1,3,5-triazin-2-yl)amino)butyl)amino)acridine-4-carboxamide) (2). A round-bottom 
flask, equipped with a stir bar, was charged with 16 (310 mg, 0.261 mmol, 1 equiv.). TFA 
(30 mL) and anhydrous DCM (70 mL) was added and the mixture stirred at room 
temperature for 2 h. The solvents were removed to afford a yellow solid (437 mg, 0.261 
mmol, 100%). 1H NMR (500 MHz, deuterium oxide) δ 8.34 (d, J = 8.3 Hz, 2H), 8.17 (d, J 
= 8.3 Hz, 2H), 8.11 (d, J = 7.4 Hz, 2H), 7.78 (t, J = 7.7 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 
7.48 – 7.39 (m, 4H), 4.07 (t, J = 6.8 Hz, 4H), 3.58 (t, J = 6.7 Hz, 4H), 3.37 – 3.29 (m, 
4H), 3.26 (t, J = 5.9 Hz, 8H), 2.31 (s, 2H), 2.14 – 2.08 (m, 4H), 1.98 – 1.91 (m, 4H), 1.71 
– 1.65 (m, 4H); Elemental analysis, Calculated for C63H70F18N20O14: C, 45.22 %; H, 4.22 
%; F, 20.44 %; N, 16.74 % ; Found: C, 45.15 %; H, 4.20 %; F, 20.09 %; N, 16.46 %, m/z 
HRMS (ESI) calculated for [M+H]+: 989.5599; Found 989.5590. 
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Chapter 5.
5
  
CUGexp Conformation Study  
5.1 Study of the effect of MBNL1 on CUGexp conformation 
Muscleblind-like 1 protein (MBNL1) is a necessary factor for mRNA alternative 
splicing. Sequestration of MBNL1 to an aberrant CUGexp is the cause of a disease called 
myotonic dystrophy type I (DM1).1 Fu et al. have suggested that MBNL1 changes the 
conformation of a mimic of one of its normal pre-mRNA targets (cTNT21) from double-
stranded (ds) to single-stranded (ss) form.2 Laurent et al. have showed that recruitment 
of p68 RNA helicase to CUG repeat would promote structural changes of the RNA that 
would facilitate and/or stabilize the binding of the splicing factor MBNL1 to the repeats.3 
On the contrary, Yuan et al. suggest that MBNL1 forms a ring-like structure which binds 
to the stem region of a pathologic ds form of CUGexp.4 On the other hand, in a crystal 
structure of MBNL1 ZnF3/4 bound to r(CGCUGU), reported by Teplova et al., it is shown 
that ZnF3 and ZnF4 target GC steps, rather than UU mismatches, providing the 
possibility of MBNL1 binding to ss form target.5 
These contradictory precedents prompted us to solve the mystery of CUGexp 
unfolding/folding upon interaction with MBNL1. It is a crucial piece of information for drug 
discovery efforts against DM1. For example, if MBNL1 prefers the ss CUGexp, ligands 
that stabilize the ds structure of CUGexp can inhibit the CUGexp·MBNL1 interaction. 
To approach this unanswered yet key structural question about how MBNL1 binds 
CUGexp, we did some preliminary bulk FRET (Fluorescence Resonance Energy 
Transfer) studies, as well as single-molecule FRET studies, in collaboration with Maria 
Spies lab in University of Iowa. These techniques have been previously used in similar 
systems.6,7 Our RNA construct is composed of a (CUG)4 RNA which is Cy3-labled at one 
end and is connected to a Cy5-labeled biotinylated ds-DNA at the other end. This ds-
DNA serves as a handle to immobilize (CUG)4 on the surface and allows us to study the 
                                                 
5
 This chapter is a collaborative project with Maria Spies lab. Data collection and analysis was 
performed by Masayoshi Honda, a postdoctoral researcher in Maria Spies lab. 
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distance of Cy3 label from Cy5 by FRET experiments as shown in figure 5.1. The 
unfolding can be induced by the addition of the DNA oligo - d(GAC)n and this serves as 
a positive control on the FRET experiment. 
Bulk (ensemble) FRET Experiments suggested that MBNL1 induces partial unfolding of 
(CUG)4 hairpin structure as we observed a partial decrease in FRET efficiency of (CUG)4 
from 0.46 to 0.30, by increasing [MBNL1] from 0 to 125 nM. Complementary DNA to 
(CUG)4 serves as our positive control for fully unfolded state. This construct represents 
FRET efficiency as low as 0.19 and was not affected by MBNL1 in the concentration 
range from 0 to 125 nM. This preliminary result is encouraging and paved the way for 
studying this system at the single-molecule level. Using Total Internal Reflection 
Fluorescence (TIRF) microscopy we did some preliminary smFRET experiments on the 
(CUG)4·MBNL1 interaction at the single molecule level. We are also working on the 
dynamics of (CUG)4 conformation and the effect of various cations such as magnesium 
on it. 
 
 
Figure 5.1. Schematic representation of the FRET pair used in the TIRFM study. CUG repeat is 
immobilized on the surface via neutravidin-biotin interaction through a DNA oligonucleotide. Cy3 is located 
at the 3' end of CUG repeat whereas Cy5 is on the 5' end of the DNA sequence. 
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smFRET experiments allow us to study the conformational dynamics of single 
(CUG)4 molecules in the presence and absence of MBNL1. We obtained (CUG)4 FRET 
efficiency histograms and studied the effect of MBNL1 on it (Figure 5.3). We observed 
that MBNL1 shifted the (CUG)4 populations toward partial unfolded states and induced a 
fast transition between folded and partially unfolded state.  
 
Figure 5.2. The effect of MBNL1 on the FRET efficiency of (CUG)4 and (CUG)4-(GAC)4. The curve of 
(CUG)4 is shown in green and The curve of (CUG)4-(GAC)4 is shown in blue. MBNL1 lowers the FRET 
efficiency of (CUG)4 whereas has no significant effect on the FRET efficiency of (CUG)4-(GAC)4. Proposed 
folding status of (CUG)4 corresponding to each state is shown in left. 
Cross-correlation/HaMMy analysis as well as study of (CUG)8 , a longer CUG repeat, 
is under way to study the folding kinetics of RNA molecules. Addition of more CUG 
repeats to the construct not only makes the study more biologically relevant, but also 
removes the effect, non-native stable UUCG hairpin loop of (CUG)4 might have affect on 
the dynamic of (CUG)4. The presence of stable UUCG hairpin loop is required for proper 
folding of (CUG)4 but not (CUG)8. The loop does not bind to MBNL1 and may trap 
(CUG)4 in a semi-folded state, even in the presence of MBNL1. This way, it may 
contribute as a hairpin swinging back and forth between a closed and semi-closed form. 
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Figure 5.3. FRET histogram revealed the distribution of (CUG)4 hairpin folding states and the effect of 
MBNL1 on them. X axis shows the FRET efficiency. (CUG)4-(GAC)4 is in the unfolded state (EFRET = 0.35). 
(CUG)4 is in folded state (EFERT = 0.9). MBNL1 shifts this peak to semi-folded state in the absence of NaCl, 
however in the presence of 150 mM NaCl, it has no effect on the EFERT (courtesy of Dr. Masayoshi Honda). 
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